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Abstract 
 
Background and aims 
 
Cystic Fibrosis (CF) is a multi-system genetic disease, but it is complications associated with 
chronic respiratory tract sepsis that most commonly result in premature death. By Adulthood, a 
chronic poly-microbial lung infection is established, and Pseudomonas aeruginosa emerges as the 
dominant pathogen. Established P. aeruginosa infection cannot be eradicated with currently 
available antibiotics and results in increased morbidity and mortality. 
 
The CF lung is inherently prone to bacterial infections, which are not cleared despite an intense host 
immune response, suggesting that defects in host innate immune defences may contribute to the 
pathobiology of CF lung infections.  
 
Iron is essential to critical metabolic pathways in humans and bacteria and is a regulator of 
phenotypic adaptation in P. aeruginosa. Detoxification and sequestration of iron in the human 
airway is an important anti-microbial defence strategy, which recent studies have suggested may be 
defective in CF.  
 
The MAIN AIMS of this PhD thesis were to examine the factors that may predispose to, and 
perpetuate, chronic P. aeruginosa infection in CF patients including: i) The impact of antibiotic 
treatment practices in Australian CF centres on rates of P. aeruginosa antibiotic resistance, ii) 
Investigation of bacterial population and host immune related factors that may result in recalcitrant 
pulmonary infection and modulate the response to anti-microbial therapy, and iii) The impact of 
disordered systemic and pulmonary iron homeostasis upon the severity of CF lung disease. 
 
Methods 
 
i) Predicting P. aeruginosa antibiotic resistance. 
Data from the Australian clonal Pseudomonas in CF study were used to identify trends in P. 
aeruginosa antibiotic resistance in Australian adult and paediatric CF centres and to identify 
treatment related factors associated with an increased risk of antibiotic resistance. 
 
 
 
3 
 
ii) Response of the CF lung microbiome to antibiotic therapy 
Bacterial DNA was extracted from expectorated sputa of subjects with CF. The 16S rRNA gene 
was amplified and sequenced by bacterial tag-encoded FLX amplicon pyrosequencing to determine 
the composition and relative abundance of bacterial genera. Changes in microbial community 
composition in response to intravenous antibiotic therapy were determined. 
 
iii) Adaptive immune responses to infection in the CF 
Multi-colour flow-cytometry was used to phenotype peripheral blood lymphocytes in CF and 
healthy subjects. Phenotypic profiles were correlated with indices of disease severity and infection. 
 
iv) Biometal composition of the CF airway 
Inductively-coupled plasma mass-spectrometry was used to detect iron and the presence of other 
bio-active metals in sputum samples from CF and healthy control subjects. Airway biometal 
composition was correlated to indices of disease severity, airway inflammation and cellular injury. 
 
v) Haemochromatosis modifier gene effects in CF 
Haemochromatosis (HFE) genotyping was performed on 163 adults, attending a single CF centre. 
The impact of HFE gene mutations upon disease phenotype and systemic iron homeostasis were 
examined. 
 
Results 
Rates of multi-antibiotic resistant P. aeruginosa (MARPA) were high in Australian CF subjects 
infected with P. aeruginosa. In large paediatric centres, increased antibiotic usage was associated 
with MARPA. In adult and paediatric centres, the centre of care predicted for MARPA. Infection 
with a major shared Australian P. aeruginosa strain correlated with increased treatment burden and 
MARPA. 
 
Culture independent analysis of the sputum microbiome of 23 adult CF subjects infected with P. 
aeruginosa, demonstrated an increased relative abundance of Pseudomonas was associated with 
overall reduced microbial diversity. Administration of intravenous antibiotics resulted in an early 
reduction in the abundance of Pseudomonas at a genus level, however, this was not sustained 
beyond the first week of antibiotic treatment. 
 
In comparison to healthy controls, peripheral blood from CF subjects contained a reduced 
proportion of mucosal associated invariant T-lymphocytes (MAIT cells). In CF, reduced MAIT cell 
4 
 
concentration was correlated with P. aeruginosa infection, increased disease severity and 
pulmonary exacerbations. 
 
Sputum of CF subjects contained increased concentrations of iron, magnesium, calcium, and zinc. 
Metal concentrations correlated with airway inflammation and cellular injury. CF subjects with 
severe disease had elevated sputum molybdenum concentrations. 
 
CF subjects with a C282Y haemochromatosis mutation experienced accelerated lung function 
decline and had an increased risk of CF related diabetes and gastro-intestinal complications. 
 
Conclusion 
 
This thesis describes wide variations in the rates of MARPA and treatment practices between CF 
centres across Australia and suggests the need to develop national treatment guidelines in order to 
maximise pulmonary outcomes and minimise treatment related complications. 
 
The CF airway bacterial microbiome of adults with established disease is complex and relatively 
resistant to intravenous antibiotic treatment. Sputum of CF subjects contains increased 
concentrations of bio-active metals which correlate with risk of P. aeruginosa infection, airway 
inflammation and cellular damage. 
 
MAIT cells concentrations were reduced in the blood of subjects with CF and associated with 
important markers of pulmonary disease severity, suggesting their concentrations may represent a 
systemic biomarker of CF lung disease. 
 
Finally the association of the C282Y haemochromatosis gene mutation with increased lung disease 
severity, risk of diabetes and gastro-intestinal complication in CF subjects, suggest HFE may be a 
modifying gene in cystic fibrosis, which offers the opportunity to therapeutically intervene. 
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Chapter 1 Review of the Literature 
 
1.1 Cystic Fibrosis 
 
1.1.1 Introduction 
 
Cystic fibrosis (CF) is the most common autosomal recessive, inherited, life-limiting condition to 
affect Caucasian populations, with a birth incidence of approximately 1 in 3200(1). Disease 
manifestations include gastro-intestinal, endocrine and male reproductive dysfunction. However, it 
is the complications associated with bronchiectasis and chronic respiratory tract infections that 
result in the greatest degree of morbidity, and early mortality associated with CF. 
 
In recent years advances in CF care, including pancreatic enzyme replacement therapy (PERT), 
nutritional supplementation, early and aggressive treatment of infection, and the development of 
specialist centre care, have led to substantial improvements in life expectancy(2). However, the 
majority of patients still die from complications associated with chronic respiratory sepsis before 
their fifth decade of life(1, 3). Equally improvements in survival have come at the cost of treatment 
related morbidity, including the emergence of multidrug resistant infections, complications of 
indwelling intravenous lines, and allergic and toxic effects of antibiotics in some patients(4-6). 
 
1.1.2 Cellular Defect 
 
CF results from mutation of both allelic copies of the cystic fibrosis trans-membrane conductance 
regulator (CFTR) gene located on long arm of chromosome 7(7). The CFTR gene encodes the 1480 
amino acid CFTR protein, which functions as an adenosine triphosphate (ATP)-Binding cassette 
(ABC) transporter ion channel (8). CFTR is expressed in high concentrations on the apical surface 
of epithelial cells lining the lung, gastro-intestinal tract, and sweat glands. At these sites CFTR 
primarily functions as a chloride (Cl-) ion channel. In addition CFTR co-localises with, and 
regulates the function of the epithelial sodium (Na+) channel (ENaC)(9).  
 
At the primarily secretory epithelial surfaces of the airways and gastro-intestinal tract, CFTR 
inhibits proteolysis of ENAC extracellular domains, thereby inhibiting its function(10). In tandem, 
CFTR activation, and inhibition of ENAC limits Na+ and Cl- reabsorption across the apical cell 
membrane of epithelial cells, thereby promoting diffusion of water down the osmotic gradient to the 
luminal surface. In contrast, in the primarily absorptive epithelial cells lining sweat glands CFTR 
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displays an opposite, positive regulatory effect on ENAC function(11). Consequently, defects in the 
production or function of CFTR result in dehydration of airway surface liquid (ASL) and 
inspissation of gastro-intestinal secretions, and excessive loss of salt and water in sweat. 
 
Following initial transcription CFTR undergoes extensive post-transcriptional modification and 
regulation on the endoplasmic reticulum and Golgi apparatus before being transported aboard 
clathrin coated vesicles to the apical cell membrane(12). Nearly 2000 different mutations within the 
CFTR gene have been described(13), however, these can be broadly divided into six functional 
classes, dependent upon the effect they have upon the transcription and post-transcription 
modification of CFTR (Table 1-1)(14, 15).  
Table 1-1 Classification of CFTR gene mutations. 
 
Class Functional effect of mutation Common phenotype causing mutations 
I Defective protein production G542X, R553X, W1282X 
II Defective protein processing  DF508del, N1303K 
III Defective protein regulation G551D, R560T 
IV Defective protein conductance R117H, R334W, G85E 
V Reduced amount of functioning protein A455E, 2789+5G→A 
VI Increased turnover of functional protein 120del23, N287Y 
 
1.1.3 Modifier Genes. 
 
In general, class I-III CFTR mutations are associated with a more severe “classical” disease 
phenotype, with class IV-VI being associated with “atypical” milder disease, and late diagnosis(15-
17). However, disease phenotype is variable between individuals with similar CF genotypes. In 
part, this variability may reflect different environmental exposures, however, the influence of 
modifier genes has also been postulated(18). Gene modifiers may alter target gene function or 
modify phenotype at the molecular, cellular, systemic or organismal level(19). 
A combination of candidate gene and gene wide association studies (GWAS) have been used to 
identify genes which may influence CF disease phenotype(18, 20, 21). To date, genes which 
influence the function of immune mediators (including mannose binding lectin, transforming 
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growth factor β, interferon-related developmental regulator 1 and interleukin-1), anti-oxidants (e.g. 
glutathione pathways), ion transporters (e.g. solute carrier family genes) and pancreatic β-cell 
function (transcription factor 7-like 2 gene) have been implicated in modifying CF phenotype(18, 
20, 22-24). 
 
1.1.4 Clinical manifestations. 
 
CF is a multisystem disease, however the greatest burden of disease falls upon the respiratory, 
endocrine, gastro-intestinal, hepato-biliary, and male reproductive systems. Subjects with the most 
severe phenotype typically present in the neonatal period with meconium ileus (MI) (impaction of 
inspissated intestinal secretion resulting in complete bowel obstruction), failure to thrive, or are 
diagnosed on the basis of an elevated “heal-prick” trypsinogen concentrations in countries such as 
Australia where new born screening is employed(2). 
 
Patients with a “classic” disease phenotype develop exocrine pancreatic insufficiency in the early 
neonatal period, and require lifelong PERT to prevent malabsorption. Over 30% of patients will 
develop diabetes by the third decade of life, with other common long term complications including 
chronic liver and bone disease(1, 2). However, the greatest burden of disease for the majority of 
subjects with CF is due to chronic pulmonary infection. To limit morbidity, sufferers are required to 
perform daily physiotherapy and use inhaled therapies to clear tenacious airway secretions, take 
regular course of antibiotics, and undergo recurrent hospitalisation for the treatment of infective 
pulmonary exacerbations. 
 
1.2 Pulmonary immune defences in CF 
 
The human lung employs physical, humoral, and cellular defence strategies to prevent chronic 
bacterial infection. It has been proposed that inherent defects in immune responses exist in CF and 
that these contribute towards the persistence of infection(25). Furthermore, it has been demonstrated 
that the previously considered “pristine”, non-infected neonatal CF lung contains increased 
concentrations of immune cells, a finding which has been used to support the hypothesis that 
pulmonary inflammation may precede infection, although this remains a matter of debate(26-28). 
 
1.2.1 Airway surface liquid 
Airway surface liquid (ASL) contains high concentrations of mucin, a large heterogeneous 
glycoprotein with variable carbohydrate side chains which are capable of trapping inhaled bacteria 
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(29). In healthy airways, inhaled bacteria adhere to mucins and are rapidly cleared by the muco-
ciliary escalator. In CF, increased Na+ and water reabsorption dehydrates ASL making it “sticky” 
and slow moving. Additionally, serine proteases released by invading pathogens degrade mucin and 
further compromise the rheological properties of ASL(30). Consequently, inhaled bacteria have the 
opportunity to multiply and establish infection before they are cleared. Furthermore, CF ASL is 
deficient in a number of humoral, anti-bacterial mediators, including the iron binding protein 
lactoferrin, hypothiocyanite, and surfactant protein A(31-33).  
 
1.2.2 Airway epithelial cells 
 
Airway epithelial cells (AECs) represent the primary interface between inhaled pathogens and the 
immune system and are vital to the coordination of normal innate and adaptive immune responses.  
 
Abnormal signalling and anti-inflammatory responses by CF AECs may promote sustained 
inflammation within the CF lung(25). In vitro, CF AECs show increased expression of genes 
involved in pro-inflammatory signalling pathways, in the absence of infective stimuli(34). 
Differences in CF AECs cytokine responses include increased production of the neutrophil 
chemoattractant interleukin (IL)-8 and the pro-inflammatory nuclear factor kappa-beta (NFkB), and 
decreased production of anti-inflammatory IL-10 in response to P. aeruginosa LPS stimulation(34). 
CF AECs also display deficient production of the anti-oxidant glutathione and exaggerated 
production of pro-inflammatory prostaglandins and cyclo-oxygenase(35, 36). 
 
The mechanism by which defective CFTR functioning results in abnormal AEC responses is 
unknown, although recent work has proposed that the loss of normal CFTR inhibition of 
intracellular calcium flux may influence gene expression profiles(37). 
 
1.2.3 Polymorphonuclear cells  
 
Polymorphonuclear cells (PMNs, neutrophils) are the primary cell of the innate immune response, 
and dominate airway inflammation in CF(38). Airway neutrophil numbers correlate with both the 
severity and progression of CF lung disease.  
 
In “healthy” people, the typical response to bacterial infection is rapid recruitment of neutrophils to 
the site of infection, driven by local production of chemo-attractants. At the site of infection, 
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bacteria are phagocytosed and killed by activated neutrophils, which then trigger self-death 
mechanisms (apoptosis) and are cleared by airway macrophages(39). 
 
Neutrophil intracellular killing occurs within the phagolysosome and is reliant on the “oxidative 
burst” in which reactive oxygen species (ROS) are generated in a step-wise manner(38). Although 
each of these oxygen species is toxic in its own right, hypochloric acid (HOCl) and hydrogen 
peroxide (H2O2) are considered the most important for bacterial killing(40). 
 
Neutrophils from people with CF demonstrate distinct gene expression profiles which suggest 
inherent abnormalities in neutrophil function may exist(41). CFTR expression in neutrophils co-
localises with intra-cellular phagosomes and in vitro CFTR mutant neutrophils exhibit reduced 
bacterial killing and chlorination of bacterial proteins(40). It is postulated that loss of CFTR 
function may result in reduced chlorination of phagolysosome and reduced production of HOCl, 
which culminate in ineffective bacterial killing(40). Furthermore, CF neutrophils demonstrate 
abnormal expression of toll like receptors (TLR’s), inflammatory cytokines (including IL-8) and 
reduced production of the anti-inflammatory protein annexin(25, 41, 42). 
 
1.2.4 Alveolar Macrophages 
 
Alveolar macrophages (AM) are involved in direct microbial killing and the removal of apoptotic 
PMNs (efferocytosis), and modulate the adaptive immune response through antigen presentation. 
As for neutrophils, CFTR is expressed within the lysosomes of alveolar macrophages(43), and CF 
AM display defective bacterial killing capabilities(25). Initial studies in a murine CF model 
suggested loss of CFTR function may lead to defective acidification of intracellular lysosomes(43). 
However, the results of this study and the experimental techniques employed have been refuted in 
subsequent studies(44). To date, an alternate mechanism has not been proposed. 
 
There are few studies of the efficacy of efferocytosis and antigen presentation by CF AM. A single 
study has suggested that efferocytosis is not impaired in CF AM(45). While ex vivo examination of 
alveolar monocytes (macrophages and dendritic cells) from explanted CF lungs suggest these cells 
have an impaired ability to present antigen, despite circulating monocytes from the same patient 
having normal antigen presenting capabilities. This finding suggests an inducible monocyte defect 
caused by local factors in the CF lung as opposed to an inherent cellular defect(46). 
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1.2.5 Lymphocytes. 
 
At the level of the airway lumen, the cellular immune response is dominated by activated 
neutrophils. In contrast, airway epithelial biopsies demonstrate a profound T lymphocyte (T-cell) 
infiltrate from an early age(47). Furthermore sub-mucosal lymphocyte concentrations correlate with 
regions of high tissue destruction and P. aeruginosa density, suggesting an important role in disease 
severity(47, 48). 
 
T-cells are instrumental in orchestrating adaptive immune responses. Historically T-cell responses 
was dichotomised to either, T helper (Th)-1 predominant, in which interferon (IFN)-γ production 
resulted in macrophage activation and a cellular immune response, or Th-2 predominant, in which 
IL-4 production resulted in a humoral response and activation of mast cells. This paradigm has 
since been superseded by a greater understanding of the complexity of T-cell responses and 
identification of other important T-cell populations. Particular attention in the setting of chronic 
pulmonary infection has been given to Th-17 and regulatory T-cells (Treg-cells, and in more recent 
times, “innate” T-cells. 
 
Initial studies of peripheral, adaptive immune responses in CF focused on the dichotomy of T-
helper (Th)-1 and Th-2 responses(49). These early studies suggested a skew towards a Th-2 in the 
majority of CF subjects infected by P. aeruginosa, which resulted in increased pulmonary 
inflammation and disease progression. However, in a minority of patient a predominant Th-1 
responses was associated with a more indolent course(49-51).  
 
Th-17 cells represent an IL-17 producing sub-population of T-cells, which develop from naïve T-
cells in response to IL-23 stimulation(52). IL-17 stimulates granulopoiesis and neutrophil 
recruitment, as well as mediating tissues destruction, by regulating the production of matrix 
metalloproteinases (MMPs)(53). Animal models suggest CFTR deficient, naïve T-cells have an 
intrinsic propensity to differentiate towards a Th-17 lineage(54). Clinically, sub-mucosal biopsies 
taken from the airways of children with CF demonstrate a high concentration of IL-17 positive T-
cells(55). Furthermore, increased concentrations of IL-17 and other Th-17 related cytokines in 
bronchioalveolar lavage fluid (BALF) correlate with disease severity, pulmonary exacerbations and 
acquisition of P. aeruginosa(56). The strong relationships between Th-17 mediators and airway 
inflammation have resulted in the postulate that CF lung disease may be a Th-17 mediated(57, 58). 
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Treg cells, which produce predominantly anti-inflammatory cytokines (including IL-10, and TGF-
β) are believed to play a crucial role in moderating T-cell responses to infections and preventing 
autoimmunity(59). In the lung, an imbalance in Th17/Treg numbers in favour of a pro-
inflammatory (Th17) response has been linked with acute exacerbations of chronic obstructive 
pulmonary disease and reduced in Treg cell number and activity has is associated with increased 
risk of atopic asthma(60, 61). Conversely, excessive Treg cell responses have been implicated in 
impeding the clearance of Mycobacterial infections and adequate response to severe sepsis(62, 63).  
 
To date, studies into the role of Treg cells in CF related lung disease are limited. Anil and Singh 
demonstrated that children with CF have reduced numbers of peripheral blood Treg cells when 
compared to healthy controls and that in these children Treg cell numbers were inversely correlated 
with lung function(64). These finding were replicated in a more recent study by Hector et al, which 
also included data from adult patients and additionally demonstrated that chronic infection with P. 
aeruginosa caused a further reduction in peripheral blood Treg cell number(65). The authors of this 
later study went on to demonstrate that Treg cell numbers were lower in the bronchoalveolar lavage 
fluid of patients with CF compared to patients with non-CF bronchiectasis.  Accompanying murine 
and ex vivo studies, demonstrated that both the absence of CFTR gene and P. aeruginosa infection, 
had independent, adverse effects on Treg cell number and function(65). 
 
Activation of the “classical” adaptive immune response involves antigen recognition, followed by 
T-cell recruitment and clonal expansion at the site of infection. Consequently, there is a time lag 
between the host’s recognition of the presence of a pathogen and the development of an effective, 
adaptive immune response. In recent times, an increasing number of unconventional, “innate” T-
cell populations have been described (including γ/δ, semi-invariant natural killer T [iNKT], M3 
restricted T- and mucosal associated invariant T [MAIT]-cells), which are capable of mounting a 
more immediate response to pathogens than was previously thought possible.  
 
γ/δ T-cells represent a minor population of circulating T-cells, which has the capacity to expand 
rapidly in response to bacterial infection(66). γ/δ T-cells produce IL-17 and preferentially migrate 
to mucosal surfaces from the circulation(67). In murine pulmonary infection models, γ/δ T-cells 
rapidly accumulate in the lung in response to a range bacterial pathogens, where they facilitate the 
influx of neutrophils and subsequent bacterial clearance(66). A single study has reported an increase 
in the proportion of circulating γ/δ T-cells in the blood of CF subjects, when compared to healthy 
subjects(68). 
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MAIT cells are a recently described sub-class of innate T-cells, which can be differentiated from 
other T-cells by the presence of an evolutionary conserved T-cell receptor (TCR) (Vα7.2-Jα33). 
MAIT cells recognise bacterial and fungal metabolites presented on the major histocompatibility 
complex (MHC) related protein-1 (MR1), however, importantly do not respond to viral stimuli(69, 
70). 
 
Innate T-cell populations provide rapid pathogen-specific responses prior to the development of 
classical MHC class I and II restricted T-cell responses and may also provide a sustained cytokine 
response in chronic infection(71, 72). However, the role of MAIT cells in CF lung disease has not 
been explored. 
 
1.3 Respiratory infection in CF 
 
1.3.1 Epidemiology 
 
Respiratory tract infections in people with CF begin very early life(73). Initial intermittent 
infections typically are caused by the common respiratory pathogens, Staphylococcus aureus (S. 
aureus), and non-typeable Haemophilus influenzae (H. influenzae). By adulthood the majority of 
sufferers have developed a chronic poly-microbial airway infection, with P. aeruginosa becoming 
the dominant pathogen in 80% of cases(1, 74). Other Gram-negative bacteria that may cause 
chronic infection in a minority of patients include Burkholderia cepacia complex (BCC), 
Stenotrophomonas maltophilia and Acromobacter xylosoxidans(75).  
 
1.2.2 The airway microbiome 
 
As bronchiectasis develops in the CF airways, a complex, poly-microbial infection develops. 
Traditional sputum microbiological techniques for routine CF respiratory samples use selective 
media to specifically culture known pathogenic bacteria, followed by determination of antibiotic 
susceptibility based on the minimum inhibitory concentration in vitro. When a single organism is 
responsible for pulmonary infection (e.g. community acquired pneumonia), the response to 
antibiotic therapy may be predicted by resulting antibiotic susceptibility profiles(76, 77). However, 
when treating CF pulmonary infections antibiotic susceptibility profiles do not predict clinical 
response(78). In part, this may be due to failure to consider the impact that non-cultured bacteria 
This thesis will examine the relationship between peripheral blood lymphocyte and CF 
phenotypes, with a focus on the MAIT cell sub-population of innate T-cells 
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and inter-bacterial interactions on airway inflammation and antibiotic efficacy. In an attempt to 
address this short-fall, culture independent (metagenomic) microbiological techniques which 
generate bacterial profiles based on the isolation and amplification of highly conserved bacterial-
derived 16S ribosomal (r)RNA from biological samples, have been applied CF respiratory 
samples(79, 80). Metagenomic methods for microbial community analysis are revolutionising the 
understanding of a wide array of infective diseases and a number of reviews have been dedicated to 
this subject (including(81-83)). Application of these techniques to the study of complex infection 
has the potential to greatly expand our understanding of the impact of antibiotic therapy on bacterial 
community composition, predict responses to antibiotic combinations, and inform decisions on the 
optimum duration of antibiotic therapy. 
 
To date, only a limited amount of research studies have applied metagenomic techniques to the 
study of CF pulmonary infection. These initial studies have demonstrated a reduction in microbial 
diversity with age and severity of lung disease(84, 85), and studies of lung explants also reveal 
significant spatial differences in community composition of airway inhabitants depending on which 
part of the lung is examined(86, 87). 
 
1.2.3 Pseudomonas aeruginosa 
 
P. aeruginosa is a versatile, aerobic gram-negative bacterium which is widespread in the terrestrial 
environment. It is an extremely robust organism and, as exemplified by its isolation from jet plane 
fuel and bottles of disinfectant fluid, capable of surviving in challenging and varied environmental 
niches(88). This adaptability is conferred by both its very large genome (~6000 genes, ~500 of 
which are involved in regulatory processes) and its ability to survive as either a planktonic 
organism, or as a member of co-dependent bacterial communities within the confines of a 
“biofilm”(89, 90). 
 
The genetic plasticity and biofilm forming attributes of P. aeruginosa make it a highly successful 
pathogen in multiple disease settings in eukaryotes. In human disease, P. aeruginosa is a major 
opportunistic pathogen responsible for life threatening acute infections in burn victims and other 
critically ill patients, as well as causing chronic infections and acute exacerbations in patients with 
respiratory diseases(91-93). 
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In the setting of CF, establishment of a chronic pulmonary P. aeruginosa infection leads to 
decreased quality of life, and increased rate of lung function decline, pulmonary infective 
exacerbations, morbidity, and mortality(94).  
 
1.2.3.1 Biofilm formation 
 
Following initial airway infection, planktonic P. aeruginosa undergo rapid phenotypic and 
genotypic adaptation to prevent immune recognition. This is achieved by the formation of a biofilm, 
which offers physical protection and down-regulation of virulence factors(89, 95). 
 
Biofilms comprise an extra-cellular matrix (ECM) of exopolysaccharides, extracellular 
deoxyribonucleic acid (eDNA), and proteins produced by the resident bacteria. By trapping 
essential nutrients and providing a physical barrier from host immune attack biofilms offer a 
survival advantage to embedded bacteria. In the CF lung it is proposed that P. aeruginosa binds 
abnormal mucins present in ASL to form biofilm “rafts” which float on the respiratory 
epithelium(95). Established biofilm infections cannot be eradicated with currently available 
antibiotics, or by the host’s immune response(96).  
 
Biofilm development is largely determined by its environment and available nutrients(97). In vitro, 
biofilms develop complex three-dimensional structures with phenotypically distinct sub-populations 
which communicate through extracellular channels(98). Iron is essential as a bacterial nutrient, but 
it also contributes to the structural integrity of the biofilm by crosslinking polysaccharide strands 
within the stalk(99). 
 
P. aeruginosa biofilm development is dependent on cell-cell communication. Quorum sensing (QS) 
is a population density dependent form of communication employed by bacteria to control the 
synthesis of key regulatory proteins. P. aeruginosa employs three QS systems (Las, Rhl, and Pqs), 
which are integral to all activities of the bacterial community, including biofilm formation(100-
103). 
 
1.2.3.2 Shared strains 
 
Historically, it was thought that most CF subjects become infected with a “unique” P. aeruginosa 
strain acquired from the environment, however, a number of epidemiological studies have 
demonstrated that groups of patients may become infected by genetically similar P. aeruginosa 
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strains, which are not found in other environmental niches(104-107). The findings of these studies 
raise the possibility of transmission of infection between patients. These common strains, have been 
described variably in the literature as “clonal”, “epidemic”, or “transmissible”, but for the remainder 
of the thesis will be referred to as “shared” strains(107). 
 
In the Australian Clonal P. aeruginosa in CF (ACPinCF) study the relatedness of P. aeruginosa 
isolates from the sputum of nearly one thousand adults and children with CF, attending eighteen CF 
centres across Australia was examined(107). In this study, two thirds of subjects were infected with 
a P. aeurginosa strain seen in at least one other person, and two “major” shared strains, AUST-1 
and AUST-2, were found in 22% and 18% of patients respectively(107). 
 
Although longitudinal data assessing the clinical impact of infection with the Australian shared 
strains is lacking, shared strains described in other parts of the world have been associated with an 
increased rate of lung function decline, morbidity, mortality, and need for lung transplantation(106, 
108). Similarly, limited data suggest segregating patients infected with shared P. aeruginosa strains 
may reduce cross infection(109). 
 
Little is known about the transmissibility of shared strains, or about the phenotypic traits, which 
allow them to successfully infect multiple subjects. It is conceivable however, that shared strains are 
more adept at competing for essential nutrients within the CF lung and consequently are able thrive 
in this environment. 
 
1.2.4 Current treatment strategies for pulmonary infection.  
 
Antibiotics are used routinely to treat pulmonary exacerbations in patients with CF, yet this is based 
on limited evidence including only two small, randomised clinical trials(110, 111). Despite neither 
study providing clear evidence of improved clinical endpoints in the antibiotic treatment arms, 
undertaking further placebo-controlled trials would be considered unethical, given the strong 
anecdotal evidence for benefit.  
 
In selecting an antibiotic regime for an individual patient important considerations include, the 
specific bacterial pathogens present within the airways, preferred location of treatment (hospital 
This thesis will examine the relationship between treatment strategies employed in Australian 
CF centres and rates of antibiotic resistant and “shared strain” P. aeruginosa infections 
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versus home), route of administration, how many antibiotics to use, and which ones to prescribe 
(112). These decisions are often influenced by exacerbation severity, available intravenous access, 
previous antibiotic allergies, adherence and the support available to the individual patient if home 
based therapy is to be considered. 
 
1.2.4.1 Non-Pseudomonas Infection. 
 
In the absence of P. aeruginosa infection, the choice of antibiotics is typically based on available 
microbiological cultures and sensitivity patterns, and single agent treatment may be employed 
(Table 1.2). 
 
1.2.4.2 P. aeruginosa Eradication. 
 
The realisation that chronic P. aeruginosa infection results in increased lung function decline, 
exacerbation frequency, morbidity and mortality has led to the development of early detection 
programs that often involve invasive bronchoscopies and aggressive antibiotic regimes aimed at 
eradicating P. aeruginosa infection at the time of first acquisition (Table 1.3)(113-116). 
Implementation of these regimes within paediatric centres has proven to be highly effective in 
delaying the onset of chronic P. aeruginosa infection by several years(116), though their impact on 
the development of bronchiectasis is not well established(117). However, the long term impact on 
survival, antibiotic resistance profiles, and the potential acquisition of other opportunistic bacterial 
pathogens is not well understood. 
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Table 1-2 Oral and Intravenous Antibiotics for the Treatment of Pulmonary Exacerbations 
where Pseudomonas aeruginosa is not Isolated#, $. 
 
Oral Antibiotics 
Bacteria Antibiotic Dose Special considerations 
Methicillin sensitive 
Staphylococcus 
aureus 
Di/Flucloxacillin 125mg BD (prophylaxis) 
25mg/kg QiD (<18 years old ) 
1-2g QiD 
Consider prophylaxis 
in 0-3 years old, but 
currently unproven 
clinical benefit Trimethorpim-
sulfamethoxazole 
160/800mg BD 
Clindamycin 450mg TDS 
Roxithromycin 150mg BD 
Stenotrophomonas 
maltophilia 
Trimethorpim-
sulfamethoxazole 
160/800mg BD Targeted treatment 
currently of unproven 
benefit Minocycline 200mg initial dose, 100mg BD* 
Tigecycline 100mg initial dose, 50mg BD* 
Intravenous Antibiotics 
Methicillin Sensitive 
Staphylococcus 
aureus 
Di/Flucloxacillin 50mg/kg (< 18years) 2-3g QID  
Methicillin Resistant 
Staphylococcus 
aureus 
Vancomycin$ 1g BD  
Teicoplanin 10mg/kg BD 3 doses, then daily  (< 
18 years) 400mg for BD 3 doses, 
then daily, 
Linezolid 10mg/kg (<12 years) 600mg daily 
Haemophilus 
influenzae 
Cefuroxime 50mg/kg TDS (1-18years old) 
1.5g TDS  
 
Cefotaxime 50mg/kg TDS (1-18years old) 
2g TDS 
Burkholderia 
cepacia complex 
Ceftazadime 50mg/kg TDS (1-18years old) 
2-3g TDS  
A combination of at 
least two antibiotics 
from different classes 
should be used 
 
 
 
 
 
 
 
Plasma concentration 
monitoring required 
Meropenem 25-40mg/kg  TDS (4-18years old) 
2g TDS  
Imipenem 22.5mg/kg TDS (<40kg) 
1g TDS  
Piperacillin-
Tazobactem 
90mg/kg QiD  (Children) 
4.5g QiD  
Trimethorpim-
sulfamethoxazole 
240mg BD (6 months-6 years old)  
480mg BD (6-12 years old) 
960mg BD (>12years old) 
 Tobramycin^ 10mg/kg Daily 
Stenotrophomonas 
maltophilia 
Ticarcillin-
clavulanate 
80-100mg/kg QiD (<18 years) 
3.1g QiD  
 
#: Intended as a guide only, antibiotic choice may vary dependent on local resistance profiles and 
antibiotic availability, $: Derived from the Report of the UK Cystic Fibrosis Trust Antibiotic 
Working Group, and the Australian Therapeutic Guidelines [129,130] BD: twice Daily, TDS: three 
times daily, QiD: four times daily kg: Kilogram, Max: Maximum dose, mg: Milligram, *: Avoid 
tetracyclines in patients under 12 years old, ^Therapeutic drug monitoring is required
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Table 1-3 Eradications Strategies for Treatment of Specific Airway Pathogens at First Isolation$. 
 
Bacteria Antibiotic Dose Special Instructions  
Methicillin Sensitive Staphylococcus 
aureus 
Flucloxacillin 100mg/kg/Day Oral 2 agents in combination for 2-4 weeks. If persistent 
infection consider two weeks of combination intravenous 
agents 
Fusidic Acid 750mg Daily Oral (>12 years old) 
Dosing <12 complicated see PI 
Methicillin Resistant Staphylococcus 
aureus 
Topical Mupirocin Intra-nasal Combined use of topical Mupirocin and two other agents 
for 5 days Trimethorpim-
sulfamethoxazole 
160/800mg BD Oral 
Fusidic Acid 750mg Daily Oral 
Dosing <12 complicated see PI 
Rifampicin 10mg/kg/Day Oral 
Max 450mg <45kg 
Max 600mg >45kg 
Haemophilus influenzae Amoxicillin-
Clavulinic Acid 
875/125mg BD Oral or  
250/125mg, 2  TDS Oral 
Dosing <12 complicated see PI 
Single agent for 2-4 weeks, repeated if still positive at end 
of course. Consider 2 week IV course if remains positive 
Doxycycline 200mg initial dose, 100mg BD 
Oral* 
Cefaclor 500mg (>7 years), 250mg (1-
7years) Oral 
Pseudomonas aeruginosa Ciprofloxacin 15mg/kg Oral BD(under 5 years) 
20mg/kg Oral BD(5-18 years) 
750mg BD Oral(adult) 
3weeks – 3months of ciprofloxacin combined with an 
inhaled antibiotic. 
Multiple regimens have been studied [91-94] 
Colistin 1million units BD Inhaled(under 2 
years) 
2million units BD Inhaled(over 2 
years) 
Tobramycin 300mg BD Inhaled 
 
$: Derived from the Report of the UK Cystic Fibrosis Trust Antibiotic Working Group, and the Australian Therapeutic Guidelines [129,130] BD: twice 
Daily, TDS: three times daily, QiD: four times daily kg: Kilogram, Max: Maximum dose, mg: Milligram, PI: Product information, IV: Intravenous, 
*Avoid tetracyclines in patients under 12 years old. 
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Table 1-4 Currently Licensed Antibiotics for the Treatment of Pseudomonas aeruginosa in Cystic Fibrosis. 
 
Class Drug Route of Administration Dose Special Considerations 
Β-Lactams 
Extended Spectrum Penicillins Ticarcillin / clavulanate# Intravenous 80-100mg/kg QiD (child) 
3.1g QiD (adult) 
Need to be administered by 
slow Intravenous infusion 
 Piperacillin / Tazobactem# Intravenous 90mg/kg QiD (child) 
4.5g QiD (adult) 
Third generation cephalosporins Ceftazidime Intravenous 50mg/kg TDS (Under 18 years) 
3g TDS (adult) 
 
Carbapenems Meropenem# Intravenous 25-40mg/kg TDS (4-18 years old) 
2g TDS (adult) 
 
 Imipenem# Intravenous 22.5mg/kg Qid (under 40kg) 
1g TDS (over 40kg) 
Need to be administered by 
slow Intravenous infusion 
Monobactam Aztreonam Intravenous 30mg/kg (under 2 years) 
50mg/kg (2-12 years) 
2g TDS (over 12 years) 
 
  Inhaled* 75mg TDS FDA (USA) approved 
Fourth generation cephalosporin Cefepime Intravenous 50mg/kg BD (under 40kg) 
2g BD (over 40kg) 
 
Aminoglycosides 
 Tobramycin Intravenous 10mg/kg Daily$ Plasma concentration 
monitoring required 
 Tobramycin inhalation solution Inhaled* 300mg BD  
Fluoroquinolones 
 Ciprofloxacin Oral 15mg/kg (under 5 years) 
20mg/kg (5-18 years) 
750mg BD (adult) 
Mild exacerbations and 
eradication regimens 
Polymyxin B 
 Colistin Intravenous 25000 units/kg TDS (under 60kg) 
2million units TDS (Over 60kg) 
Need to be administered by 
slow Intravenous infusion 
  Inhaled* 1million units BD (under 2 years) 
2million units BD (over 2 years) 
 
Other agents 
 Fosfomycin Intravenous 100mg/kg (under 40kg) 
5g TDS (over 40kg) 
 
 
mg: milligrams, kg: kilograms, QiD: four times daily, TDS: three times daily, BD: twice daily,*Have not been studied in treatment of 
exacerbations, # Co-administration of Probenecid may be considered to increase drug levels, $ Therapeutic drug monitoring is required 
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1.2.4.2 Chronic P. aeruginosa infection. 
 
Once a chronic biofilm P. aeruginosa airway infection has become established it cannot be 
eradicated with currently available antibiotics and the focus of treatment moves from eradication to 
the treatment of exacerbations. Pulmonary exacerbations are characterised by increasing respiratory 
symptoms and acute deterioration of lung function. They are associated with significant morbidity 
and mortality and may accelerate lung function decline(118, 119), as well as being associated with 
diminished quality of life(120) and increased health care costs(121). In the presence of P. 
aeruginosa antibiotic therapy is usually specifically directed towards this pathogen, and modified to 
target co-infections if clinical response with anti- P. aeruginosa antibiotics is sub-optimal (Table 
1.4).  
 
Antibiotic options for treatment of P. aeruginosa are limited. Fluoroquinolones are the only orally 
administered bioavailable anti-pseudomonal agents. Ciprofloxacin is the most commonly prescribed 
quinolone, and is frequently combined with a nebulised agent in out-patient treatment regimens for 
mild exacerbations. Nebulisation allows delivery of high drug concentration directly to the airway 
whilst avoiding systemic adverse effects. Unfortunately inhaled administration of antibiotics fails to 
treat recalcitrant bacteria sequestered in poorly ventilated lung regions. Until recently 
aminoglycosides such as tobramycin and the polymyxin, Colistin were the only nebulised agents in 
clinical use. However, multicentre phase III randomised controlled trials (RCT’s) have recently 
demonstrated the safety and efficacy of aerosolised Aztreonam lysine in stable patients with 
moderate to severe lung function impairment(122, 123), which has supported Food and Drug 
Administration (USA) approval for use as a maintenance treatment in CF. Despite oral and 
nebulised combination regimes often being used in clinical practice, there is limited evidence to 
support their use in the acute setting. A Cochrane Review identified three small, randomised 
controlled trials comparing ciprofloxacin monotherapy with combination intravenous therapy. No 
major differences in outcome were seen, but each of the trials were under-powered and treatment 
arms were not blinded (124).  
 
Intravenous antibiotic regimes remain the cornerstone of treatment of severe exacerbations in 
hospitalised patients. The superiority of combination intravenous therapy for gram negative 
nosocomial pneumonia has been clearly demonstrated(125). However, in the setting of chronic 
pulmonary infection in CF, systematic reviews comparing combination with mono-therapy have 
failed to clearly demonstrate superiority of combination therapy(126-128). However, whilst 
acknowledging the current lack of evidence, treatment guidelines recommend dual anti-
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pseudomomal antibiotic therapy(127, 129). No combination regimen has demonstrated clear 
superiority over the others, but in practice two agents from different anti-microbial classes (usually 
a β-lactam and aminoglycoside) are typically administered. 
 
In selecting specific agents current practice guidelines recommend reference be made to available 
sensitivity profiles, and to avoid agents to which organisms are resistant(129, 130). However, there 
is a poor correlation between sensitivity profiles and clinical response, and an alternate approach is 
to select antibiotics to which the individual patient has previously responded. Anecdotally, 
clinicians may only refer to antibiotic sensitivity profiles when second line agents are being 
selected, in the situation where the patient has failed to improve with initial treatment regimen.  
 
There are no randomised controlled trials studying the optimum duration of antibiotic therapy for 
pulmonary exacerbations in CF(127, 131). Theoretical concerns that a shorter duration of antibiotic 
therapy may reduce the time to next exacerbation, or increase the rate of lung function decline, need 
to be balanced against the potential adverse effects(5), and risk of promoting antibiotic resistant 
organisms(4) which may be associated with prolonged treatment courses. 
 
Prospective studies into the treatment of acute exacerbations of chronic bronchitis, and 
microbiologically proven ventilator associated pneumonia (VAP) have demonstrated non-inferiority 
of shorter courses of antibiotics(132, 133). Although, of note in the case of VAP, patients infected 
with gram negative organisms (commonly P. aeruginosa) had an increased risk of microbiological 
relapse with shorter treatment(133). 
 
In a small prospective cohort study of 22 CF patients undergoing hospital based treatment for 
pulmonary exacerbations, improvements in spirometry, and oxygenation plateaued after eight days 
of treatment(134). These limited prospective data are supported by a recent large retrospective study 
of outcomes following pulmonary exacerbations in over 1500 people, which suggested that further 
improvements in spirometry after eight-to-ten days of therapy were small, and that shortening 
antibiotic duration did not adversely affect the time to next exacerbation. Adequately powered 
prospective studies are required to more fully understand the optimal duration of treatment for 
pulmonary exacerbations in CF(135). 
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1.2.4.3 Effect of antibiotics on the CF airway microbiome. 
 
Studies examining the effects of antibiotic therapy on the CF lung microbiome are limited. Tunney 
et al. have demonstrated that despite total bacterial numbers being reduced in response to antibiotics 
(culture-based assessment), there was relative stability in overall community composition as 
assessed by terminal restriction fragment length polymorphisms analysis when sputum samples 
were collected from subjects with CF before and after treatment of a pulmonary exacerbation(136). 
Daniels et al examined the impact of antibiotics on CF sputum microbial diversity in a group of 
adult CF subjects(137). Sputum samples collected following the initial 72 hours of antibiotic 
therapy were compared with samples collected during a period of clinical stability prior to the 
exacerbation and after 10-14 days of treatment. In comparison to samples collected at 72 hours, 
samples collected at 10-14 days demonstrated an increase in relative abundance of Pseudomonas 
species compared with non-pseudomonads, accompanied by a reduction in community 
diversity(137). The authors concluded that antibiotic therapy was exerting a significantly greater 
effect on bacterial species other than Pseudomonas, culminating in the dominance of P. aeruginosa.  
 
 
1.3. Iron homeostasis in health and Cystic fibrosis 
 
1.3.1 Systemic iron homeostasis 
 
Iron (Fe) is an essential nutrient, critical to the oxygen carry capacity of haemoglobin and 
myoglobin, and as a co-factor in a multitude of metabolic pathways(138). Conversely, due to its 
high redox activity iron is a potential cellular toxin, capable of generating harmful reactive oxygen 
species (ROS) through fenton chemistry (Figure 1-1)(139). The toxic potential of iron means that 
tight control of iron absorption and bioavailability must be maintained to prevent harm. 
Figure 1-1 Fenton Reactions. 
1) Fe2+ + H2O2  F 3+ + OH- + OH. 
2) Fe 3+ + H2O2  Fe 2+ + OOH. + H+ 
------------------------------------------------------- 
With the exception of loss from denuded epithelial cells, menstrual blood, and minor incidental 
quantities in urine and faeces, humans do not have a mechanism of iron excretion. Consequently, 
This thesis will examine changes in the airway microbiome of CF patients infected with P. 
aeruginosa in response to intravenous antibiotic treatment of a pulmonary exacerbation. 
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control of absorption from the gastro-intestinal tract is the sole mechanism for regulation of total 
body iron. Iron absorption is increased in response to iron deficiency and increased erythropoiesis, 
and reduced when hepatic iron stores are replete. 
 
1.3.1.1 Hepcidin 
 
Hepcidin, identified by three independent research groups between 1998 and 2001 has gained 
acceptance as the “Master Regulator” of iron homeostasis(140-142). Hepcidin is a 25 amino acid 
cationic peptide produced by the liver which is synthesised in response to iron loading and 
inflammation, and suppressed by hypoxia and anaemia(143). 
 
Hepcidin binds to, and induces internalisation and degradation of ferroportin on the surface 
membrane of hepatocytes, macrophages and duodenal enterocytes. Ferroportin expression is 
required for export of iron from cells, consequently under conditions of iron loading, iron may be 
taken up by duodenal enterocytes, however, it cannot be released into the plasma, instead being 
retained within the cells and cleared from the body by the natural shedding of enterocytes.  
 
Hepcidin is transcriptionally regulated, however, the mechanisms by which this is achieved are 
incompletely understood. Much of our knowledge of these regulatory pathways comes from the 
study of genetic diseases associated with iron loading and deficiency, and have been reviewed in 
detail elsewhere(144). In brief, hepatic cells sense increased iron concentrations through an 
interaction between iron-bound transferrin and the membrane bound transferrin receptors. This 
sensing system is dependent on HFE, which in response to high transferrin levels, relays a signal 
via bone morphogenic protein (BMP)-6 and its associated receptor to the SMAD pathway, which 
in-turn promotes transcription of hepcidin mRNA(144). Under circumstances of iron restriction or 
increased erythropoiesis these pathways are down-regulated and hepcidin mRNA expression 
decreases. 
 
1.3.1.2 Hereditary Haemochromatosis 
 
Hereditary haemochromatosis (HH), the most common autosomal recessive condition in Caucasian 
populations, impacts iron homeostasis, by inhibiting the production and release of the iron 
regulatory hepcidin from the liver in response to iron loading and infection(145). HH typically 
occurs due to mutations in the HFE gene and 1 in 200 Australian’s carry a potentially disease 
causing HFE genotype, although phenotypic penetrance is much lower(146). Two point mutations 
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(C282Y and H63D) in the HFE gene mutations account for >90% of cases of HH and homozygotes 
for the C282Y mutation demonstrate the most severe phenotype, typified by increased systemic iron 
absorption (and decreased storage), liver cirrhosis, small joint arthropathy and diabetes 
mellitus(145). 
 
1.3.1.3 Iron homeostasis and infection. 
 
Hypoferraemia is an ancient innate, anti-microbial defence mechanism, which is believed to be 
regulated by hepcidin. The pro-inflammatory cascade generated by infections results in the 
production of a host of cytokines, including IL-6. IL-6 acts on hepatocytes to stimulate hepcidin 
synthesis, and thereby limits circulating iron and produces a state of “functional iron deficiency”. If 
this hypoferraemia is maintained for a prolonged period it results in decreased erythropoiesis and 
the development of the “anaemia of chronic disease” (ACD).  
 
1.3.2. Clinical assessment of iron stores. 
 
Illness may result from either insufficient (iron deficiency anaemia) or excessive 
(haemochromatosis) total body iron, and accurate methods of determining iron stores are important 
clinically. The “gold standard” test of body iron stores is quantification of stainable iron on a 
trephine bone marrow biopsy, however this test is invasive, painful, and impractical for population 
screening. Consequently, bone marrow biopsy is restricted to individual cases where accurate 
assessment by non-invasive means has not been possible(147). As an alternative, assays have been 
developed to detect the presence of proteins involved in iron homeostasis in venous blood, which 
may be employed as surrogate markers of iron stores. 
 
Ferritin is the major human iron storage protein and although predominantly intracellular it may 
also be detected in peripheral blood. Transferrin is the major circulating, iron carrier protein in 
blood which may be measured, and the percentage of binding sites occupied by iron determined and 
expressed as transferrin saturation (TS). In health blood ferritin and TS mirror changes in whole 
body iron stores, being low in the iron deficient, and increasing with iron loading. However, with 
infection or systemic inflammation, hepcidin induced iron redistribution results in a fall in TS and 
This thesis we will examine whether mutations within the Haemochromatosis (HFE) gene serve 
as modifiers of CF phenotype 
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increase serum ferritin. Consequently, measuring ferritin and TS result in an over- or under-
estimation of iron stores respectively in the presence of systemic inflammation(148). 
 
Iron requiring cells express transferrin receptors (TfR) on their surface in proportion to their iron 
requirements. A proportion of these TfR are non-selectively cleaved from the surface of the cells 
and are detectable in blood as soluble transferrin receptors (STfR). The STfR concentration is 
proportional to the cellular “need” for iron and increases in response to iron deficiency. STfR 
concentration is unaffected by the acute phase response and has advocated for assessment of iron 
status in the presence of systemic inflammation(149). In the setting of chronic disease, 
differentiation between the anaemia of chronic disease and iron deficiency anaemia is challenging, 
and the two conditions may co-exist. Working with the premise that ferritin is the best indicator of 
whole body iron stores, and the STfR most reliably reflects functional iron requirements, the 
STfR/Log10ferritin ratio (STfR ratio) has been proposed and validated as a mechanism of detecting 
the presence of iron deficiency in situation where the ACD may be present(150-152). 
 
1.3.3 Lung iron homeostasis 
 
The combination of high oxygen concentration and appreciable amounts of catalytically active iron 
in atmospheric particulate matter provides the lung with unique challenges with regards to iron 
homeostasis(153). Airway cells must rapidly sequester and detoxify iron to prevent both damage 
from the generation of free radicals, as well withhold this key nutrient from invading pathogens. 
 
The lung employs similar iron homeostatic mechanism as the gastro-intestinal tract to detoxify the 
airways, although their regulatory mechanisms appear different(154). The iron binding protein 
lactoferrin is a member of the anti-microbial defensins produced by neutrophils and submucosal 
serous cells of the lungs. Lactoferrin is released into ASL in response to inflammation and iron 
loading, where it chelates unbound iron, and modulates the innate immune response by suppressing 
the generation of reactive oxygen species and binding microbial derived pro-inflammatory 
cytokines(155, 156). Iron laden lactoferrin binds to the lactoferrin receptor, which is in-turn 
internalised and delivers complexed iron to ferritin(157). Ferritin is present in high concentrations 
in airway epithelial cells, and may be exported to the airway surface liquid or plasma to prevent 
excessive accumulations within cells(154). Ferroportin and transferrin also contribute towards iron 
export from pulmonary epithelial cells(158). 
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AEC’s are also capable of divalent metal transporter (DMT)-1 receptor mediated uptake of unbound 
iron and increase DMT-1 expression in response to iron loading through increased transcription of 
an iron responsive element (IRE) negative isoform of the protein(159). DMT can only bind ferrous 
iron, consequently iron is first reduced by duodenal cytochrome-b (DYCTB) or O2
- (produced by 
anion exchange proteins, which facilitate electron-neutral exchange of Chloride and bicarbonate 
anions at the apical cell membrane)(160, 161). 
 
Finally AM’s contribute to iron detoxification in the lung through natural resistance-associated 
macrophage protein (NRAMP)-1 (analogous to DMT-1) mediated phagocytosis of iron containing 
particulate matter(162). 
 
1.3.3.1 Iron Homeostasis in pulmonary disease. 
 
There is an abundance of associational data to suggest that ineffective iron handling within the lung 
is associated with predisposition to a number of acute and chronic pulmonary diseases(157). 
 
Acute respiratory distress syndrome (ARDS) is typified by an intense parenchymal inflammatory 
reaction within the lungs in response to a pulmonary, or extra-pulmonary insult, and results in 
severe hypoxaemia. Increased serum ferritin and BALF iron content have each been associated with 
the risk of development, and severity of ARDS(163, 164). In addition polymorphisms in iron 
handling genes have been linked with an increased risk of developing ARDs in response to an 
appropriate insult(165). 
 
The risk of pulmonary Mycobacterium tuberculosis (MTB) has similarly linked with the increased 
dietary iron intake in endemic regions(166). In these studies, it has been proposed that iron overload 
within AM’s impairs mycobacterial killing. However, the co-existence of Human 
immunodeficiency virus infection (HIV) in many of the subjects included in these studies makes the 
results difficult to interpret. 
 
Defective iron handling has also been implicated in the pathology of toxin induced fibrotic lung 
diseases, pulmonary alveolar proteinosis, and lung transplant rejection(157). 
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1.3.4 Iron Homeostasis in CF 
 
1.3.4.1 Systemic iron stores in CF 
 
Anaemia occurs in up to 30% of subjects with CF, with true iron deficiency and the ACD being 
reported as common causes(167). Chronic inflammation, pulmonary haemorrhage and 
malabsorption occur commonly in CF, and through their impact on hepcidin release, can each effect 
iron homeostasis(168). 
 
Iron deficiency rates in excess of 60% have been reported in adult subjects with CF, however, as 
discussed previously accurate assessment in the setting of systemic inflammation is difficult, and 
rates of decreased total body iron stores are likely significantly less than this(169, 170). It is 
possible iron indices which are unaffected by inflammation may be of greater value in determining 
“true” iron deficiency(170). However, a recent study has suggested STfR is insensitive for the 
detection of iron deficiency in children with CF(171). 
 
Accurate assessment of iron stores is important for guiding the need for iron replacement therapy. 
In CF this is of particular relevance, as theoretical concerns exist that injudicious administration of 
iron supplements may override innate iron withholding mechanism and promote infection and 
inflammation(167, 172). 
 
In support of the hypothesis that iron handling may be important in CF, several authors have 
suggested mutations in the HFE gene may modulate CF phenotype(173-175). In two studies, 
performed in children with CF, a trend towards an increased risk of bowel obstruction was reported 
in subjects who carried a C282Y HFE mutation(173, 175). Furthermore, a single centre study, of a 
heterogeneous group of adults and children demonstrated lower absolute lung function values and 
increased rate of forced vital capacity (FVC) decline, as well as an increased risk of gastrointestinal 
complications and diabetes in subjects who carry a HFE gene mutation(174). 
 
1.3.4.2 Pulmonary iron homeostasis in CF 
 
Respiratory secretions and sputum from subjects with CF contain micromolar concentrations of 
iron, making this micronutrient more readily available to inhaled pathogens (airway iron indices 
from existing studies are presented in Table 1.5)(176-178). In this setting, iron content correlates 
53 
 
with the concentration of the iron regulatory cytokines Interleukin (IL)-1β and tumour necrosis 
factor alpha (TNF-α), which in turn stimulate ferritin and transferrin production(177). Furthermore, 
iron concentrations positively correlate with P. aeruginosa colony counts in the sputum of patients 
with CF confirming its importance in vivo(179). 
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Table 1-5 Studies reporting iron concentration in respiratory secretions from patients with Cystic fibrosis. 
Author Year Population Controls Substrate Assay Iron concentration 
Controls 
Iron concentration CF 
Gifford 
AH et al 
[160] 
2011 
 
Adults None Expectorated 
sputum 
Inductively 
coupled 
plasma mass 
spectrometry 
Not available Stable 
1.11 mg/ml (0.09-4.01)* 
Exacerbation  
2.22 mg/ml (0.77-7.04)* 
Reid 
DW et al 
[172] 
2007 Adult and 
Paediatric 
Healthy Expectorated 
sputum 
Colorimetric 0 µmol/Litre (0-15.8)* P. aeruginosa infection 
34 µmol/Litre (2.4-78)* 
No P. aeruginosa infection 
18 µmol/Litre (8-118)* 
 
Reid 
DW et al 
[170] 
2004 Adult Healthy Expectorated 
sputum 
Colorimetric  0 µmol/Litre (0-13.2)* Stable 
33.3 µmol/Litre (0-111.2)* 
Exacerbation  
44.4 µmol/Litre (17.0-128.7)* 
Stites S 
et al 
[169] 
1999 Adult Healthy non-
smokers 
BAL Colorimetric 0 µg/dl# 42 µg/dl (11.6)# 
Stites S 
et al 
[171] 
1998 Adult Non-smokers 
recent URTI 
Expectorated 
sputum 
Coulometry 0 ng/mg# 242 ng/mg (47)# 
CF: Cystic fibrosis, URTI: Upper respiratory tract infection, BAL: Bronchoalveolar lavage, µmol: Micromoles, µg: Micrograms, dl: decilitre, 
ng: nanograms, mg milligrams, * Median and range, # Mean and standard deviation. 
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In vitro studies have demonstrated DF508del CFTR mutant human AEC’s contain increased 
intra-cellular iron and “leak” excessive iron to their apical surface, which in turn promotes 
the growth of P. aeruginosa biofilms on the apical cell surface(180). Furthermore, patients 
frequently have frank blood in their sputum and sub-clinical bleeding into the airway is 
probably common(181). 
 
The combination of the in vitro and in vivo work support a hypothesis that iron handling in 
the CF lung is intrinsically defective and results in increased availability of bioactive iron in 
the lung, which may potentially “feed” chronic infection and promote oxidative damage of 
host tissues. 
 
1.3.5 Iron homeostasis in P. aeruginosa. 
 
P. aeruginosa is intrinsically reliant on iron for survival and 6% of its transcribed genes are 
iron-responsive(182). The concentration of bioavailable iron is a powerful regulator of P. 
aeruginosa behaviour, influencing inter-cellular communication and biofilm formation(182).  
 
P. aeruginosa may take up iron from either haem or non-haem iron sources (Figure 1.2). Two 
haem uptake systems have been described in P. aeruginosa (Phu and Has)(183). The Phu 
system relies on direct binding of haem or haem-containing proteins to a membrane bound 
receptor, whereas the Has system secretes a haem binding protein (HasAp) which is 
reabsorbed through the Has Receptor (HasR) when bound to haem(184, 185). The P. 
aeruginosa genome contains a third haem receptor encoding gene (hxuC), however, its 
functional regulation has yet to be characterised(186).  
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Figure 1-2 Pseudomonas aeruginosa iron acquisition pathways. 
 
Free or transferrin bound ferric (III) iron (blue spheres) binds to either P. aeruginosa specific 
(e.g. pyoverdine [green spheres]) or xeno-siderophores (purple spheres) and is taken up 
through siderophore specific channels. In anoxic lung regions, it is postulated that limited 
amounts of Ferrous (II) iron (red spheres) is present that can be taken up directly by binding 
to FeoB surface receptors. Finally direct uptake of haem (double grey spheres) may occur 
directly through Phu receptors, or by first being bound to HasAP before uptake via and Has 
receptors. 
---------------------------------------------------------- 
Haem is an uncommon iron source in the natural environment and P. aeruginosa must also be 
capable of scavenging non-haem iron, which in aerobic environments is present in the 
insoluble ferric (Fe3+) form. P. aeruginosa produces high affinity ferric-iron chelating 
siderophores(187). Siderophores are secreted by P. aeruginosa into the local environment to 
chelate free iron and “strip” iron from host iron binding proteins.  
 
Two distinct siderophores have been characterised in P. aeruginosa; pyoverdine and 
pyochelin. Over fifty distinct pyoverdine sub-types have been described and they are 
responsible for the distinctive yellow-green fluorescence of certain Pseudomonads(188). 
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Pyoverdines are the primary siderophore produced by P. aeruginosa, with one of three 
distinct sub-classes being produced by individual strains(189).  
 
Pyochelin is considered a secondary siderophore in P. aeruginosa having a much lower iron 
binding affinity than pyoverdine(186, 187). Pyochelin appears to have less influence on the 
biofilm forming capacity of P. aeruginosa than pyoverdine, and its importance for iron 
acquisition during clinical airway infections is unclear(187, 190). In addition to acquiring 
iron using autologous siderophores, P. aeruginosa has a high capacity to take up iron-laden 
siderophores produced by other bacteria and fungi(186). 
 
P. aeruginosa is naturally an aerobic bacterium, but it is highly capable of adaptating to 
survive in the low oxygen environment encountered within plugged CF airways. Within these 
regions of low oxygen tension and low pH there is potential for the redox status of Fe to 
change to the more “soluble” ferrous (Fe2+) form. Ferrous iron may be acquired by P. 
aeruginosa by passive diffusion or uptake through the FeoB receptor, although the role of 
these mechanisms in the clinical setting is unclear(191). 
 
P. aeruginosa iron acquisition systems are tight controlled by the ferric uptake regulator 
(Fur). Fur acts both directly, and indirectly through extra-cytoplasmic sigma factors 
(including PvdS) to limit iron absorption(192). Under iron-replete conditions, Fur binds 
ferrous iron and attaches to a consensus sequence (Fur-Box) in the promoter region of genes 
instrumental in iron acquisition thus suppressing their transcription(193). In the presence of 
iron, Fur inhibits “iron conservation” strategies by suppressing the production of two small 
RNA’s (PrrF1 and PrrF2)(194). In the absence of iron, these sRNA’s are synthesised and 
facilitate inhibition of genes which encode “non-essential” iron-containing proteins thereby 
maintaining the cytoplasmic iron pool for essential use(195). In low iron environments 
siderophore synthesis increases and non-essential iron consuming processes are down-
regulated. Several excellent comprehensive reviews of the iron acquisition systems employed 
by P. aeruginosa have recently been published(186, 187, 190, 192, 195), but the above 
overview highlights the central role of iron in P. aeruginosa biofilm development.  
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1.3.6 Targeting P. aeruginosa iron acquisition as novel therapeutic strategy   
 
The critical role of iron in P. aeruginosa survival and biofilm formation may represent a 
potential “Achilles Heel” in the defensive armamentarium of this fastidious pathogen. Thus 
considerable research endeavours on a variety of fronts are being undertaken to develop 
novel therapeutic strategies based on disruption of bacterial iron homeostasis. 
 
Proposed therapeutic strategies include: i) delivery of toxic amounts of iron to biofilm 
dwelling bacteria, ii) blocking iron dependent metabolic pathways with iron or siderophore 
mimetics, iii) use of high affinity iron chelators to “starve” bacteria of iron and iv) 
development of vaccine which target highly conserved iron uptake receptors(196). Research 
in each of these areas is currently at the stage of in vitro or early pre-clinical study stage. Iron 
targeted therapies are discussed in detail in the published review manuscript, which is 
included as part of this thesis submission (Appendix 1 - Targeting iron uptake to control 
Pseudomonas aeruginosa infections in cystic fibrosis). 
 
1.4 Thesis Aims and Objectives 
 
1.4.1 Background and Scope. 
 
Despite the high initial success of eradication regimens in delaying acquisition, the majority 
of CF subjects will eventually develop a chronic P. aeruginosa infection(116, 197-199). 
Establishment of P. aeruginosa infection is a sentinel event in the life of patients with CF and 
is associated with increased rates of pulmonary exacerbations, accelerated lung function 
decline, reduced quality of life and poorer survival(200, 201). The importance of P. 
aeruginosa is recognised in consensus statements for the treatment of pulmonary infection in 
CF(94, 127, 202). Furthermore, the emergence of shared (and likely transmissible) P. 
aeruginosa strains in many CF clinics, is likely add further complexity to the treatment and 
cohort segregation in the future(107). 
This thesis will examine the relationship between the concentration of iron and other bio-active 
metals in the airway secretions of patients with CF and the severity of airway inflammation and 
lung disease 
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The expansion of health information systems has allowed data to be collected and collated on 
large populations of patients and CF Data Registries are now available in many parts of the 
world(1, 3, 203, 204). Utilisation of data collected through registries has enabled between-
centre comparisons to identify variations in clinical outcomes between CF centres and has led 
to the establishment of quality improvement programs, including benchmarking of outcomes 
with “high-performing” centres(203-205). Studies based on large patient registries and 
databases have suggested more aggressive use of antibiotics to treat clinical deterioration 
results in better clinical outcomes for children and adults with CF(203, 206-208). A recent 
analysis of the CF Foundation Benchmarking Project, identified characteristics of CF centres 
(paediatric and adult) achieving outstanding clinical outcomes which included: a) strong 
leadership and a well-functioning care team working systematically to provide consistent 
care; b) high expectations for outcomes by the healthcare team and families; c) early and 
aggressive management of clinical deterioration and d) engaged and empowered 
patients/families who were well informed on CF management and its rationale(203). The 
high performing teams identified in this project had a low threshold for aggressive treatment 
of clinical decline, which resulted in high levels of use of antibiotics for pulmonary 
symptoms.  
 
However, to date, few studies have used national datasets to assess the variability and impact 
of antibiotic treatment strategies for P. aeruginosa in CF patients. The generation of 
antibiotic resistance in P. aeruginosa by aggressive antibiotic treatments runs the risk of 
adverse clinical outcomes later in the natural history of CF lung disease and paradoxically 
may contribute to persistence. Consequently, the first aim of this thesis was to utilise data 
from the ACPinCF study(107) and the Australian CF Data Registry (ACFDR) to examine 
differences in managing P. aeruginosa infection and determine the relationship between 
treatment intensity and antimicrobial resistance of P. aeruginosa in the Australian CF 
population.  
------------------------------ 
Established P. aeruginosa pulmonary infection cannot be cleared by currently available 
antibiotics and new therapies are required to tackle chronic infections. The development of 
new therapeutic strategies is reliant on a good understanding of the environmental, host and 
bacterial factors that may contribute towards the persistence of infection. 
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Traditional sputum microbiological techniques are capable of culturing only a limited number 
of the bacteria present in established bronchiectasis, and antibiotic susceptibility profiles 
generated by conventional single agent antibiotic testing, do not correlate with response to 
treatment(209, 210). In response, techniques to test the sensitivity of P. aeruginosa to 
combinations of antibiotics have been developed(78). However, again, this approach has had 
limited success, with similar clinical and bacteriological responses observed in patients 
receiving treatment based on single agent sensitivity testing results, compared to multiple 
combination bactericidal testing, in a randomised controlled trial(78, 211). 
 
The discrepancy between the results of in vitro susceptibility testing results and clinical 
response are probably attributable to factors not accounted for in currently used susceptibility 
testing strategies including: i) environmental factors present in the CF lung not replicated in 
vitro (e.g. pH, oxygen and nutrient availability), ii) mode of growth (e.g. planktonic versus 
biofilm) and iii) bacterial synergy in a polymicrobial infection. 
 
As pulmonary disease progresses, plugging of the distal airways by dehydrated sputum, 
creates micro-aerobic or frankly anaerobic pockets, with low pH and altered nutrient 
availability(212, 213). The highly abnormal environment within these regions drives 
phenotypic adaptation of bacteria. Furthermore, non-bacterial factors within this milieu may 
directly contribute towards local tissue destruction by generating reactive oxygen species and 
proteolytic enzymes(214). Bio-active trace metals (biometals) are essential co-factors in a 
wide range of human and bacterial enzyme systems, however, strict regulation of their 
bioavailability is essential to prevent toxicity(215). A limited number of previous studies in 
patients with CF, non-CF bronchiectasis and chronic bronchitis have demonstrated increased 
iron, zinc and copper concentrations in airway secretions, and have postulated that these 
metals may influence disease severity(179, 216). In vitro studies demonstrate that iron 
strongly influences the ability of P. aeruginosa to form biofilms and manipulation of iron 
availability has been proposed as a novel therapeutic strategy for the treatment of chronic P. 
aeruginosa infection(196, 217). An observational study by Gray and colleagues, 
demonstrated increased concentrations of zinc and copper in the CF lung(216), and in 
separate in vitro studies these metals have been shown to induce P. aeruginosa resistance to 
carbapenem antibiotics(218). The origin of airway metal ions has not been determined, with 
potential sources including vascular leak, channelopathies and release from necrotic airway 
cells, or the bacteria themselves.  
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Emerging, culture independent microbiological (metagenomic) techniques, aim to more 
completely characterise the microbiome of poly-microbial infections. These techniques are 
based on the amplification of highly conserved, bacterial-derived 16S rRNA from biological 
samples(209). Generated sequences reads are then compared to established bacterial DNA 
databases to allow bacterial identification(219). It is anticipated that the application of 
metagenomics to the study of the lung microbiome will provide novel information on how the 
microbiome responds to currently applied antibiotic regimens, and inform the development of 
more successful treatments in the future. 
 
The intrinsic susceptibility of the CF lung to infection, supports supposition that immune 
responses in CF are defective(25). At the level of the airway lumen, the cellular immune 
response is dominated by activated neutrophils. However, in contrast, airway epithelial 
biopsies demonstrate a profound T-cell infiltrate, supporting an important role for adaptive 
immune responses in the orchestration of a sustained inflammatory response(47). To date, 
studies of immune responses in CF have tended to concentrate on innate immune and 
neutrophil responses, and there has been less consideration of adaptive immune responses.  
 
Research into adaptive immune responses in CF have largely focused on the classic 
dichotomy of T-helper (Th)-1 and Th-2 responses(49). These early studies suggested a skew 
towards a Th-2 response in most CF subjects with P. aeruginosa infection, which resulted in 
increased pulmonary inflammation and disease progression(49-51). Subsequently, the 
identification of high levels of IL-17 in BALF, combined with the presence of large numbers 
of IL-17 positive T-cells in airways biopsy from people with CF, resulted in postulation that 
CF lung disease may be Th-17 mediated(55-58). Innate T-cells, are capable of providing an 
immediate response to infection and a number of lineages can also produce large quantities of 
IL-17(67, 71, 220). However, to date the role of innate T-cells in defending the CF lung from 
established infection have not been considered. 
 
Based upon the above observations, the next broad aim of this thesis was to determine 
bacterial and host factors that may influence pulmonary infection and response to 
antimicrobial therapy, with a specific focus on innate T-cell responses, iron and other 
biometal content of airways secretions, and how the whole lung microbiome responds to 
currently administered intravenous antibiotics. 
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------------------------------ 
The pulmonary phenotype is variable between individuals with similar CF genotypes. In part, 
this variability may reflect different environmental exposures and quality of clinical care 
provided, however, the influence of non-CFTR gene modifiers has also been postulated(18, 
25). Genes that encode immune mediators, anti-oxidants, ion transporters and pancreatic β-
cell function have each been implicated in modifying CF phenotype(18, 20, 22-24).  
 
Recognising the potential for iron to generate ROS in the airway and “feed” bacterial 
infection(139, 179), led to the hypothesis in this thesis that mutations in genes involved in 
iron homeostasis may influence CF phenotype(175). 
 
Mutations in the HFE gene increase the risk of excessive systemic iron absorption and result 
in abnormal iron handling at the cellular level(146, 221). Furthermore, earlier studies have 
suggested HFE mutations may result in a more severe CF phenotype, however, these studies 
have been either underpowered, or have been performed in heterogeneous groups of 
patients(173-175). 
 
Consequently the final broad aim of this thesis was to examine how iron handling and HFE 
genotype may modify the CF phenotype. 
 
1.4.2 Broad Research Aims 
 
The Research within this thesis was based on the overarching aims to: 
 
i) Determine the relationship between treatment practices in Australian CF centres and 
rates of P. aeruginosa antibiotic resistance. 
 
ii) Determine host and bacteria related factors which may influence pulmonary infection 
and response to anti-microbial therapy. 
 
iii) Determine the relationship between systemic and pulmonary iron homeostasis and CF 
lung disease. 
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1.4.3 Specific Research Aims 
 
The specific aims of the research within this thesis were to: 
 
i) Investigate the relationship between treatment intensity and the antimicrobial 
resistance of P. aeruginosa in the Australian CF population. 
 
ii) Determine the relationship between shared P. aeruginosa strains and antimicrobial 
resistance and treatment intensity in the Australian CF population. 
 
iii) Explore the effects of intravenous antibiotics, administered to treat an infective 
pulmonary exacerbation, on the CF lung microbiome. 
 
iv) Determine whether the lymphocyte sub-sets are different in subjects with CF 
compared to healthy controls. 
 
v) Determine the association between lymphocyte sub-sets and disease phenotype in 
subjects with CF. 
 
vi) Explore the bio-active metal composition of airway secretions in health and CF 
airways disease. 
 
vii) Examine the association between airway bio-active metals, airway inflammation and 
outcomes in CF. 
 
viii) Explore whether mutations in the HFE gene have a modifying effect on CF phenotype 
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Chapter 2. Trends in P. aeruginosa antibiotic resistance in Australian CF centres. 
 
2.1 Abstract 
 
Introduction: In cystic fibrosis (CF), chronic Pseudomonas aeruginosa infection is 
associated with increased morbidity, antibiotic treatments and mortality. By linking 
Australian CF registry data with a national microbiological dataset we examined the 
association between treatment intensity and P. aeruginosa antibiotic resistance. 
 
Methods: Sputa were collected from paediatric and adult CF patients from 18 Australian CF 
centres. P. aeruginosa antibiotic susceptibilities determined by local laboratories were 
correlated with clinical characteristics, treatment intensity and infection with strains 
commonly shared amongst Australian CF patients. Between-centre differences in treatment 
and antibiotic resistance were compared. 
 
Results: Large variations in antibiotic usage, maintenance treatment practices and multi-
antibiotic resistant P. aeruginosa (MARPA) prevalence exist between Australian CF centres, 
although overall proportions of MARPA isolates were similar in paediatric and adult centres 
(31% versus 35%, p=0.29). Among large paediatric centres MARPA correlated with 
intravenous antibiotic usage and centre, while inhaled antibiotics, reduced lung function and 
centre predicted intravenous antibiotic usage. In large adult centres, body-mass index and 
centre correlated with MARPA, while intravenous antibiotic use was predicted by gender, 
centre, inhaled antibiotics and lung function. P. aeruginosa strains AUST-01 and AUST-02 
independently predicted intravenous antibiotic usage and MARPA. 
 
Conclusion: Increased treatment intensity in paediatric centres is associated with greater risk 
of MARPA, but not worse clinical outcomes in adults or children. Innovative approaches to 
chronic P. aeruginosa infection are needed to optimise the benefits of early and aggressive 
therapy, while minimising treatment-related morbidity. 
 
 
 
 
 65 
 
2.2 Introduction 
 
In cystic fibrosis (CF) chronic Pseudomonas aeruginosa infection is associated with 
accelerated pulmonary decline, reduced quality of life, increased treatment burden and poorer 
survival.(200, 222) CF consensus statements therefore emphasise the importance of managing P. 
aeruginosa pulmonary infections.(127, 202) However, commonly shared and multi-antibiotic 
resistant P. aeruginosa (MARPA) strains emerging in CF centres worldwide add further 
complexity to patient management and infection control policies.(223)  
 
Utilising data collected by national CF data registries allows between-centre comparisons and 
quality improvement programs to benchmark against “high-performing” centres.(203-205) 
However, few studies have assessed P. aeruginosa treatment strategies using national 
datasets. Here, data from the Australian Clonal Pseudomonas aeruginosa in CF (ACPinCF) 
study(107) and the Australian CF Data Registry (ACFDR) were linked to examine differences 
in managing P. aeruginosa infection. The aim was to explore in the Australian CF population 
the association between treatment intensity and P. aeruginosa antibiotic resistance.  
 
2.3 Methods 
 
2.3.1 Patients, data and sample collection  
 
The ACPinCF study involved 18 Australian CF centres and is described in detail 
elsewhere.(107) Briefly, it examined the point prevalence, diversity and clinical impact of P. 
aeruginosa strains in Australian CF clinics, and included 2,677 patients (1,300 aged ≥18-
years; centre size: 25-294), representing 91%, 89% and 90% of the paediatric, adult and total 
Australian CF population respectively.(224)  
 
Human Ethics Committees of all participating institutions approved the study. Participants 
provided written, informed consent, which for children included parents or legal guardians.   
 
Each patient provided a single sputum specimen either during a routine clinic visit or during 
hospitalisation between September 2007 and June 2010. Age, gender, inhaled maintenance 
therapies (tobramycin, colistin, dornase-alpha and hypertonic saline) and oral azithromycin in 
the previous 30-days; and number of courses and total days of intravenous antibiotics, and 
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out-patient clinic visits during the previous 12-months were recorded. The best forced 
expiratory volume in one-second (FEV1) in the calendar year of sample collection (and 
forced vital capacity [FVC] and body-mass index [BMI] from the same day) reported to the 
ACFDR were also recorded. In children, age-adjusted pulmonary function prediction 
equations(225, 226) and standard deviation (SD) z-scores for BMI were utilised.(227) 
 
2.3.2 Laboratory testing  
 
Sputum culture and antibiotic susceptibility testing were performed routinely by hospital 
laboratories. Six centres performed sensitivity testing on a “mixed” colony sweep of culture 
plates, while in the remaining 12 individual “pure” colonies were selected for testing.(228) 
Disk diffusion sensitivity testing was applied by all centres, 12 used Clinical and Laboratory 
Standards Institute (CLSI) guidelines, five the Continuous Dichotomous Susceptibility (CDS) 
test, and one applied European Committee on Antimicrobial Sensitivity Testing (EUCAST) 
methods and breakpoints(229-231) (Table 2.1). Three P. aeruginosa colonies representing 
different morphotypes from each specimen were selected locally and transported to the 
research laboratory to confirm their identity(232) and for enterobacterial repetitive intergenic 
consensus polymerase chain reaction (ERIC-PCR) genotype testing.(107) 
 
MARPA isolates were defined as being resistant to all antibiotics tested in two or more 
classes of anti-pseudomonal agents (β-lactam, fluoroquinolone and aminoglycoside 
antibiotics).(233) Where antibiograms for multiple isolates from the same sample existed 
(398/934 samples), the most resistant isolate was used. If an isolate’s susceptibility to an 
antibiotic class was not tested, it was excluded from analysis of resistance to that antibiotic 
class, and if not already identified as a MARPA, from this category too. Thus, 19 isolates 
were excluded from the MARPA analysis because of lacking data for aminoglycoside (n=1), 
β-lactam (n=2) and fluoroquinolone (n=21) susceptibilities. 
 
2.3.3 Shared P. aeruginosa strains  
 
Shared P. aeruginosa strains had indistinguishable ERIC-PCR gel patterns from sputum 
isolates cultured from at least two patients as described previously.(107) To explore their 
influence on antibiotic resistance, differences between patients infected with the two most 
prevalent Australian shared strains (AUST-01 and AUST-02) and those with unique strains 
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were examined. To increase the likelihood that antibiotic susceptibility profiles from local 
laboratories reflected strains genotyped by the reference laboratory, this analysis was limited 
to patients with the same ERIC-PCR genotype for each of the three isolates typed. 
 
2.3.4 Between-centre comparisons  
 
Between-centre differences in treatment and outcome were conducted by selecting the largest 
paediatric and adult centre in each state. This helped minimise data skewing from small 
centre effects. Each of the analysed States is identified by the letter, A-to-F, with the suffix 
(p) or (a) denoting paediatric and adult centres respectively. 
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Table 2-1 Site specific antibiotic susceptibility testing methods and % of samples tested against individual agents. 
 Percentage of Isolates tested against each antibiotic 
Site Technique Strain 
Selection 
Reference 
Range 
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A(p1) Disk Mixed CLSI 100 91 90 93 0 100 9 0 23 77 0 79 28 
A(a2) Disk Pure CLSI 100 97 99 99 3.5 100 96 1 99 97 0 97 99 
A(p3) Disk Mixed CLSI 100 100 100 100 0 100 0 0 0 100 0 100 0 
A(a4) Disk Mixed CLSI 100 100 100 100 0 94 0 0 0 97 0 100 0 
A(a5) Disk Pure CLSI 100 100 100 100 100 100 87 40 100 100 0 100 93 
A(p6) Disk Mixed CLSI 100 100 100 100 100 100 75 50 100 100 0 100 100 
B(p1) Disk Pure CDS 100 100 94 94 83 100 100 6 0 83 83 89 0 
B(a2) Disk Pure CLSI 100 0 100 0 100 100 0 0 0 100 0 100 0 
B(p3) Disk Mixed CDS 100 100 100 100 100 100 0 3 100 100 100 100 0 
B(a4) Disk Pure CDS 100 90 90 85 80 100 85 0 45 85 5 100 5 
B(p5) Disk Pure CDS 100 39 39 23 39 100 31 0 8 23 0 100 0 
C(p1) Disk Mixed CLSI 100 100 100 100 100 100 100 100 97 100 0 100 0 
C(a2) Disk Pure EUCAST 1 99 1 98 0 98 0 1 1 98 0 98 1 
C(a3) Disk Pure CLSI 100 100 100 100 100 100 100 100 0 100 0 100 96 
D(a1) Disk Pure CLSI 100 100 100 100 0 0 100 0 0 100 0 100 0 
D(p2) Disk Pure CLSI 100 100 0 100 0 0 100 0 100 100 0 100 100 
E(a1) Disk Pure CLSI 100 99 98 0 99 100 0 99 99 99 0 100 98 
F(a1) Disk Pure CDS 100 58 58 100 0 100 0 0 84 0 58 100 0 
Disk: Disk diffusion sensitivity testing, Pure: Isolate selected from the plate for sensitivity testing, Mixed: Sweep taken from the plate for 
sensitivity testing, CDS: Continuous Dichotomous Susceptibility. CLSI: Clinical and Laboratory Standards Institute; EUCAST: European 
Committee on Antimicrobial Sensitivity Testing; Site A(a/pX): Denotes a treatment centre in State A-F (adult/paediatric)
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2.3.5 Statistical Analysis  
 
Data analysis was performed using PASW, Version 18.0 (SPSS Inc. Chicago, IL, USA). 
Between-group differences of continuous variables were analysed by t-tests, analysis of 
covariance, Mann-Whitney or Kruskal-Wallis tests according to the normality of the data 
distribution. Correlations were examined by Spearman’s Rho and categorical variables by 
Chi-squared tests. Multi-logistic and linear-regression analyses were performed to identify 
independent predictors of MARPA and intravenous antibiotic usage in the previous 12-
months respectively. To determine the impact of shared strains, regression models were re-
run on a sub-group of 574 subjects harbouring either AUST-01, AUST-02 or a unique   P. 
aeruginosa strain, with the variable P. aeruginosa strain type incorporated. State A 
(coordinating State for ACPinCF) acted as the reference state in all models. A P-value <0.05 
was considered statistically significant.   
 
2.4 Results 
 
Antibiotic resistance data were available for at least one isolate from 934/983 (95%) patients 
(228 children) culturing P. aeruginosa from their sputum. Forty-eight percent of patients 
were F508del homozygotes, 32% F508del heterozygotes, 3% had other mutations and 17% 
had unknown CF genotypes. The clinical characteristics and isolate antibiotic resistance 
profiles of subjects treated in the major paediatric and adult centre in each state are 
summarised in Tables 2.2A and 2.3A and for all treatment centres included in the study, in 
Tables 2.2B and 2.3B. 
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Table 2-2 Comparison of clinical characteristics, treatment burden and Pseudomonas aeruginosa resistance profiles of patients 
attending each Australian paediatric centres included in the study. 
Part A. The major paediatric treatment centre in each state.  
 Whole Cohort 
(n=228) 
State-A(p1) 
(n=57) 
State-B(p3) 
 (n=31) 
State-C(p1) 
 (n= 62) 
State-D(p2) 
(n=23) 
P-value‡ 
Age 14     (11-17) 14     (12-16) 13     (12-15) 14     (9-17) 17     (15-19)   0.001 
Males, number (%) 114   (50) 25     (44) 15     (48) 34     (55) 16     (70)   0.19 
FEV1 % predicted* 74     (55-88) 79     (55-90) 70     (60-81) 68     (53-87) 73     (46-87)   0.75 
FVC % predicted* 88     (70-98) 89     (68-100) 87     (77-98) 87     (68-97) 88     (71-96)   0.93 
BMI z-score* -0.35 (-0.96 – 0.23) -0.16 (-0.75-0.35) -0.72 (-1.1- -0.16) -0.32 (-1.00-0.36) -0.02 (-1.32-0.28)   0.06 
       
No. of outpatient visits* 6       (4-8) 7        (4-9) 5        (2-7) 6        (4-7) 7        (5-7)    0.13 
No. of IV antibiotic courses*  1       (0-3) 1        (0-3) 1        (0-2) 1        (0-2) 3        (1-4)   0.001 
No of IV antibiotic days* 14     (0-35) 15      (0-37) 14      (0-23) 10      (0-23) 55      (19-81) <0.001 
       
% Inhaled antibiotic†  46  35 65 54 67  <0.05 
% Dornase alpha†  56 63 65 46 81  <0.05 
% HTS†  29 39 13 9 77  <0.001 
%Azithromycin† 54 67 36 37 73  <0.01 
       
Antibiotic susceptibility testing methodology - CLSI CDS CLSI CLSI  
P. aeruginosa antibiotic resistance, %       
- Aminoglycosides  43 56 32 24 74  <0.001 
- β-lactam agents 21 30 7 5 61  <0.001 
- Fluoroquinolones§ 30 49 26 16 39    0.002 
- MARPA¶ 31 55 16 10 65  <0.001 
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Part B. Other paediatric treatment centres included in the study 
 State A(p3) State A(p6) State B(p1) State B(p5) 
Participants, n (% of total clinic population) 20 (20) 4 (16) 18 (12) 13 (20) 
Age 14 (11-16) 12 (6-17) 15 (11-16) 14 (11-17) 
Males, number (%) 8 (40) 1 (25) 10 (56) 5   (39) 
FEV1 % predicted*  66 (53-93) 74 (18-N/A) 75 (63-87)  74 (55-99) 
FVC % predicted*  83 (64-99)  79 (16-N/A)  92 (80-103) 76 (56-99)  
BMI z-score*  -0.36  
(-0.52- -0.36)  
-0.62  
(-1.09- -0.42) 
 -0.56  
(-0.75- -0.22)  
-0.62  
(-1.58-0.53)  
     
No. of outpatient visits* 7 (4-10) 2 (2-3) 6 (5-9) 2 (0-6) 
No. of IV antibiotic courses*  2 (1-4) 2 (0-7) 1 (0-2) 0 (0-0) 
No of IV antibiotic days* 28 (14-58) 33 (0-106) 5 (0-26) 0 (0-0) 
% Inhaled antibiotic†  15 25 67 8 
% Dornase alpha† 35 75 50 46 
% HTS† 25 0 22 54 
% Azithromycin† 45 75 89 39 
     
Antibiotic susceptibility testing methodology CLSI CLSI CDS CDS 
P. aeruginosa antibiotic resistance, %     
- Aminoglycosides  50 75 39 39 
- β-lactam agents 30 50 11 8 
- Fluoroquinolones‡ 45 50 31 0 
- MARPA§ 35 75 25 8 
Due to the skewed distributions of the data the differences between continuous variables were examined by the Kruskal-Wallis test and reported as medians and inter-quartile 
ranges. Differences between categorical variables were examined by chi-squared tests.*In the 12-months prior to sample collection, for FEV1% predicted this was the best 
value recorded for this period and the FVC and BMI recorded on that day; †in the      30-days prior to sample collection. N/A: Not available, FEV1: Forced expiratory volume 
in 1 second, FVC: forced vital capacity, BMI: body-mass index, HTS: hypertonic saline, MARPA: multi-antibiotic resistant P. aeruginosa. Antibiotic susceptibility testing 
data unavailable on ‡14 samples and §12 samples. Site A(pX): denotes a paediatric treatment centre in State A. CDS: Continuous Dichotomous Susceptibility. CLSI: Clinical 
and Laboratory Standards Institute, EUCAST: European Committee on Antimicrobial Sensitivity Testing. 
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Table 2-3 Comparison of clinical characteristics, treatment burden and Pseudomonas aeruginosa resistance profiles of patients 
attending each Australian adult centres included in the study. 
Part A. The major adult treatment centre in each state.  
 Whole Cohort 
(n=706) 
State-A(a2) 
(n=171) 
State-B(a2) 
(n=108) 
State-C(a3) 
(n=124) 
State-D(a1) 
(n=72) 
State-E(a1) 
(n=92) 
State-F(a1) 
(n=18) 
P-value‡ 
Age 27 (22-33) 26 (22-33) 27 (23-35) 29 (24-38) 27 (23-32) 27 (23-35) 27 (23-35) 0.013 
Males, number (%) 409 (58) 101 (59) 63 (58) 70 (57) 49 (68) 48 (52) 12 (67) 0.42 
FEV1 % predicted* 53 (38-69) 51 (36-68) 59 (41-74) 47 (34-63) 57 (37-78) 49 (36-64) 49 (36-64) 0.026 
FVC % predicted* 73 (58-86) 73 (55-87) 76 (61-94) 68 (57-83) 75 (60-91) 65 (52-77) 65 (52-77) <0.001 
BMI* 21 (19-24) 21 (19-25) 22 (20-25) 21 (20-24) 22 (20-23) 22 (19-25) 22 (19-25) 0.26 
         
No. of outpatient visits* 5    (3-9) 7    (4-10) 3    (1-6) 6    (5-10) 3    (1-5) 6    (2-11) 8    (4-12) <0.001 
No. of IV antibiotic courses*  1    (0-2) 1    (0-3) 0    (0-1) 2    (1-3) 1    (0-3) 1    (0-2) 1    (0-2) <0.001 
No of IV antibiotic days* 14  (0-32) 15  (0-36) 0    (0-14) 21  (7-34) 14  (0-38) 14  (0-32) 7    (0-22) <0.001 
         
% Inhaled antibiotic†  48 23 65 65 38 52 70 <0.001 
% Dornase alpha† 50 36 47 62 61 44 94 <0.001 
% HTS† 32 29 38 44 33 27 53 <0.05 
% Azithromycin† 65 47 84 72 52 55 59 <0.001 
         
Antibiotic susceptibility testing methodology - CLSI CLSI CLSI CLSI CLSI CDS  
P. aeruginosa antibiotic resistance, %         
- Aminoglycosides§ 53 42 62 68 60 45 53 <0.001 
- β-lactam agents¶ 16 18 18 14 6 10 5 0.08 
- Fluoroquinolones¥ 46 27 37 79 35 37 68 <0.001 
- MARPA¥ 35 22 38 62 21 24 44 <0.001 
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Part B. Other adult treatment centres included in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the skewed distributions of the data the differences between continuous variables were examined by the Kruskal-Wallis test and reported as medians and inter-quartile 
ranges. Differences between categorical variables were examined by chi-squared tests. *In the 12-months prior to sample collection, for FEV1% predicted this was the best 
value recorded for this period and the FVC and BMI recorded on that day; †in the 30-days prior to sample collection. FEV1: forced expiratory volume in 1 second, FVC: 
forced vital capacity, BMI: body-mass index, HTS: hypertonic saline, MARPA: multi-antibiotic resistant P. aeruginosa. Antibiotic susceptibility testing data unavailable on 
‡one, §two and ¶seven samples. State A(aX): denotes an adult treatment centre in State A. CDS: Continuous Dichotomous Susceptibility. CLSI: Clinical and Laboratory 
Standards Institute, EUCAST: European Committee on Antimicrobial Sensitivity Testing. 
 State A(a4) State A(a5) State B(a4) State C(a3) 
Participants, n (% of total clinic population) 36 (64) 15 (30) 20 (35) 50 (29) 
Age 25 (21-32) 25 (18-28) 24 (21-28) 23 (18-28) 
Males, number (%) 21 (58) 8   (53) 11 (55) 26 (52) 
FEV1 % predicted* 46 (37-64) 51 (37-83) 54 (42-87) 62 (49-81) 
FVC % predicted* 66 (53-74) 79 (50-94) 72 (60-87) 78 (66-90) 
BMI* 21 (20-24) 19 (17-21) 22 (20-24) 21 (19-24) 
     
No. of outpatient visits* 4 (3-6) 4 (3-9) 9 (4-12) 4 (2-6) 
No. of IV antibiotic courses*  1 (0-3) 3 (0-4) 1 (0-2) 1 (0-3) 
No of IV antibiotic days* 13 (0-28) 64 (0-85) 14 (0-21) 15 (0-43) 
     
% Inhaled antibiotic†  72 40 15 50 
% Dornase alpha†  39 73 55 56 
% HTS† 19 13 5 26 
% Azithromycin† 92 80 80 72 
     
Antibiotic susceptibility testing methodology CLSI CLSI CDS CLSI 
P. aeruginosa antibiotic resistance, %     
- Aminoglycosides‡ 39 73 65 42 
- β-lactam agents§ 40 40 20 18 
- Fluoroquinolones¶ 58 47 40 64 
- MARPA¶ 36 40 50 38 
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2.4.1 Paediatric centres  
 
Eight paediatric centres (4-61 patients) from four states provided samples. Of patients 
culturing P. aeruginosa, 31% had MARPA isolates, with 43%, 21% and 30% of all isolates 
showing resistance to aminoglycoside, β-lactam and fluoroquinolone antibiotics respectively 
(Table 2.2). MARPA and resistance to β-lactam and fluoroquinolone antibiotics correlated 
with increased number of intravenous antibiotic days and outpatient visits in the preceding 
year (Table 2.4). 
 
Comparing the largest centres in each state (Table 2.2A) showed similar patient 
characteristics, except for higher patient ages in State-D (p) and lower BMI z-scores in State-
B (p). Large differences in intravenous antibiotic use, maintenance therapies and antibiotic 
resistance rates existed between states. Logistic regression demonstrated intravenous 
antibiotic usage and state were each independently associated with MARPA, while linear 
regression found recent inhaled antibiotic use, reduced FEV1% predicted and state were 
associated independently with intravenous antibiotic usage (Tables 2.5 and 2.6). 
 
2.4.2 Adult centres  
 
Ten adult centres (15-171 patients) from six states participated. Of those harbouring P. 
aeruginosa, 35% had MARPA, with 53%, 16% and 46% showing resistance to 
aminoglycoside, β-lactam and fluoroquinolone antibiotics respectively (Table 2.3). In 
contrast with paediatric centres, the number of intravenous antibiotic courses and days did not 
correlate with antibiotic resistance. However, a weak correlation existed between number of 
outpatient visits, maintenance therapies (mucolytics and azithromycin) and MARPA isolates 
(Table 2.4).  
 
Comparisons between the major centres demonstrated greater heterogeneity across clinical 
parameters than seen in paediatric centres. Similarly, there were significant differences in 
intravenous antibiotic and maintenance treatment usage, and rates of antibiotic resistance 
between adult centres (Table 2.3A). Treatment centre and BMI were independent 
determinants of MARPA. However, no relationship was found between MARPA and 
intravenous antibiotic administration in the previous 12-months. Being female, receiving 
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inhaled antibiotics, reduced FEV1% predicted and state were independently associated with 
intravenous antibiotic usage (Table 2.5 and 2.6).  
 
2.4.3 Shared P. aeruginosa strains  
 
Of the 934 patients, 574 (61%) had the same unique (289), AUST-01 (160) or AUST-02 
(125) genotype for each of their three isolates typed. Rates of AUST-01 (19%) and  AUST-02 
(14%) were significantly higher in adult than paediatric centres (9% and 8% respectively). 
Clinical parameters between the three groups were similar, however, compared to patients 
with unique isolates, AUST-01 and AUST-02 infected patients were more likely to have 
MARPA, β-lactam or aminoglycoside resistant isolates. Moreover, AUST-01 isolates had 
higher fluoroquinolone resistance rates (Table 2.7). Infection with a shared strain was an 
independent predictor of both increased intravenous antibiotic usage and MARPA (Tables 2.8 
and 2.9). 
 
2.4.4 Testing Methodology and MARPA  
 
Overall, 743 (79.6%) sputum samples were collected during out-patient visits. Within each 
state MARPA prevalence did not differ significantly between inpatient and outpatient 
samples (Table 2.10) or between mixed and pure isolate selection techniques (30.4% versus 
35.4% respectively, P=0.16). Although samples analysed using CDS or CLSI breakpoints 
provided similar MARPA rates (28.6% versus 30.1%, p=0.76), these were significantly 
higher (62.3%) in the single centre (C(a)2) employing EUCAST breakpoint values (Table 
2.11). 
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Table 2-4 Correlation co-efficients of treatment burden with antibiotic resistance in all participating Australian paediatric and adult 
centres. 
 
 
Spearmans Rho, Correlation significant at the *0.05 or †0.01 level (2-tailed). Paediatric centres (grey triangles), adult centres (white triangles).  
IV: intravenous; HTS: hypertonic saline. 
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Table 2-5 Factors associated with MARPA by logistic regression analysis between 
major treatment centres. 
 Paediatric Centres  
(States = 4, n=150) 
Adult Centres  
(States = 6, n=572) 
Variable Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Univariate     
Age 1.08 (1.00-1.18)   0.049 1.01 (0.99-1.03)     0.26 
Female gender  0.97 (0.50-1.90)     0.94 1.00 (0.71-1.42)     0.98 
FEV1% predicted*  0.35 (0.07-1.72) 0.20 0.55 (0.22-1.17)     0.11 
BMI† 1.20 (0.83-1.74) 0.32  0.94 (0.90-0.99)      0.014 
Inhaled antibiotic‡  0.50 (0.24-1.01)  0.05   1.37 (0.97-1.95)      0.08  
Dornase alpha‡  2.09 (1.00-4.36)    0.049  1.51 (1.07-2.13)      0.020  
HTS‡ 2.86 (1.38-5.95)    0.005 1.71 (1.19-2.44)     0.003 
Azithromycin‡  1.83 (0.92-3.66) 0.08  1.49 (1.06-2.14)     0.032 
No. of IV antibiotic days§ 1.02 (1.01-1.03)   0.001 1.00 (0.99-1.01)     0.53 
     
States  A      1.00 (ref)       1.00 (ref)  
            B 0.17 (0.06-0.52)   0.002  2.21 (1.29-3.78)     0.004 
            C  0.09 (0.03-0.26) <0.001    5.97 (3.55-10.03)   <0.001 
            D   1.64 (0.58-4.64)   0.350  0.95 (0.48-1.87)     0.88 
            E -   1.14 (0.62-2.08)     0.68 
            F   -   3.25 (1.23-8.60)     0.018 
     
Multivariate     
BMI ¶  0.93 (0.88-0.99)   0.018 
Inhaled antibiotic 0.45 (0.18-1.13)   0.088 ¶  
No. of IV antibiotic days 1.02 (1.00-1.03)   0.021 ¶  
     
State   A      1.00 (ref)       1.00 (ref)  
           B   0.24 (0.08-0.80)   0.020      2.36 (1.37-4.07)   0.002 
           C   0.14 (0.05-0.41) <0.001   6.12 (3.62-10.37) <0.001 
           D   1.14 (0.35-3.70)   0.832 0.99 (0.50-1.96)   0.970 
           E   -  1.24 (0.67-2.28)   0.497 
           F   -  2.68 (0.93-7.72)   0.068 
     
 
BMI: body-mass index, FEV1: forced expiratory volume percentage, HTS: hypertonic saline, 
IV: intravenous. *Best FEV1 recorded in prior 12-months, †z-scores used for paediatric data, 
‡in the 30-days prior to sample collection, §in the 12-months prior to sample collection, ¶non-
significant in univariate analysis and not carried forward to multivariate analysis. 
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Table 2-6 Factors associated with intravenous antibiotic usage by linear regression 
analysis among subjects treated in a major treatment centre. 
 
 
BMI: body-mass index, FEV1%: forced expiratory volume percentage, HTS: hypertonic 
saline, *Best FEV1 recorded in prior 12-months, †z-scores used for paediatric data, 
‡in the    
30-days prior to sample collection, §non-significant in univariate analysis and not carried 
forward to multivariate analysis. 
 
 
 
 
 
 Paediatric Centres 
(States = 4, n=150) 
Adult Centres 
(States = 6, n=572) 
Variable  (95% CI) P-value  (95% CI) P-value 
Univariate     
Age   1.42   (0.23-2.61)     0.020   0.01    (-0.26-0.27)  0.95  
Female gender  5.65   (-5.23-16.52)     0.31   12.67  (8.01 – 17.33) <0.001 
FEV1% predicted* -83.87 (-106.24- -61.50)  <0.001  -48.16  (-58.84 - -37.49)  <0.001 
BMI† -7.77   (-13.54- -1.99)    0.009 -1.84    (-2.49 - -1.18)  <0.001 
Inhaled antibiotic‡   17.87 (6.83-28.91)    0.002  5.44    (0.60-10.27)  0.028 
Dornase alpha‡  10.46 (-0.71-21.63)            0.07 10.08  (5.44-14.71) <0.001 
HTS‡   27.79 (16.07-39.50) <0.001  7.53    (2.60-12.45)  0.003 
Azithromycin‡   28.91 (18.64-39.19)  <0.001  11.46  (6.67-16.24)    <0.001 
     
States  A    1.00   (ref)   1.00    (ref)  
            B   -9.47   (-24.40-5.46)  0.21 -16.93  (-23.76 - -10.10) <0.001 
            C  -10.63  (-23.24-1.99)  0.10   0.43   (-6.14 – 7.00)  0.90 
            D     28.64  (12.25-45.04)   0.001   0.28   (-7.54 – 8.10)  0.94 
            E -  -4.59    (-11.76 – 2.57)  0.21 
            F   -  -10.77  (-24.81 – 3.26)  0.13 
     
Multivariate     
Female gender §   10.24   ( 5.63 – 14.86) <0.001 
BMI §  -0.60     (-1.28 – 0.07) 0.08 
Inhaled antibiotic  10.63  (0.60-20.67)   0.038  5.79     (1.03 – 10.54)   0.017 
FEV1% predicted -78.99  (-100.11- -57.87) <0.001 -39.56   (-50.85- -28.28) <0.001 
     
State   A  1.00    (ref)   1.00     (ref)  
           B   -15.19  (-28.52- -1.87)   0.026 -17.07   (-23.75- -10.39) <0.001 
           C   -15.62  (-27.43- -3.81)   0.010 -3.60     (-10.01 – 2.81)  0.27 
           D    26.49  (11.41-41.56)   0.001 3.08      (-5.43 – 11.59)  0.48 
           E   -  -7.34     (-14.15- -0.53)   0.04 
           F   -  -12.13   (-25.77-1.51)   0.08 
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Table 2-7 Comparison of patient demographics and antibiotic resistance in patients 
with unique, AUST-01 and AUST-02 P. aeruginosa strain infection. 
 Unique 
(n=289) 
AUST-01 
(n=160) 
AUST-02 
(n=125) 
Age 24  (16-33) 24  (20-28) 25  (20-28) 
FEV1 % predicted* 60  (43-76) 54  (42-68) 56  (37-74) 
FVC % predicted* 76  (60-92) 73  (62-87) 74  (55-88) 
BMI* 21  (18-23) 21  (19-23) 20  (19-23) 
    
P. aeruginosa antibiotic resistance, %    
- Aminoglycosides 39 60§ 52† 
- β-lactam agents 13 22‡ 22† 
- Fluoroquinolones 39 51† 40 
- MARPA¶ 27 43§ 37† 
 
Due to the skewed distributions of the data the differences between continuous variables were 
examined by Kruskal-Wallis test and reported as median and inter-quartile range, and 2x2 
tables and chi-squared tests were used to compare dichotomous variables for AUST-01 and 
AUST-02 to unique strains. *For FEV1% predicted this was the best value recorded for the 
12-months prior to sample collection and the FVC and BMI recorded on that day. †P<0.05, 
‡P<0.01, §P<0.001. FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, 
BMI: body-mass index, MARPA: multi-antibiotic resistant P. aeruginosa. ¶Antibiotic 
susceptibility testing unavailable on 14 samples. 
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Table 2-8 Factors associated with MARPA by logistic regression analysis among 
subjects infected with unique, AUST-01 or AUST0-2 treated in a major treatment 
centre. 
 Paediatric Centres  
(States = 4, n=100) 
Adult Centres  
(States= 6, n=353)  
Variable Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Univariate     
Age 1.08 (1.00-1.18)  0.049 1.01 (0.99-1.03) 0.26 
Female gender  0.97 (0.50-1.90)     0.94 1.00 (0.71-1.42)  0.98 
FEV1% predicted*  0.35 (0.07-1.72)     0.20 0.55 (0.22-1.17)  0.11    
BMI† 1.20 (0.83-1.74) 0.32  0.94 (0.90-0.99)    0.014 
Inhaled antibiotic‡ 0.50 (0.24-1.01)  0.052   1.37 (0.97-1.95)     0.08  
Dornase alpha‡  2.09 (1.00-4.36)  0.049      1.51 (1.07 – 2.13)     0.020    
HTS‡ 2.86 (1.38-5.95)  0.005 1.71 (1.19-2.44)      0.003 
Azithromycin‡   1.83 (0.92-3.66) 0.08 1.49 (1.06-2.14)      0.032   
No. of IV antibiotic days§ 1.02 (1.01-1.03)   0.001 1.00 (0.99-1.01)    0.53 
      
Unique P. aeruginosa      1.00 (ref)       1.00 (ref)  
AUST-1   3.96 (1.06-14.75)   0.040 2.20 (1.31-3.69)     0.003 
AUST-2     19.17 (5.14-71.41) <0.001 1.24 (0.71-2.18)   0.44 
     
States  A      1.00 (ref)       1.00 (ref)  
            B 0.17 (0.06-0.52)   0.002 2.21 (1.29-3.78)     0.004 
            C 0.09 (0.03-0.26) <0.001  5.97 (3.55-10.03)  <0.001 
            D   1.64 (0.58-4.64)  0.35 0.95 (0.48-1.87)   0.88 
            E -  1.14 (0.62-2.08)   0.68 
            F   -  3.25 (1.23-8.60)     0.018 
     
Multivariate     
State   A      1.00 (ref)       1.00 (ref)  
           B   0.05 (0.01-0.53) 0.014 3.01 (1.48-6.16)    0.002 
           C   0.05 (0.01-0.34) 0.002   5.82 (2.74-12.37)  <0.001 
           D   1.02 (0.13-7.70)    0.99 1.26 (0.48-3.29)  0.63 
           E   -  0.99 (0.46-2.12)  0.98 
           F   -    4.48 (0.99-20.28)  0.05 
     
Unique P. aeruginosa     1.00 (ref)       1.00 (ref)  
AUST-01 5.95 (1.11-31.80) 0.037 1.64 (0.94-2.89)  0.08 
AUST-02 4.22 (0.78-22.78)    0.09 2.36 (1.22-4.55)   0.010 
 
 
*For FEV1% predicted this was the best value recorded for the 12-months prior to sample 
collection and the FVC and BMI recorded on that day, †z-scores used for paediatric data, ‡in 
the 30-days prior to sample collection, §in the 12-months prior to sample collection.  BMI: 
body-mass index, FEV1% predicted: forced expiratory volume percentage predicted, HTS: 
hypertonic saline, IV: intravenous, 
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Table 2-9 Factors associated with intravenous antibiotic usage by linear regression 
analysis among subjects infected with unique, AUST-01 or AUST-02 treated in a major 
treatment centre. 
 Paediatric Centres 
(States = 4, n=100) 
Adult Centres 
(States= 6, n=353) 
Variable  (95% CI) P-value  (95% CI) P-value 
Univariate     
Age     1.42    (0.23 – 2.61)    0.020      0.01    (-0.26-0.27)   0.95  
Female gender     5.65    (-5.23-16.52) 0.31     12.67 (8.01-17.33) <0.001 
FEV1% predicted*    -83.87  (-106.24 - -
61.50)    
  <0.001  -48.16  (-58.84- -37.49)  <0.001 
BMI†    -7.77    (-13.54 - -1.99)   0.009  -1.84    (-2.49- -1.18) <0.001 
Inhaled antibiotic‡      17.87  (6.83 – 28.91)   0.002   5.44    (0.60-10.27)  0.028 
Dornase alpha‡    10.46  (-0.71-21.63) 0.07  10.08  (5.44-14.71) <0.001 
HTS‡    27.79  (16.07-39.50) <0.001   7.53    (2.60-12.45) 0.003 
Azithromycin‡      28.91  (18.64-39.19) <0.001 11.46  (6.67-16.24)     0.003 
     
Unique P. aeruginosa    1.00    (ref)    1.00    (ref)  
AUST-01    21.42  (6.03-36.81)    0.007   10.58  (3.14-18.00)   0.005 
AUST-02    11.85  (-3.53-27.24)  0.13   10.12  (2.34-17.91)   0.011 
     
States  A    1.00    (ref)    1.00    (ref)  
            B   -9.47    (-24.40 – 5.46)  0.21 -16.93   (-23.76- -10.10) <0.001 
            C  -10.63   (-23.24 – 1.99)  0.10   0.43    (-6.14-7.00)  0.90 
            D     28.64   (12.25 – 45.04)    0.001   0.28    (-7.54-8.10)  0.94 
            E -  -4.59     (-11.76-2.57)  0.21 
            F   -  -10.77   (-24.81-3.26)  0.13 
     
Multivariate     
Female gender §    13.77  (7.85-19.70) <0.001 
FEV1% Predicted -57.06 (-81.23- -32.88) <0.001 -38.35   (-52.21- -24.49) <0.001 
     
State   A  1.00    (ref)    1.00    (ref)  
           B    1.61 (-17.81-21.05) 0.87  -10.87  (-19.52- -2.21)   0.014 
           C   -3.52 (-20.91-13.85) 0.69   2.89    (-6.25-12.02) 0.54 
           D    22.80 (-0.93-46.52) 0.06   7.43    (-3.69-18.56) 0.19 
           E   -  -1.30     (-9.98-7.37) 0.77 
           F   -  -5.07     (-23.03-16.17) 0.64 
     
Unique P. aeruginosa  1.00   (ref)    1.00    (ref)  
AUST-01  22.63 (7.71-37.55)   0.003   11.10  (4.00-18.21)   0.002 
AUST-02  9.16 (-8.79-27.12)    0.31   9.08    (1.38-16.79)   0.021 
 
*For FEV1% predicted this was the best value recorded for the 12-months prior to sample 
collection and the FVC and BMI recorded on that day, †z-scores used for paediatric data, ‡in 
the 30-days prior to sample collection, §non-significant in univariate analysis and not carried 
forward to multivariate analysis. BMI: body-mass index, FEV1% predicted: forced expiratory 
volume percentage predicted, HTS: hypertonic saline. 
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Table 2-10 Relationship between sampling location and rates of MARPA. 
Site Number of samples collected as 
an inpatient (% MARPA infected) 
Number of samples collected as an 
outpatient (% MARPA infected) 
P-value 
A(p1) 10   (70) 37    (51.4) 0.48 
A(a2) 26   (15.4) 140  (22.9) 0.40 
A(p3) 2     (50.0) 18    (33.3) 1.00 
A(a4) 6     (50.0) 30    (33.3) 0.65 
A(a5) 3     (33.3) 12    (41.7) 1.00 
A(p6) 1     (100.0) 3      (66.7) 1.00 
B(p1) 0 16    (25.0) n/a 
B(a2) 3     (66.7) 105  (37.1) 0.56 
B(p3) 4     (0) 27    (18.5) 1.0 
B(a4) 3     (66.7) 17    (47.1) 1.0 
B(p5) 0 13    (7.7) n/a 
C(p1) 16   (12.5) 46    (8.7) 0.64 
C(a2) 78   (61.5) 44    (63.6) 0.82 
C(a3) 6     (50) 44    (36.4) 0.66 
D(a1) 2     (50.0) 70    (20.0) 0.38 
D(p2) 14   (71.4) 9      (55.6) 0.66 
E(a1) 5     (40.0) 87    (23.0) 0.59 
F(a1) 5     (40.0) 12    (41.7) 1.00 
 
n/a. Not applicable Site A(a/pX): denotes a treatment centre in State A (adult/paediatric). 
MARPA: Multi-antibiotic resistant P. aeruginosa. 
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Table 2-11 Rate of MARPA stratified by testing methodology. 
Sampling Methodology No. of sample 
(No. of centres) 
Percentage 
MARPA 
Isolate Selection   
- Mixed 210 (6) 30.0% 
- Pure 724 (12) 35.4%* 
   
Reference Range   
- CLSI 695 (12) 30.1% 
- CDS 98    (5) 28.6%† 
- EUCAST 122  (1) 62.3%‡ 
 
Pure: isolate selected from the plate for sensitivity testing, Mixed: sweep taken from the plate 
for sensitivity testing, CDS: Continuous Dichotomous Susceptibility; CLSI: Clinical and 
Laboratory Standards Institute;  EUCAST: European Committee on Antimicrobial Sensitivity 
Testing. *P=0.16 compared to sweep, †P=0.76 compared to CLSI, ‡P<0.001 compared to 
either CLSI or CDS. 
---------------------------------------- 
2.5 Discussion 
 
By linking data from the ACFDR and the national ACPinCF study we found that Australian 
CF patients harbouring P. aeruginosa had MARPA rates, intravenous antibiotic usage and 
maintenance treatment practices that varied noticeably between centres. In children, antibiotic 
treatment intensity correlated with antibiotic resistance, while intravenous antibiotic 
treatments were associated with recent inhaled antibiotic use, reduced lung function and 
treating centre. In contrast, in adults MARPA was associated with centre and BMI, but not 
with intravenous antibiotic treatment intensity, while being female, recent inhaled antibiotics, 
reduced lung function and treating centre were also independently associated with 
intravenous antibiotic usage.  
 
Inhaled tobramycin, frequent intravenous antibiotics, CF-related diabetes, hospitalisation for 
acute exacerbations, and treatment in a centre with an already high MARPA prevalence were 
identified previously as risk factors for MARPA in CF patients with newly acquired P. 
aeruginosa infection.(4) Longitudinal studies of P. aeruginosa infection in non-CF individuals 
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have also found   MARPA prevalence closely parallels intravenous antibiotic use.(234, 235) 
Thus our observations that MARPA in CF adults did not correlate with intravenous antibiotic 
usage or maintenance treatment burden in our study was unexpected. This may indicate more 
complex factors influence P. aeruginosa phenotype in these older patients, including a 
greater impact from shared strains, antibiotic resistance related to long-term, cumulative 
antibiotic exposure from childhood and the altered microenvironment present in more severe 
bronchiectasis.(213, 236) For example, despite similar lung function and clinicians being 
unaware of strain typing status, patients with highly-prevalent AUST-01 and AUST-02 
strains were more likely to receive greater intensity of antibiotic treatments and to possess 
MARPA isolates than those infected with unique strains.   
 
It is important to highlight that in chronic P. aeruginosa infection antibiotic susceptibility 
does not predict clinical response to treatment and the clinical significance of MARPA in CF 
remains contentious.(210, 237) While a single centre study involving CF adults reported an 
increased rate of pulmonary decline in patients with MARPA infection,(238) this was not 
supported by a recent large data registry-based study, which found instead MARPA were 
more likely markers for advanced disease or intensive antibiotic therapy.(239) Furthermore, a 
CF Foundation Benchmarking Project, identified early and aggressive antibiotic management 
of pulmonary decline, to be a distinguishing feature of CF centres (paediatric and adult) 
achieving outstanding clinical outcomes.(203)  
 
The prevalence of MARPA among paediatric centres is comparable with the rates reported in 
an earlier single centre study and are concerning.(240) However, in two large paediatric 
centres providing the most intense treatments there was some evidence to suggest improved 
nutritional outcomes despite associated higher antibiotic resistance, while there was no clear 
association between MARPA and adverse clinical outcomes. Nevertheless, increasing 
treatment and its complexity in response to MARPA infection may lead to treatment-related 
morbidity and promote emergence of shared strains.(5, 241, 242),(243) 
 
These findings underline the dilemma facing CF physicians. Maintaining lung function and 
quality of life, while attempting to minimise antibiotic resistance and treatment-related 
adverse effects is especially challenging when the mechanisms of antibiotic action in CF lung 
disease are incompletely understood(244). Although consensus recommendations for 
managing pulmonary exacerbations and prescribing maintenance therapies have been 
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published, their uptake may be variable.(127, 202, 245)  Recognised barriers to adopting 
guidelines into clinical practice include: i) lack of knowledge or agreement with 
recommendations, ii) inertia in adopting change to management and iii) external barriers (e.g. 
drug availability and cost, as well as resistance to adopting specific therapies) and may have 
contributed to their incomplete uptake and variations in practice seen in Australian CF 
centres.(246) A US-based survey of CF physicians identified perceived benefit and presence of 
external barriers to be major factors influencing their willingness to adopt guidelines.(247) 
 
Our study has several limitations. First, in-vitro antibiotic susceptibility testing methods 
varied between CF centres (Table 2.1), however there are no standardised approaches to 
antibiotic resistance testing nationally or internationally.(248) The large number of isolates 
received by the reference laboratory meant it was not feasible to confirm the susceptibility of 
each isolate using a standard method. However, antibiotic resistance rates did not differ 
significantly between mixed versus pure testing methodologies. Furthermore, despite CLSI 
applying higher minimum inhibitory concentration (MIC) breakpoints for determining 
resistance to b-lactams antibiotics than CDS (Table 2.12), centres applying CLSI 
methodology showed higher rates generally of antibiotic resistance (Table 2.2 and 2.3). These 
data indicate that differences between CDS and CLSI testing methodologies are unlikely to 
have contributed to our findings. MARPA rates were however higher in the single centre 
using EUCAST MIC breakpoints, but we were unable to determine if this was from testing 
methodology or genuinely higher resistance rates. Second, our cohort included only those 
capable of providing sputum. This meant that those with more severe lung disease were likely 
to be selected, as younger patients and those with mild disease often cannot produce a sputum 
sample on demand.(249, 250) Third, as this study was cross-sectional, we could not differentiate 
between those with chronic or intermittent infections. This is especially relevant in young 
children where newly infecting strains are more likely to be susceptible to anti-pseudomonal 
antibiotics. However, paediatric subjects were on average 6-years older than the mean age of 
the clinic population from where they were selected (data not shown) and had relatively high 
rates of antibiotic resistance, suggesting that most were chronically infected. Fourth, the 
cross-sectional design also meant that we could not ascertain if increased antibiotic resistance 
in adults was ‘imported’ from a paediatric centre with high antibiotic use or resulted from a 
lifetime of accumulated antibiotic exposure and in addition whether MARPA isolates were 
associated directly with worse clinical outcomes. Fifth, we did not collect information on the 
type of intravenous antibiotics prescribed for each course treatment, which may have varied 
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between centres and influenced induction of antibiotic-resistant strains.(243) Finally, 
maintenance therapies were recorded from hospital dispensing data systems and patient 
medical records, which may not represent actual treatment adherence. 
 
Table 2-12 Equivalent susceptible minimum inhibitory concentration breakpoints of the 
disk diffusion methodologies. 
 Minimal inhibitory concentrations (mg/L) 
Antibiotic CLSI CDS EUCAST 
Gentamicin ≤4 ≤4 ≤4 
Tobramycin ≤4 ≤4 ≤4 
Amikacin ≤16 ≤16 ≤8 
Ceftazidime ≤8 ≤4 ≤8 
Cefepime ≤8 ≤2 ≤8 
Ticarcillin-clavulanate ≤64/2 ≤16/2 ≤16 
Piperacillin ≤64 ≤16 ≤16 
Piperacillin-tazobactam ≤64/4 ≤16/2 ≤16 
Aztreonam ≤8 ≤8 ≤1 
Meropenem ≤4 ≤2 ≤2 
Imipenem ≤4 ≤4 ≤4 
Ciprofloxacin ≤1 ≤1 ≤0.5 
Colistin sulphate ≤2 NA ≤2 
  
CLSI: Clinical and Laboratory Standards Institute, CDS: Continuous Dichotomous Susceptibility, EUCAST: 
European Committee on Antimicrobial Sensitivity Testing. mg/L: milligrams per litre. 
------------------------------------------------------- 
2.6 Conclusions.  
 
This national study found large between-centre differences in treatment practices and P. 
aeruginosa antibiotic resistance profiles. Increased antibiotic resistance in paediatric, but not 
adult, centres was associated with intravenous antibiotic usage, while in both paediatric and 
adult centres MARPA was not associated with worse lung function. We plan to continue 
monitoring this cohort longitudinally to determine whether MARPA isolates do actually 
result in worse clinical outcomes or simply reflect more advanced disease and/or intensive 
treatment strategies adopted by some centres. This study emphasises the need to develop a 
greater understanding of how antibiotics work in CF lung disease so that they can be used 
most effectively and safely. While awaiting these developments greater communication 
between centres may allow standardised national therapeutic guidelines to be developed to 
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promote the pulmonary benefits of early intensive treatment, while reducing the risk of 
treatment-related morbidity. 
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Chapter 3. Response of the CF lung Microbiome to intravenous antibiotics . 
3.1 Abstract. 
 
Introduction: Chronic airway infection in adults with CF is polymicrobial and the impact of 
intravenous (IV) antibiotics on the bacterial community composition is poorly understood. 
We employed culture-independent molecular techniques to explore the early effects of IV 
antibiotics on the CF airway microbiome. 
 
Methods: DNA was extracted from sputum samples collected from adult subjects with CF at 
three time points (before commencement of treatment, and at day 3 and day 8-10 of IV 
antibiotics) during the treatment of an infective pulmonary exacerbation. Microbial 
community profiles were derived through analysis of bacterial-derived 16S ribosomal RNA 
by pyrosequencing and changes over time compared. 
 
Results: Fifty nine sputum samples were collected during 24 pulmonary exacerbations from 
23 subjects. Between treatment onset and day 3 there was a significant reduction in the 
relative abundance of Pseudomonas and increased microbial diversity. By day 8-10, bacterial 
community composition was similar to pre-treatment. Changes in community composition 
did not predict improvements in lung function. 
 
Conclusion: The relative abundance of Pseudomonas falls rapidly in subjects with CF 
receiving IV antibiotic treatment for a pulmonary exacerbation and is accompanied by an 
increase in overall microbial diversity. However, this effect is not maintained beyond the first 
week of treatment. 
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3.2 Introduction 
 
Despite advances in the management of cystic fibrosis (CF), chronic pulmonary infection 
remains responsible for most patient morbidity and mortality(1). Culture-dependent analysis 
of CF airway infection reveals that Pseudomonas aeruginosa (P. aeruginosa) is the dominant 
bacterial pathogen in most adults with CF(251). However, the recent application of culture-
independent molecular techniques, based on the sequencing of the gene encoding bacterial 
16S ribosomal RNA (rRNA), have revealed a complex microbiome in the CF airway(79, 80, 
136, 252-255).  
 
Chronic infection with P. aeruginosa is associated with an increased rate of lung function 
decline, increased frequency of pulmonary exacerbations, impaired quality of life and 
increased mortality(200, 201). Guidelines recommend that pulmonary exacerbations are 
treated aggressively with a combination of at least two intravenous (IV) anti-pseudomonal 
antibiotics for fourteen days(202, 256). However, this practice is based on limited 
evidence(256).  
 
Two studies - one prospective and one large registry-based retrospective - have suggested 
that the maximum clinical and metabolic response to IV antibiotics occurs in the first week of 
treatment, with little additional benefit being achieved from extending treatment beyond this 
point(134, 135). Unfortunately, these studies did not assess the relationship between clinical 
improvement and microbiological response and their findings have not been considered 
sufficiently robust to change clinical practice. 
 
In this current study, we utilised culture-independent molecular techniques to explore the 
effect on the CF airway microbiome of IV antibiotic therapy administered for the treatment of 
an acute pulmonary exacerbation. The focus was primarily on the impact of antibiotic therapy 
on microbial community composition during the first week of treatment. 
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3.3 Methods 
 
3.3.1 Participants 
 
Adult subjects (n = 23; aged 18–54 years) with CF, admitted to hospital for IV antibiotic 
treatment of an acute, infective pulmonary exacerbation were recruited from The Prince 
Charles Hospital in Queensland (n = 14) and the Royal Hobart Hospital in Tasmania (n = 9), 
Australia. Institutional human research and ethics committee approval was gained at both 
sites (HREC2008:2885 and H0009813 respectively). Individuals who had undergone lung 
transplantation or were using systemic immunosuppression were excluded. Based on standard 
microbiological cultures, all patients were infected with Pseudomonas aeruginosa (Appendix 
2.1). 
 
Spontaneously expectorated sputum samples were collected at day 1, before IV antibiotics 
(Time-point 1, TP-1), and at day 3-4 (TP-2) and day 8-10 (TP-3) following commencement 
of IV antibiotics. 
 
A pulmonary exacerbation was defined clinically, based on the attending physician’s 
assessment that the subject required intravenous antibiotics to treat an increase in respiratory 
symptoms or a decline in lung function.  
 
Participant demographics and lung function and antibiotic treatment are outlined in Table 3.1. 
Disease severity was determined based on the participants best FEV1 in the 12 months prior 
to recruitment (FEV1 >70% mild, 40-70% moderate, <40% severe). 
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Table 3-1 Participant demographics, CF genotypes and antibiotic treatment#. 
Gender (male:female) 
Age 
BMI 
FEV1 
FEV1 % Predicted 
Absolute improvement in FEV1 
Relative improvement in FEV1 
17:6 
27 years    (18-54) 
20 kg m-1   (17-26) 
1.7 Litres   (0.9-4.2) 
50 %          (21-97) 
0.2 Litres   (0-1.2) 
16 %          (0-76) 
Genotype#: 
- p.F508del homozygote 
- p.F508del heterozygote 
- G551D heterozygote 
- Other / Other 
 
12  
8  
1 
2 
Intravenous antibiotic treatment*: 
- β–Lactam + Aminoglycoside$ 
- Dual β–Lactams 
- Dual β–Lactams + Aminoglycoside 
- Dual β–Lactams + Colistin 
- β–Lactam  + Monobactam + Aminoglycoside 
 
18 
2 
1 
1 
1 
Azithromycin*&: 18 
 
BMI: Body mass index; FEV1: Forced expiratory volume in one second: kg: kilograms; m: 
metres. Age, BMI and lung function parameters are expressed as median (range).  
* Maintenance usage of oral azithromycin, dosage either 250mg daily or 500mg alternate day.  
& Data were unavailable for one subject.  
$ Nebulised aminoglycoside was used in one subject. 
# Individual participant data are available in Appendices 2.1 and 2.2. 
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3.3.2 Sputum collection. 
 
Sputum was expectorated directly into 10 mL of RNA Later® (Life Technologies, Victoria) 
and stored for at least 24 hours at 4°C to allow full penetration into the sputum sample. 
Sputum samples were stored at -80°C for later batch DNA extraction.  
 
3.3.3 DNA extraction. 
 
A saliva-free aliquot of  each frozen sputum sample was selected and manually homogenised 
with 500 µL lysis buffer (50 mM Tris-HCl (Sigma-Aldrich, Missouri), pH 6.8, 50 mM 
ethylenediaminetetraacetic acid (AnalaR, Pennsylvania), 50 mM sucrose (AnalaR), 100 mM 
sodium chloride (Univar, NSW) and 1% sodium dodecyl sulfate (SDS) (Amresco, Ohio). The 
samples were incubated at 37°C for 1 hour with 100 µL chicken egg lysozyme (100 mg/mL, 
Sigma-Aldrich), then at 56°C with shaking overnight with 100 µL of proteinase K (20 
mg/mL, Promega, NSW) and 75 µL of 10% SDS. If samples were not completely digested, 
overnight incubation with additional proteinase was repeated until complete digestion was 
achieved. DNA was extracted and purified using PureLink Genomic DNA Mini Kit (Life 
Technologies, Victoria) and eluted in 50 µL kit elution buffer. Purified genomic DNA was 
analysed for quality (A260/A280 ratio of 1.8 – 2.0) and concentration using a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific, Denver) and samples were diluted to 20 ng/µL 
prior to DNA amplification and sequencing. 
 
3.3.4 DNA amplification, sequencing and statistical analysis. 
 
Sequencing was performed by Research and Testing Laboratories (Lubbock, Texas) applying 
Molecular Research DNA© protocols (Shallowater, Texas). The 16S rRNA gene was 
amplified using primers 939F (5’-TTGACGGGGGCCCGCAC-3’) and 1492R (5’-
TACCTTGTTACGACTT-3’) and products sequenced using bacterial tag-encoded FLX 
amplicon pyrosequencing (bTEFAP) as described previously (257). 16S rDNA amplicon 
sequences were processed with QIIME 1.5 (258). Sequences with ambiguous base calls 
(“quality score” < 25 and ≥ 6 homopolymers) were discarded. Forward and reverse primer 
sequences were removed allowing one mismatch. Chimeras were removed with 
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ChimeraSlayer (259) using default parameters. Samples with less than 500 sequence reads 
were excluded. 16S rDNA sequences were clustered into Operational taxonomic units 
(OTUs) using UCLUST v5.2.32(260), employing an identity threshold of 97%. RDP 
Classifier v2.2 was retrained on the database Greengenes version 13.8 and used for the 
taxonomic assignment of representative sequences of each OTU with a confidence threshold 
of 0.6(261). Genera were categorised as aerobic or anaerobic, as described previously(262). 
Data-mining, statistical analysis and data visualization were carried out using the Calypso 
software, bioinfo.qimr.edu.au/calypso, and Krona(263). 
 
Groups were compared using paired t-tests: TP-1 versus TP-2; TP-1 versus TP-3; and TP2 
versus TP-3. Analysis was limited to subjects for whom samples at both compared time 
points were available. P values were adjusted for multiple testing using the False Discovery 
Rate (FDR). Microbial community diversity was assessed by Shannon index (OTU level). 
Canonical Correlation Analysis (CCA) and Anosim were performed on the sputum 
microbiome at TP-1 using the relative genera abundance (number of 16S sequences assigned 
to each genus divided by the total number of sequences obtained for each sample). 
Associations between clinical variables (age and FEV1) and the relative abundance of each 
genus at TP-1 or TP-3 were determined by the Pearson product-moment correlation 
coefficient. Analogously, Pearson correlation was utilised to infer associations between the 
relative abundance of genera, age and relative improvement in FEV1 between early and late 
treatment. For the purpose of determining the differences between the relative abundances of 
bacterial groups at the genus level, Shannon diversity and FEV1 at TP-1 and TP-3 were 
calculated, and then evaluated for relationships by means of Pearson correlation. 
 
3.3.5 Real-time PCR quantification of P. aeruginosa. 
 
In 18 sputum samples, from nine subjects, P. aeruginosa concentration was determined by 
RT-qPCR, using a previously established primer pair for Pseudomonas 16S RNA, psd7, 
Forward (CAAAACTACTGAGCTAGAGTACG) 
Reverse (TAAGATCTCAAGGATCCCAACGGCT)(264).  
 
The full methods employed have previously been described(265). In brief a 0.01 to 0.15g 
aliquot of saliva free RNA Later® stored sputum, 1.4 ml of Tri Reagent® (Sigma-Aldrich, 
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Australia) and 1mL of 0.1 mm zirconia/silica beads (Biospec products inc.) were combined in 
a 2 mL tube and homogenised for 4 minutes at low speed using a Mini-Beadbeater (Biospec 
products inc.). RNA was extracted using Tri Reagent® as per the manufacturer instructions. 
Air-dried RNA was resuspended in 50 μL of pH 7.0 TE buffer with heating for 10 min at 
55ºC. DNA was removed from the RNA using Turbo DNase (Ambion) according to the 
manufacturer’s instructions. RNA was quantified using the Quant-iT™ RNA Assay Kit 
(Invitrogen) and a fluorimeter (Spectramax M2, Molecular Devices, California). RNA 
integrity was confirmed by agarose gel electrophoresis. For standard curve generation, RNA 
was serially diluted in pH 7.0 TE buffer prior to reverse transcription. cDNA was generated 
(20μL reactions) with SuperScript® III First-Strand Synthesis SuperMix (Invitrogen) kit, by 
the manufacturers methods, using a mixture of random hexamers and oligo(dT)20 for 
priming. RNA was removed with 1μL of the kit supplied RNAase. Each 20μL of cDNA was 
diluted with 46.7 μL of water before qPCR. Duplicate real-time PCR reactions were set 
up with 10μM of each primer according to the Platinum® SYBR® Green qPCR 
SuperMix-UDG (Invitrogen) kit instructions, using a CAS-1200 liquid pipetting robot 
(Corbett Life Science, Australia). Product amplification was carried out using the 
following conditions, enzyme activation (2 min at 50°C), initial denaturation (2 min at 
95°C), thermocyling (40 cycles of melting at 15 s at 95°C, annealed at 30 s and 
extended 30 s at 72°C). Data were collected at 72 °C. The annealing temperatures 
used was 62°C, Melt curve analysis was under-taken to confirm the specificity of the 
PCR products by heating from 70 to 95 °C at a linear rate of 0.5 °C/s. Excitation 
wavelength was 470 nm, with detection wavelength set at 510 nm. A calibrator and 
no-template control were included in each assay for each primer set. The calibrator 
consisted of CF sputum cDNA that showed expression of P. aeruginosa 16S rRNA. 
An aliquot of all RNA from sputum samples was analysed by qPCR, without prior 
reverse transcription, to confirm the absence of contaminating gDNA using the primer 
set for P. aeruginosa 16S rRNA. Presence of transcripts in sputum samples was 
defined as detection in technical replicate qPCRs of the same cDNA sample and 
appropriate Ct and melt analysis. Only Ct values between 6 and 31 were accepted for 
analysis. If a product amplified in the RNA-only control, indicating gDNA 
contamination, within 3 cycles of the cDNA product or with a Ct of <30 then the 
sample was excluded from analysis.  
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Pearson’s correlation was used to explore the relationship between P. aeruginosa load and 
relative abundance of Pseudomonas at the genus level. 
 
3.4 Results. 
 
3.4.1 Sample quality 
 
Fifty nine sputum samples were collected during 24 pulmonary exacerbations from 23 
subjects. Sequencing yielded 420,145 reads with an average read length of 457 base-pairs. 
After quality control and chimera detection, 57 samples (18 for TP-1, 18 for TP-2 and 21 for 
TP-3) and 336,973 high-quality sequencing reads remained, with a median of 5478 sequences 
per sample and a range from 1,468 to14,164. 
 
3.4.2 Sputum microbiota before antibiotic treatment (TP-1) 
 
Eighteen sputum specimens were analysed at TP-1 and showed a complex microbiota, with a 
median of 113 OTUs per sample (range 23-210 per sample). A total of 100 different genera 
were observed (median, 13 per sample, range 2-39) (Figure 3.1). Pseudomonas was the 
dominant genus in 94% (17/18) of samples, with a mean relative abundance of 78.5% (range 
41.9-99.6%). In one subject, Fusobacterium was the dominant genus (49% of 16S 
sequences), followed by Pseudomonas (41.9% of sequences). Streptococcus was the second 
most abundant genus in 13 sputum samples, with a mean relative abundance of 7.3%. The 
most prevalent anaerobic genera were Prevotella (mean relative abundance 2.7%, range 0-
13.8%) and Veillonella (mean relative abundance 1.2%, range 0-5.9%), which were present 
in 72% and 78% of the subjects, respectively. Other pathogenic genera were recovered 
infrequently, including Actinomyces (44% of samples), Staphylococcus (17%) and 
Haemophilus (11%). The mean percentage of sequences that could not be assigned to any 
known genus was 3% (Appendix 2.3). Statistical analysis of the taxonomic profiles at TP-1 
did not identify a relationship between global microbial community composition (rank genus) 
and age (CCA p=0.55; Anosim p=0.59) or FEV1 (CCA p=0.99; Anosim p=0.7).  
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Figure 3-1 Taxonomic profile of all sputum samples segregated by time -point. 
 
 
Px.y (Patient number.Timepoint). Representation limited to genera which were present in at 
least one sample at a relative abundance of ≥ 10% are presented. 
----------------------------------- 
The relative abundance of Pseudomonas showed a strong negative correlation with microbial 
diversity (Shannon index; r=-0.81, p<0.01, Pearson correlation). Conversely, the relative 
abundance of Streptococcus (r=0.63, p<0.01) and Prevotella (r=0.63, p<0.01) were positively 
correlated with community diversity (Figure 3.2). We did not observe an association between 
microbial diversity and subject age (p=0.29) or lung function (FEV1, p=0.3). 
3.4.3 Effects of antibiotic treatment on the airway microbiome  
 
There was a significant reduction in the relative abundance of Pseudomonas during the first 
72 hours of antibiotic treatment (p<0.005; FDR=0.02, paired t-test TP-1 vs. TP-2). The mean 
relative abundance of Pseudomonas decreased from 78.5% of 16S sequences before 
antibiotic treatment to 47% after 72h of treatment. The reduction in Pseudomonas was 
accompanied by a significant increase in overall microbial diversity (Shannon index; paired t-
test p=0.012) and a trend towards an increase in the relative abundance of anaerobes, which 
was mainly driven by increases in the abundance of Prevotella (TP-1 2.7% of 16S sequences; 
TP-2 12.2%; p=0.06; FDR=0.13) and Veillonella (TP-1 1.2%; TP-2 6.8%; p<0.02; 
FDR=0.07) (Figure 3.3). 
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Figure 3-2 Scatterplot matrix visualizing pairwise correlations between bacterial 
community diversity and composition, as well as subject demographics. 
 
 
The diagonal of the matrix lists the variables (grey boxes) compared in the scatterplots. 
Variables considered were FEV1, age, Shannon diversity and relative abundance of the most 
abundant bacterial genera. Each panel in the matrix contains a scatterplot for a pair of 
variables. Each dot in the scatterplots corresponds to the measurements of the variable for an 
individual subject and is coloured according to the hierarchical cluster (H, M, L) assigned to 
the subject at TP-1 . The scatterplots in the upper triangle (above the diagonal) or lower 
triangle (below the diagonal) illustrate the relationships of the variables at TP-1 and TP-3, 
respectively. The relationship between the relative abundance of Pseudomonas and microbial 
diversity was negatively correlated (Pearson, r=-0.87, p<0.01). A positive correlation was 
seen between microbial diversity and Streptococcocus (r=0.63, p<0.01) and Prevotella 
(r=0.6, p=0.01). 
 98 
 
Figure 3-3 Changes in CF sputum microbiota between TP-1, TP-2 and TP-3. 
 
A. Shannon index, demonstrating changes in overall microbial diversity B. Changes in the relative abundance of Pseudomonas C. Circle plots 
demonstrating changes in global community structure at TP-1 (left), TP-2 (middle), TP-3 (right). Each ring represents a taxonomic rank (phylum 
(inner-most), class, order, family, genus (outer-most)). The colour code for the rank phylum is illustrated in the legend. 
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Figure 3-4 Scatterplot matrix visualizing pairwise correlations of variables participant 
demographics and change in microbial composition between TP-1 and TP3 
 
The diagonal of the matrix lists the variables (grey box) that were compared in the 
scatterplots. Variables included were; improvement in FEV1, age, change in Shannon 
diversity and change in relative abundance of selected bacterial genera. The change was 
determined by calculating the difference of the Shannon diversity or relative abundance of 
the genus between TP-1 and TP-3. Each dot in the scatterplots corresponds to the 
measurements of the variable for an individual subject and is coloured according to the 
hierarchical clustered (H, M, L) assigned to the subject at TP-1. The change in microbial 
diversity demonstrated a negative correlation with the relative abundance of Pseudomonas 
(Pearson, r=-0.76, p<0.001) and a positive correlation with the relative abundance of 
Streptococcus (r=0.6, p=0.01). 
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At TP-3, overall microbial diversity (Shannon index) and Pseudomonas relative abundance 
were similar to TP-1, suggesting a return to pre-treatment community composition (Figure 
3.3).  The change in overall microbial diversity correlated negatively with the change in 
abundance of Pseudomonas (r=-0.7, p<0.01) and positively with change in abundance of 
Streptococcus (r= 0.6, p<0.05) (Figure 3.4). 
 
A principal coordinates analysis demonstrated samples from TP-1 and TP-3 clustered 
together, however, TP-2 formed a distant, separate cluster (Figure 3.5). This clustering was 
significant; comparison of intra- and inter-group Jarrard distances of TP-1 versus TP-3 were 
not significant (p=0.75), but significant between TP-1 versus TP-2 and TP-2 versis TP-3 
(p<0.01). 
 
We did not observe any significant associations between the changes in abundance of 
individual genera and improvement in FEV1 between TP-1 and TP-3. A negative relationship 
between relative abundance of Pseudomonas and FEV1 was observed at TP-3, but did not 
reach statistical significance (r=-0.46, p=0.07). 
 
In the nine subjects for whom P. aeruginosa quantification was performed, there was a weak, 
positive correlation between P. aeruginosa load and the relative abundance of Pseudomonas 
at the genus level (r2 = 0.24, p= 0.04) (Figure 3.6). 
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Figure 3-5 PCoA (A) and hierarchical clustering of CF sputum samples based on OTU 
profiles (B).  
 
A. PCoA of the sputum microbiome showing a shift in the microbiota at TP-2 (rectangle). 
TP-1 (triangle) and TP-3 (circle) for some subjects clustered together indicating a return to 
the initial community composition.  B. Only OTUs that had a relative abundance >10% in at 
least one sample are shown. Hierarchical clustering demonstrated grouping of samples based 
on the abundance of OTUs related to Pseudomonas spp: (L) Mixed community consisting of 
low levels of Pseudomonas and presence of several other bacterial groups, (M) Intermediate 
abundance of Pseudomonas and only minor other bacterial groups, (H) Pseudomonas-
dominated samples. Group L can further be subdivided according to the prevalence of 
Staphylococcus and Fusobacterium (L1), Streptococcus (L2) and other unknown 
Gammaproteobacteria species (L3). 
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Figure 3-6 Pearson’s correlation demonstrating the relationship between the relative 
abundance of Pseudomonas (genus) and P. aeruginosa colony forming units (CFU) per 
gram of sputum, determined by RT-qPCR. 
 
------------------------------------------------------ 
 
3.4.4 Sub-group analysis based on the relative abundance of P. aeruginosa. 
 
Clustering of OTUs based on the relative abundance of Pseudomonas spp revealed three 
distinct groups: (L) low abundance of Pseudomonas spp. (<40%) with a complex community 
structure and presence of various other bacterial genera, (M) medium abundance of 
Pseudomonas spp. (40 to <75%), and (H) high abundance of Pseudomonas spp. (≥75%) 
(Figure 3.7). 
 
Samples from subjects with severe disease tended to cluster in the H and M categories, 
whereas samples from subjects with mild to moderate disease clustered in the L category 
(Figure 3.8). Antibiotic treatment rarely resulted in a change in a subject’s category at the end 
of treatment, and changes in the relative abundance of Pseudomonas in response to treatment 
were not associated with an improvement in lung function. 
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Figure 3-7 Community diversity (Shannon index) of samples by hierarchical clustering 
group. 
  
The greatest diversity is seen in the L group, with low diversity seen in the H group.  
 
Figure 3-8 Categorization of subjects according to identified sputum microbiota groups. 
 
 
The time-point (TP-1: green, TP-2: red, TP-3: blue) of the samples for each subject is 
categorized according to the groupings retrieved from hierarchical clustering. Subjects are 
stratified by order of the degree of lung function impairment (FEV1 percentage predicted), 
with most severe impairment at the bottom and least severe at the top (Px: mild, Px: 
moderate, Px: severe lung function impairment). Samples from subjects with a severe CF 
lung function impairment tended to cluster in group H or M, whereas samples from subjects 
with mild-moderate impairment clustered in the L group. The microbial diversity (Shannon 
index) of samples by hierarchical cluster is presented in Figure 3.7.  
------------------------------------------------ 
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Non-Pseudomonas genera were categorised as obligate anaerobes or aerobes/facultative 
anaerobes (Figure 3.9). By TP-2 the relative abundance of aerobic bacteria increased 
(median, TP-1: 4.5% of 16S sequences; TP-2: 11.7%; p=0.03; FDR=0,049) and a similar 
trend was observed in the abundance of anaerobic bacteria (median, TP-1: 3.4%, TP-2: 
22.6%, p=0.1). A reversal in these trends was seen between TP-2 and TP-3 (aerobes TP-3, 
median 9.5%, paired t-test between TP-2 and TP-3 p=0.44; anaerobes TP-3, median: 2.4%, 
p=0.048, FDR=0.1) and at TP-3, the sputum community composition once again resembled 
TP-1 (Figure 3.9). 
------------------------------------------------ 
 
Figure 3-9 Relative abundance (median) of aerobic and anaerobic genera in CF sputum 
samples after exclusion of reads assigned to Pseudomonas. 
 
------------------------------------------------ 
 
 
There was a significant increase in the relative abundance of aerobic bacteria between TP-1 
and TP-2, with a similar trend seen in anaerobic bacteria, followed by a significant decrease 
in anaerobic bacteria between TP-2 and TP-3. P-values were calculated using paired t-test. 
Changes in the relative abundance of aerobic and anaerobic genera in response to treatment in 
individual subjects is presented in Figure 3.10. 
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Figure 3-10 Relative abundance of, A. aerobic and, B. anaerobic bacteria for each CF 
subject. 
 
The colour indicates the hierarchical clustering group of the subjects at time-point 1 (red: 
group H, orange: group M, green: group H, grey: unknown [no sample at time-point 1]) 
------------------------------------------------ 
 
3.5 Discussion 
 
In this study, we demonstrate a significant perturbation of the airway microbiome over the 
first 72 hours of IV antibiotic treatment for pulmonary exacerbations in adult subjects with 
CF. This perturbation was characterised by a reduction in the dominance of Pseudomonas 
and an accompanying increase in microbial diversity. These changes were, however, short-
lived, with bacterial community composition resembling that of the initial profile after one 
week of antibiotic treatment. These novel findings suggest that disturbance of the bacterial 
composition of the CF airway in response to IV antibiotics is transient, and potentially 
challenge current antibiotic management strategies for CF pulmonary exacerbations. 
 
Evidence in the literature to support the application of culture-independent techniques to 
examine the effect of antibiotic therapy on the CF airway microbiome remains limited. 
Tunney et al. have demonstrated that despite total bacterial numbers being reduced in 
response to antibiotics (culture-based assessment), there was relative stability in overall 
community composition as assessed by terminal restriction fragment length polymorphisms 
analysis when sputum samples were collected from subjects with CF before and after 
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treatment of a pulmonary exacerbation(136). More recently, Daniels et al examined the 
impact of antibiotics on CF sputum microbial diversity in a group of adult CF subjects(137). 
Sputum samples collected following the initial 72 hours of antibiotic therapy were compared 
with samples collected during a period of clinical stability prior to the exacerbation and after 
10-14 days of treatment. In comparison to samples collected at 72 hours, samples collected at 
10-14 days demonstrated an increase in relative abundance of Pseudomonas species 
compared with non-pseudomonads accompanied by a reduction in community diversity(137). 
The authors concluded that antibiotic therapy was exerting a significantly greater effect on 
bacterial species other than Pseudomonas, culminating in the dominance of P. aeruginosa.  
 
By examining microbial diversity at the onset of the exacerbation, prior to the administration 
of antibiotics, we have advanced the findings of Daniels et al and shown that bacterial 
communities appear most susceptible to IV antibiotics at the beginning of antibiotic therapy. 
In addition to performing sampling prior to the onset of antibiotics, a number of important 
differences between the current study and that of Daniels and colleagues should be 
highlighted. Firstly, in the earlier study, subjects were treated with a range of oral, inhaled 
and IV antibiotics which may have affected the ability to pick up consistent changes in 
community composition, whereas the subjects reported here were consistently treated with 
conventional IV antibiotic combinations. Additionally, sample processing and sequencing 
techniques differed between the two studies, most notably the samples in Daniel’s study were 
treated with propidium monoazide (PMA) to cross-link DNA from non-viable bacteria, a 
technique we did not employ. Nevertheless, both studies confirm that community 
composition remains essentially unchanged after at least a week of IV antibiotic therapy, 
which, given the early alterations in the microbiome that we observed, suggests that current 
treatment practices may need to be revised(266, 267).  
 
The reduction in relative abundance of Pseudomonas from day 1 to days 3-4 suggests initial 
preferential killing of Pseudomonas in response to IV antibiotics. Recrudescence of P. 
aeruginosa infection under antibiotic pressure after this early response may occur as a result 
of increased replication of an inherently antibiotic resistant sub-population, or through 
population-wide adaptive mechanisms involving the up-regulation of antibiotic resistance 
genes, which may occur rapidly in the treatment course(268, 269). Whilst alternative 
explanations for the clinical improvements (reduction in respiratory symptoms and subjective 
wellbeing) in subjects beyond the first few days of treatment should also considered, 
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including the impact of adjunctive therapies, such as inhaled mucolytics, airway clearance 
techniques, rehydration and nutritional support(127, 134, 245), our findings challenge the 
convention of prescribing the same IV antibiotic combination for more than a few days at a 
time. A potential new strategy may involve the rapid cycling of different antibiotic regimes 
during treatment, but this would require investigation in large-scale, adequately powered 
randomised and blinded clinical trials.  
 
To explore the effect of antibiotics on bacterial species other than P. aeruginosa, we 
examined microbial community changes with Pseudomonas reads excluded. Contrary to the 
earlier study by Daniels et al, the relative abundance of both aerobes and anaerobes increased 
in the early stages of treatment, suggesting antibiotic therapy was having a lesser impact on 
the other bacterial species present compared to Pseudomonas. The effects of IV antibiotics in 
adults not infected with P. aeruginosa who are experiencing an acute exacerbation warrants 
further investigation, particularly as these individuals represent an increasing group of 
subjects transitioning from paediatric to adult care(270).  
 
Greater sputum microbial diversity in our study subjects was positively associated with the 
abundance of Streptococcus, accompanied by a reduction in the relative abundance of 
Pseudomonas. These findings are consistent with a previous cross-sectional study in which 
microbial profiles of stable CF outpatients and inpatients were compared(271). In this earlier 
report, three distinct sub-groups of CF subjects were identified by the relative abundance of 
Streptococcus and Pseudomonas in sputum. Importantly, outpatients with high Streptococcus 
and low Pseudomonas abundance had greater lung function stability over time. In our study, 
sputum samples with a high relative abundance of Pseudomonas and low community 
diversity formed a cluster, predominantly in subjects with severe lung disease. However, in 
contrast to other studies, we were unable to confirm a reduction in microbial diversity with 
increasing age and severity of lung disease in the CF subjects we studied(84, 266).  
 
One potential limitation of our study is that PMA was not used to exclude DNA from non-
viable bacterial cells in the sputum samples prior to analysis(272). The use of PMA has been 
advocated due to appropriate theoretical concerns that molecular based techniques may 
identify both viable and non-viable bacteria and limit the ability to detect changes in bacterial 
number in antibiotic treatment responses studies(273). However, the reduction in the relative 
abundance of Pseudomonas at day 3 that we observed would not be consistent with the 
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inclusion of non-viable organisms(272). The use of PMA remains a topic of debate and the 
method carries its own potential drawbacks, including a limited ability to expediently 
penetrate purulent, non-homogenised sputum prior to the death of resident organisms deep 
within the sputum sample. Furthermore, the extended processing time involved may result in 
less hardy bacteria (e.g. anaerobes) preferentially dying ex vivo, while more robust bacteria 
proliferate and skew the true bacterial composition, even if samples are maintained at 4C(74, 
136). 
 
Our conclusions are based on changes in relative abundance and not quantitative bacterial 
load. We have previously performed enumeration of P. aeruginosa number by RT-qPCR and 
demonstrated heterogeneous changes in bacterial numbers in response to antibiotics(265). 
The findings for some subjects in this earlier work were consistent with the current study, 
with an early reduction in P. aeruginosa numbers, being followed by a recrudescence by the 
end of the first week of treatment(265). Quantification of P. aeruginosa by RT-qPCR in nine 
subjects from the current study revealed a positive correlation between P. aeruginosa load 
and the relative abundance of Pseudomonas at the genus level (Figure 3.6) and supports 
conjecture that changes in community composition in the CF lung reflect changes in P. 
aeruginosa concentration, however, this relationship was weak. Matching changes in 
community structure with enumeration of individual bacterial species is complex and changes 
in individual species, may not be equivalent to changes at the level of the genus. Future 
advances in pyrosequencing technology may allow for identification and enumeration of 
bacteria at the species level, which will substantially advance understanding of the dynamics 
of the lung microbiome.  
 
Approximately 3% of all obtained sequences in our study could not be assigned to a genus, 
which is consistent with the findings of others(274). The success of read assignment is 
dependent on read length, primer pairs and the particular reference database applied to the 
analysis(219). To date, there is no universal method of analysis agreed upon, which further 
confounds direct comparisons of the human microbiome between studies. 
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3.6 Conclusions. 
 
We have demonstrated for the first time that the relative abundance of P. aeruginosa falls 
rapidly in subjects with CF receiving IV antibiotics for pulmonary exacerbations, and that 
this is accompanied by an increase in microbial diversity. This effect was not maintained 
beyond the first week of treatment. These findings have implications for how IV antibiotic 
treatment should be employed for exacerbations and for how long. Future clinical trials 
should consider the impact of IV antibiotics on the whole lung microbiome in CF, how 
changes in microbial community composition relate to reductions in absolute bacterial counts 
and in turn, how these parameters relate to the clinical response to treatment.  
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Chapter 4. Lymphocyte Phenotype in CF 
 
4.1 Abstract. 
 
Background: Primary defects in host immune responses have been hypothesised to 
contribute towards an inability of subjects with cystic fibrosis (CF) to effectively clear 
pulmonary infections. Innate T-lymphocytes provide rapid pathogen-specific responses prior 
to the development of classical MHC class I and II restricted T-cell responses and are 
essential to the initial control of pulmonary infection. We aimed to examine the relationship 
between peripheral blood lymphocyte phenotype and clinical outcomes in adults with CF. 
 
Methods: We studied 41 subjects with CF and 22, age matched, non-smoking healthy control 
subjects. Lymphocytes were extracted from peripheral blood samples and phenotyped by 
flow-cytometry. Lymphocyte phenotype was correlated with sputum microbiology and 
clinical parameters. 
 
Results: In comparison to healthy control subjects, mucosal associated invariant T (MAIT)-
lymphocytes were significantly reduced in the peripheral blood of subjects with CF (1.1% 
versus 2.0% of T-lymphocytes, P=0.002). MAIT cell concentration was lowest in CF subjects 
infected with P. aeruginosa and in subjects receiving treatment for a pulmonary exacerbation. 
Furthermore a reduced MAIT cell concentration correlated with severity of lung disease. 
 
Conclusion: Reduced numbers of MAIT cells in subjects with CF were associated with P. 
aeruginosa pulmonary infection, pulmonary exacerbations and more severe lung disease. 
These findings provide the impetus for future studies examining the utility of MAIT cells in 
immunotherapies and vaccine development. Longitudinal studies of MAIT cells as 
biomarkers of CF pulmonary infection are awaited. 
 
 
 
 
 
 111 
 
4.2 Introduction. 
 
Cystic fibrosis (CF) pulmonary disease is typified by a vicious cycle of bacterial infection 
and exuberant, but ineffective host immune response(275). The inability of the intense 
inflammatory response to clear infection has led to speculation that intrinsic immune defects 
may contribute to the persistence of pathogens in CF(25). At the level of the airway lumen, 
the cellular immune response is dominated by activated neutrophils. However, in contrast, 
airway epithelial biopsies demonstrate a profound T lymphocyte (T-cell) infiltrate, supporting 
an important role for adaptive immune responses in the orchestration of a sustained 
inflammatory response(47). 
 
To date, studies of peripheral, adaptive immune responses in CF have largely focused on the 
classic dichotomy of T-helper (Th)-1 and Th-2 responses(49). These early studies suggested a 
skew towards a Th2 in most CF subjects with P. aeruginosa infection, which resulted in 
increased pulmonary inflammation and disease progression(49-51). The activation of the 
“classical” adaptive immune response involves antigen recognition, followed by T-cell 
recruitment and clonal expansion at the site of infection. Consequently, there is a time lag 
between the host’s recognition of the presence of a pathogen and the development of an 
effective, adaptive immune response. In recent times, an increasing number of 
unconventional “innate” T-cell populations have been described (including γ/δ, semi-
invariant natural killer (iNKT) and M3-restricted T-cells), which are capable of mounting a 
more immediate response to pathogens than was previously thought possible. Mucosal 
associated invariant T (MAIT) cells are a recently described sub-class of innate T-cells, 
which can be differentiated from other T-cells by the presence of an evolutionary conserved 
T-cell receptor (TCR) (Vα7.2-Jα33). MAIT cells recognise bacterial and fungal metabolites 
presented on the major histocompatibility complex (MHC) related protein-1 (MR1) 
(including the common CF pathogens Pseudomonas aeruginosa and Staphylococcus aureus), 
but not viruses(69, 70). These “innate” T-cell populations provide rapid pathogen-specific 
responses prior to the development of classical MHC class I and II restricted T-cell responses 
and importantly may also provide a sustained cytokine response in chronic infection(71, 72). 
 
To date, there is limited knowledge of how changes in circulating lymphocyte populations 
may relate to pulmonary infection in CF(276). In this study we performed extensive 
phenotyping of peripheral blood mononuclear cell populations (PBMCs) obtained from 
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subjects with CF and compared these profiles to those in healthy, age matched, controls. Our 
particular focus was on the correlation of γ/δ and MAIT innate T-cell values with clinical and 
microbiological parameters.  
 
4.3 Methods. 
 
4.3.1 Participants and sample collection. 
 
Forty-one subjects with CF attending the Adult CF Centre, The Prince Charles Hospital, 
Queensland, Australia and 22 age-matched, non-smoking, healthy control subjects each 
supplied a single venous blood sample.  
 
In subjects with CF, total white cell count (WCC), C-reactive protein (CRP) and clinical 
demographics including, age, CF genotype, lung function, body mass index, pulmonary 
exacerbation frequency and pulmonary pathogens (based on standard sputum microbiological 
testing) were recorded. Longitudinal rate of decline in forced expiratory volume in one 
second (FEV1) was determined in CF subjects by means of linear regression analysis (limited 
to subjects with at least five FEV1 measurements recorded over a minimum surveillance 
period of 2 years).  
 
To explore the effect of pulmonary exacerbations on lymphocyte concentrations a sub-set of 
13 “stable” CF subjects (stable respiratory symptoms and a CRP < 5 mg L-1 at time of blood 
collection) were compared to eight CF subjects in whom blood was collected within 72 hours 
of admission to hospital for the intravenous antibiotic treatment of a “pulmonary 
exacerbation”, defined as increased respiratory symptoms (cough, sputum volume or 
purulence, dyspnoea) (Figure 4.1). 
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Figure 4-1 Flow diagram of subjects included in sub-group analysis 
 
 
 
 
Ethics approval was obtained from The Prince Charles Hospital, Queensland, Australia, 
Human Research and Ethics Committee (HREC/11/QPCH/36 and HREC2008:2885) and all 
subjects provided written, informed consent. 
 
4.3.2 Separation and storage of peripheral blood mononuclear cells (PBMCs). 
 
Twelve millilitres of venous blood was collected into lithium heparinised tubes and separated 
into plasma and cellular components. The cellular component was re-suspended in RPMI 
(Gibco®) + 2% heat inactivated Foetal Calf Serum (HiFCS) and PBMCs separated by means 
of Histopaque® 1.077 (Sigma-Aldrich®) density gradient separation, as per the 
manufacturer’s protocol. Following separation, PBMCs were washed twice, re-suspended in 
RPMI and 15% dimethyl sulfoxide (DMSO), gradually frozen to -80°C and transferred to 
storage in liquid nitrogen for later batch analysis (concentration 5-20x106 cells/ml). 
 
4.3.3 Flow Cytometry. 
 
PBMCs were rewarmed and re-suspended by drop-wise addition of 10ml of 
RPMI+2%HiFCS, washed twice and re-suspended in phosphate buffered saline (PBS) with 
1% HiFCS (FACS buffer). A cell count was performed and the volume adjusted to obtain a 
cell concentration of 10 x106 cells/ml. 
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One hundred micro-litre aliquots of cells were incubated with each of two antibody staining 
panels as follows: 
 
Panel 1 [adapted from (277)]: FITC anti-human CD16, Pacific Blue anti-human CD14, APC 
anti-human CD1c, Alexa Fluor700 anti-human CD3, APC/Cy7 anti-human HLA-DR, 
PE/Cy7 anti-human CD56, PE/Cy7 anti-human CD20, Anti-CD8 antibody – PE Texas 
(Abcam) and V500 anti-CD4 (BD biosciences) were added to 100µL of cells and incubated 
in the dark for 15 minutes. Cells were washed twice in 1ml of FACS buffer and fixation was 
performed by incubation with 500µl of Cytofix (BD biosciences) for 10 minutes. Finally, 
samples were washed and suspended in 300µl of FACS buffer (example staining panel Figure 
4.2). 
 
Panel 2: Surface staining was performed by incubation with V500 anti-CD4, FITC anti-TCR 
Va7.2, PerCP/Cy5.5 anti-CD161, APC/Cy7 anti-CD3, PE anti-TCR γ/δ, PE Texas red Anti-
CD8 for 15 minutes at room temperature in the dark. Cells were washed twice in 1ml of 
FACS buffer, fixed and resuspended in 300µl of buffer solution (example staining panel 
Figure 4.3).  
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Figure 4-2 Representative flow-cytometry gating plots for determination of Major 
Lymphocyte sub-sets. 
 
Cell Characteristic; Lymphocytes (Appropriate forward and side scatter properties and CD14-
), T-Cells (CD3+/CD16-), CD3+/CD16+ cells, NK-Cells (CD16+/CD3-/HLA-DR-, CD16-
/CD3-/CD56+/HLA-DR- and CD16-/CD3-/CD56+/HLA-DR+), CD4+ T-Cells 
(CD3+/CD16-/CD4+/CD8-), CD8+ T-Cells (CD3+/CD16-/CD4-/CD8+), CD4+/CD8+ T-
Cells (CD3+/CD16-/CD4+/CD8+), CD4-/CD8- T-Cells (CD3+/CD16-/CD4-/CD8+), B-Cells 
(CD3-/CD16-/CD20+/HLA-DR+) 
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Figure 4-3 Representative flow-cytometry gating plots for determination of MAIT cells 
and γ/δ T-Cells. 
 
Cell Characteristics: MAIT Cells (CD3+/CD4-/TCR Va7.2+/CD161+), γ/δ T-Cells 
(CD3+/TCR γ/δ+). 
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Unless stated otherwise, antibodies were obtained for Biolegend®, San Diego. Antibody 
titration was performed to optimise antibody-cell concentration prior to testing. 
 
Sample analysis was performed on a Fortessa IV flow cytometer (BD Biosciences). A 
lymphocyte gate was set based on forward and side scatter properties and a minimum of 
50,000 gated events were capture for each sample. 
 
MAIT cells were defined as CD3+/CD4-/CD8+or-/CD161+/TCR Va7.2+(278). 
 
For subjects with CF, automated haemocytometer, absolute lymphocyte counts were obtained 
and T-cell sub-types were considered as both, absolute numbers of cells per mL of blood and 
percentage of the whole T-cell population. 
 
Data analysis was performed using Flowjo version 7.6 (Treestar). 
 
4.3.4 Statistical Analysis. 
 
Statistical analysis was performed using PASW, version 18 (SPSS Inc. Chicago IL, USA) 
and Graph-pad Prism, version 6. Between group differences in PBMC populations were 
examined using student’s t-test or Mann-Whitney U test. Shapiro-Wilk test and q-q plots 
were used to determine normal distribution of continuous variables. Non-normally distributed 
continuous variables (WCC, CRP, MAIT cell absolute count and percentage, B-cell count, 
NKT-cell and NK-cell percentage) were natural logarithm transformed and Pearson’s 
correlation used to determine relationships between variables. A p-value <0.05 was 
considered to represent statistical significance.  
 
4.4 Results. 
 
The characteristics of subjects with CF and healthy controls are provided in Table 4.1. Thirty-
six of the 41 subjects with CF had chronic pulmonary infection with P. aeruginosa (either in 
isolation or in combination with another CF respiratory pathogen) on routine microbiological 
cultures. The remaining five subjects did not have P. aeruginosa infection on current, or 
previous sputum cultures (See Appendix 3.1 for complete sputum microbiological data). 
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Table 4-1 Subject demographics 
 
 Healthy Controls Cystic Fibrosis P value 
Sex                          (Female:Male) 11:11 17:24 0.5 
Age                         (years) 26      (25 - 32) 28     (22 - 32) 0.9 
BMI                         (kg/metre2) 24.6   (21.4 – 
28.3) 
23.5  (20.5 – 25.8) 0.3 
    
FEV1                        (Litres) 4.1  (3.5 -4.7) 2.2 (1.4 – 2.5) <0.001 
FEV1 % Predicted  (%) 110 (101 – 120) 58  (37 - 75) <0.001 
FVC                         (Litres) 4.9   (4.4 – 5.7) 3.1 (2.6 – 4.1) <0.001 
FVC % Predicted   (%) 107  (95 – 112) 76  (58 - 84) <0.001 
    
CFTR Genotype 
- F508del Homozygotes 
- F508del Heterozygotes 
- Other mutations 
  
20 
18 
3 
 
    
Sputum Microbiology* 
- Pseudomonas aeruginosa 
- Staphylococcus aureus 
- Aspergillus fumigatus 
- Haemophilus influenzae 
- Stenotrophomonas maltophilia 
- Chryseobacterium indologenes 
- Scedosporium apiospermum 
- Mycobacterium intracellulare 
- Burkholderia gladioli 
- Achromobacter xylosoxidans 
- Methicillin resistant S. aureus 
  
36 
12 
5 
4 
3 
2 
2 
1 
1 
1 
1 
 
 
Data presented as median (interquartile range). *Summary data, subjects may have had more 
than one pathogen isolated in sputum, individual microbiological data available in Appendix 
3.1. 
--------------------------- 
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A greater number of subjects in the pulmonary exacerbation group were male, these subjects 
were also older, with more severe lung disease, when compared to the stable subjects (Table 
4.4). 
 
Comparison of lymphocyte sub-sets between groups, demonstrated a reduction in the 
percentage of MAIT cells in subjects with CF, compared to healthy controls (median 1.1% 
versus 2.0%, p=0.002), with an accompanying increase in the percentage of γ/δ T-cells 
(median 10.4% versus 6.4%, p=0.012). CF subjects also displayed reduced percentages of 
NK-cells (median 9.5% versus 13.1%, p=0.013). The percentage of cells in all of the other 
major lymphocyte sub-sets was similar between groups (Table 4.2).  
 
4.4.1 Relationship between MAIT cells, microbiological and clinical parameters in 
subjects with CF. 
 
Absolute MAIT cell concentrations and the proportion of T-cells that were MAIT cells 
(MAIT cell percentage), in the five subjects without P. aeruginosa infection were 
significantly higher than in patients with chronic P. aeruginosa infection (Table 4.3 and 
Figure 4.4A). MAIT cell percentages in subjects not infected with P. aeruginosa were similar 
to healthy controls subjects. No difference was seen in the MAIT cell percentage of subjects 
with a P. aeruginosa infection, based on their co-pathogen (Figure 4.5).  
 
Absolute blood MAIT cell counts in the sub-group of stable CF subjects were higher, when 
compared to subjects sampled early in the course of treatment for a pulmonary exacerbation 
(Figure 4.4B). However, the MAIT cell percentage was similar between stable and 
pulmonary exacerbation subjects (Table 4.4). 
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 Table 4-2 Comparison of lymphocyte sub-sets between CF and healthy control subjects. 1 
 2 
Lymphocyte Population (size gated, CD14-) CF (n=41)  Non-CF (n=22) P-Value 
T-Cells (CD3+CD16-) 72.6             (68.1 – 79.6) 74.9              (67.9 – 79.0) 0.6 
- CD4+CD8- 
- CD8+CD4- 
- MAIT Cells (CD161+, TCR Va7.2+) 
-      γ/δ T-cells (TCR γ/δ+) 
- CD4+CD8+ 
- CD4-CD8-* 
- 65.2       (56.1 – 70.5) 
- 25.7       (21.1 – 32.5) 
- 1.1         (0.4 – 1.9) 
- 10.4       (6.5-13.4) 
- 0.3         (0.2 – 1.0) 
- 2.1         (0.9 – 3.3) 
- 65.1       (59.9 – 71.4) 
- 27.4       (22.7 – 32.8) 
- 2.0         (1.4 – 3.1) 
- 6.4         (4.6 – 9.4) 
- 0.4         (0.3 – 1.7) 
- 1.6         (1.1 – 2.3) 
0.6 
0.6 
0.002 
0.012 
0.1 
0.3 
B-Cells (CD3-CD16-CD20+HLA-DR+) 9.5                 (4.9 – 14.3) 4.8                 (3.9 – 8.7) 0.1 
- Non-Resting (CD1c-) 
- Resting (CD1c+) 
- 64.6       (57.0 – 74.4) 
- 35.0       (24.8 – 43.0) 
- 71.6      (60.5 – 75.1) 
- 28.1      (25.0 – 38.3) 
0.5 
0.4 
NK-Cells (CD3-) 9.5                 (6.9 – 12.2)  13.1                (8.0 – 18.0) 0.013 
- CD16+ CD56dim HLA-DR- 
- CD16-  CD56+ HLA-DR- 
- CD16-  CD56+ HLA-DR+ 
- 75.1       (61.0 – 86.7) 
- 8.9         (6.1 – 13.2) 
- 14.4       (5.1 – 24.1) 
- 88.0      (84.7 – 92.6) 
- 6.1        (4.5 – 9.1) 
- 4.3        (2.7 – 9.2) 
0.001 
0.016 
0.005 
CD3+CD16+ 2.2                 (1.1 – 3.8) 1.8                (1.1 – 3.6) 0.7 
Contaminants / Undefined 3.7                 (3.0 – 5.2) 2.4                (1.9 – 3.9) 0.013 
 3 
* After exclusion of MAIT and γ/δ T-cells. Values expressed as percentage of parent population, Median (interquartile range). Significance of 4 
between group differences determined by Mann-Whitney U test.  5 
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Table 4-3 Lymphocyte sub-set phenotypes in CF subjects based on the presence of P. aeruginosa infection compared to healthy control 1 
subjects 2 
 CF, No P. aeruginosa (n=5) CF, P. aeruginosa infection (n=36) P-Value^ Non-CF (n=22) P-Value$ 
Sex                          (Female:Male) 3:2 14:22 0.4 11:11 1.0 
Age                         (years) 23.3         (18.4-41.7) 28            (24.5-32.6) 0.8 26            (25 - 32) 0.5 
BMI                         (kg/metre2) 24.7         (19.9-31.7) 23.4         (20.5-25.3) 0.5 24.6         (21.4 – 28.3) 0.8 
FEV1 % Predicted  (%) 72.4         (59.1-88.8) 63.6         (43.4-80.1) 0.3 110          (101 – 120) 0.001 
FVC % Predicted   (%) 83.9         (68.1-95.9) 79.3         (71.1-88.7) 0.5 107          (95 – 112) 0.012 
Lymphocyte Population (size gated, CD14-)  
T-Cells (CD3+CD16-) 68.2          (63.4 – 76.8) 72.9          (68.3 – 81.3) 0.4 74.9          (67.9 – 79.0) 0.3 
- CD4+CD8- 
- CD8+CD4- 
- MAIT Cells (CD161+, TCR Va7.2+) 
-      γ/δ T-cells (TCR γ/δ+) 
- CD4+CD8+ 
- CD4-CD8-* 
- 64.4  (49.6 – 70.0) 
- 26.2  (22.8 – 38.8) 
- 2.4    (1.4 – 3.6) 
- 8.0    (6.0 – 16.0) 
- 0.2    (0.2 – 0.2) 
- 3.1    (1.6 – 4.1) 
- 65.2  (56.9 – 70.5) 
- 25.1  (20.5 – 33.1) 
- 1.0    (0.3 – 1.8) 
- 10.5  (6.6 – 13.4) 
- 0.3    (0.2 – 1.1) 
- 2.1    (0.7 – 2.8) 
0.6 
0.6 
0.023 
0.7 
0.014 
0.2 
- 65.1  (59.9 – 71.4) 
- 27.4  (22.7 – 32.8) 
- 2.0    (1.4 – 3.1) 
- 6.4    (4.6 – 9.4) 
- 0.4    (0.3 – 1.7) 
- 1.6    (1.1 – 2.3) 
0.5 
0.9 
1.0 
0.2 
0.004 
0.1 
B-Cells (CD3-CD16-CD20+HLA-DR+) 17.2           (14.0 – 20.9) 8.5           (3.6 – 13.0) 0.002 4.8            (3.9 – 8.7) 0.003 
- Non-Resting (CD1c-) 
- Resting (CD1c+) 
- 74.5   (69.1 – 79.0) 
- 24.9   (20.3 – 30.5) 
- 64.1  (55.5 – 73.7) 
- 35.9  (25.3 – 43.9) 
0.1 
0.1 
- 71.6  (60.5 – 75.1) 
- 28.1  (25.0 – 38.3) 
0.1 
0.1 
NK-Cells (CD3-) 9.6             (4.6 – 10.9)  9.5            (7.8 – 12.5)  0.5 13.1          (8.0 – 18.0) 0.039 
- CD16+ CD56dim HLA-DR- 
- CD16-  CD56+ HLA-DR- 
- CD16-  CD56+ HLA-DR+ 
- 69.2   (48.5 – 80.9) 
- 10.9   (7.1 – 14.5) 
- 21.4   (10.8 – 37.4) 
- 76.1  (63.8 – 88.1) 
- 8.5    (6.1 – 13.3) 
- 14.2  (4.5 – 23.8) 
0.2 
0.5 
0.2 
- 88.0  (84.7 – 92.6) 
- 6.1    (4.5 – 9.1) 
- 4.3    (2.7 – 9.2) 
0.006 
0.1 
0.006 
CD3+CD16+ 2.0             (0.9 – 2.6) 2.5            (1.0 – 4.2) 0.4 1.8            (1.1 – 3.6) 0.9 
Contaminants / Undefined 1.8             (1.6 – 3.5) 3.7            (3.1 – 5.4) 0.017 2.4            (1.9 – 3.9) 0.4 
 3 
^CF No P. aeruginosa versus CF P. aeruginosa infection. $CF No P. aeruginosa versus Non-CF. *After exclusion of MAIT and γ/δ T-cells. 4 
Values expressed as percentage of parent population, Median (interquartile range). Significance of between group differences determined by 5 
Mann-Whitney U test. 6 
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Table 4-4 Lymphocyte sub-sets in CF subjects based on clinical stability and compared to healthy control subjects 1 
 CF, Pulmonary 
exacerbation (n=8) 
CF, Stable (n=13) P-Value^ Non-CF (n=22) P-Value$ 
Sex                          (Female:Male) 1:7 8:5 0.027 11:11 0.5 
Age                         (years) 32.2         (30.1-39.1) 22.7         (20.5-26.9) 0.001 26            (25 - 32) 0.010 
BMI                         (kg/metre2) 24.6         (23.5-26.0) 23.0         (21.5-27.0) 0.4 24.6         (21.4 – 28.3) 0.7 
FEV1 % Predicted  (%) 49.7         (40.3-68.5) 83.2         (74.1-88.8) 0.001 110          (101 – 120) <0.001 
FVC % Predicted   (%) 74.6         (71.2-79.3) 90.0         (85.9-96.4) 0.001 107          (95 – 112) 0.001 
Lymphocyte Population (size gated, CD14-)  
T-Cells (CD3+CD16-) 71.6          (68.1 – 82.3) 71.3          (67.1 – 77.1) 0.6 74.9           (67.9 – 79.0) 0.3 
- CD4+CD8- 
- CD8+CD4- 
- MAIT Cells (CD161+, TCR Va7.2+) 
-      γ/δ T-cells (TCR γ/δ+) 
- CD4+CD8+ 
- CD4-CD8-* 
- 65.9  (52.2 – 76.2) 
- 23.8  (16.4 – 37.8) 
- 1.1    (0.3 – 2.1) 
- 11.1  (7.1 – 16.5) 
- 0.2    (0.2 – 1.0) 
- 2.6    (1.4 – 3.5) 
- 58.3  (55.3 – 68.9) 
- 29.2  (23.6 – 35.3) 
- 1.1    (0.9 – 1.9) 
- 10.5  (6.4 – 13.6) 
- 0.2    (0.2 – 0.3) 
- 2.2    (1.3 – 3.4) 
0.5 
0.3 
0.7 
0.8 
0.5 
0.6 
- 65.1  (59.9 – 71.4) 
- 27.4  (22.7 – 32.8) 
- 2.0    (1.4 – 3.1) 
- 6.4    (4.6 – 9.4) 
- 0.4    (0.3 – 1.7) 
- 1.6    (1.1 – 2.3) 
0.1 
0.7 
0.018 
0.017 
0.010 
0.1 
B-Cells (CD3-CD16-CD20+HLA-DR+) 9.6            (2.5 – 14.0) 13.1           (8.5 – 16.7) 0.3 4.8             (3.9 – 8.7) 0.001 
- Non-Resting (CD1c-) 
- Resting (CD1c+) 
- 73.4  (65.5 – 79.9) 
- 25.6  (19.9 – 34.1) 
- 70.4  (59.9 – 79.9) 
- 29.3  (18.1 – 40.1) 
0.8 
0.8 
- 71.6  (60.5 – 75.1) 
- 28.1  (25.0 – 38.3) 
0.7 
0.7 
NK-Cells (CD3-) 10.1          (5.9 – 12.6)  9.6             (5.4 – 11.8)  0.7 13.1           (8.0 – 18.0) 0.020 
- CD16+ CD56dim HLA-DR- 
- CD16-  CD56+ HLA-DR- 
- CD16-  CD56+ HLA-DR+ 
- 70.7  (52.9 – 83.7) 
- 9.9    (8.6 – 12.6) 
- 19.4  (5.8 – 37.2) 
- 69.2   (55.3 – 80.5) 
- 8.0     (6.7 – 13.3) 
- 21.4   (13.2 – 30.6) 
0.9 
0.6 
0.8 
- 88.0   (84.7 – 92.6) 
- 6.1     (4.5 – 9.1) 
- 4.3     (2.7 – 9.2) 
<0.001 
0.026 
<0.001 
CD3+CD16+ 2.0            (1.2 – 4.0) 2.5              (1.1 – 4.2) 1.0 1.8              (1.1 – 3.6) 0.7 
Contaminants / Undefined 3.6            (3.1 – 4.2) 3.5              (2.5 – 4.1) 0.6 2.4              (1.9 – 3.9) 0.4 
 2 
^ CF pulmonary exacerbation versus CF stable, $CF stable versus Non-CF. *After exclusion of MAIT and γ/δ T-cells. Values expressed as 3 
percentage of parent population, Median (interquartile range). Significance of between group differences determined by Mann-Whitney U test.4 
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Figure 4-4 MAIT Cell percentage in CF subjects based on A. Presence of P. aeruginosa 
in sputum cultures, B. Clinical status.  
 
PE: pulmonary exacerbations, *two and ^one not infected with P. aeruginosa, between group 
differences determined by Mann-Whitney U test. 
Figure 4-5 MAIT cell percentage in CF subjects with Pseudomonas aeruginosa and a co-
pathogen in sputum culture.  
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Individual subjects may be represented multiple times, dependent on the number of co-
pathogens isolated from sputum cultures. Horizontal lines represent Median and interquartile 
range. No significant difference between groups when examined by Kruskal-Wallis test.
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Figure 4-6 Relationship between MAIT and γ/δ T-cell counts and percentages with lung function.  
 
A. Pearson’s Correlation co-efficient (r) and significance value (p) of MAIT and γ/δ T-cells and B. Correlation plots for MAIT Cell expressed as 
percentage of T-cell population, with FEV1 and FVC % predicted, C-reactive protein and body mass index.  MAIT: Mucosal invariant T-
Lymphocytes, γ/δ T-Cell: Gamma-Delta T-lymphocytes, FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity.
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Absolute MAIT cell count and MAIT cell percentage correlated positively with FEV1 and 
FVC percentage predicted. A weak relationship was seen between increased rate of FEV1 
decline and MAIT cells counts, but this did not reach statistical significance (Figure 4.6). 
MAIT cell percentage and absolute MAIT cell concentrations were inversely correlated with 
CRP (r= -0.34, p= 0.044 and r= -0.39, p= 0.021, respectively), however, there was no 
relationship between MAIT cells and total WCC.  
 
4.4.2 Relationship between γ/δ T-cells, microbiological and clinical parameters in 
subjects with CF. 
 
Absolute γ/δ T-cell counts correlated with FEV1 and FVC percentage predicted values. A 
trend toward more rapid rate of lung function decline in FEV1 was seen in subjects with 
lower γ/δ T-cells numbers (Figure 4.6A). No relationship between γ/δ T-cells when expressed 
as a percentage of total T-cells and lung function parameters was observed.  
γ/δ T-cell percentage and absolute cell number were inversely correlated with CRP (r= -0.44, 
p=0.008) and absolute γ/δ T-cell number was higher in stable CF subjects compared to 
subjects experiencing a pulmonary exacerbation (Figure 4.7). 
There was no relationship between γ/δ T-cell counts or percentages and absolute WCC or 
profile of infection with P. aeruginosa (Table 4.3).   
 
4.4.3 Relationship between other lymphocyte sub-subset and clinical parameter. 
 
Absolute blood lymphocyte count was positively correlated with FEV1 and FVC (litres and 
percentage predicted), however, no relationship was seen between absolute WCC and the 
percentage of the major lymphocyte sub-sets (T-cells, B-cells, NK-cells, CD3+/CD16+ cells) 
or lung function (Table 4.5). 
 
Total lymphocyte count was decreased in CF subjects being treated for a pulmonary 
exacerbation.  
 
B-cell percentage was higher in subjects not infected with P. aeruginosa, compared to CF 
subjects with chronic P. aeruginosa infection and healthy controls. There was a trend towards 
lower B-cell percentages in CF subjects during a pulmonary exacerbation compared to stable 
CF patients (Figure 4.8A and B). 
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Table 4-5 Relationship between White cell count and lymphocyte subsets, and C-
reactive protein, body mass index and lung function. 
 
 FEV1 % 
Predicted 
FVC % 
Predicted 
BMI 
(Kg/m2) 
CRP (mg/L) 
White Cell Count* (x106 per mL) r = 0.17 
p = 0.30 
r = 0.18 
p = 0.28 
r = -0.14 
p = 0.38 
r = -0.02 
p = 0.92 
Lymphocyte (x106 per mL) r = 0.50 
p = 0.001 
r  = 0.49 
p = 0.002 
r = -0.07 
p = 0.69 
r  = -0.45 
p = 0.007 
T-cell (% of lymphocytes) r  = -0.12 
p = 0.48 
r  = -0.11 
p = 0.50 
r  = -0.15 
p = 0.0.36 
r  = 0.28 
p = 0.10 
B-Cell (% of lymphocytes) r  = 0.27 
p = 0.09 
r  = 0.17 
p = 0.30 
r  = 0.34 
p = 0.031 
r  = -0.17 
p = 0.31 
NKT-Cell* (% of lymphocytes) r  = 0.08 
p = 0.61 
r  = 0.13 
p = 0.43 
r  = -0.14 
p = 0.48 
r  = -0.12 
p = 0.48 
NK-Cell* (% of lymphocytes) r = -0.07 
p = 0.68 
r  = -0.04 
p = 0.79 
r = -0.10 
p = 0.53 
r  = -0.25 
p = 0.15 
CRP* (mg/L) r = -0.54 
p = 0.001 
r = -0.51 
p = 0.002 
r = -0.22 
p = 0.20 
 
 
FEV1: Forced expiratory volume for one second, FVC: Forced vital capacity. *Ln 
Transformed prior to analysis. Pearson’s correlations (r) and p-value. 
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Figure 4-7 Comparison of γ/δ T-cell counts in stable subjects and subjects undergoing 
antibiotic treatment for a pulmonary exacerbation. 
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PE: pulmonary exacerbations. Between group differences determined by Mann-Whitney U 
test. 
Figure 4-8 Comparison of lymphocyte counts and percentage of lymphocyte sub-sets 
between A. Stable and pulmonary exacerbations B. P. aeruginosa infected and non-
infected CF subjects. 
 
Between group differences examined by Mann-Whitney U test. ** P=0.001 # P=0.004 
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4.5 Discussion. 
 
In this study we demonstrate for the first time that the peripheral blood of subjects with CF is 
characterized by a relative lymphopenia and major reductions in circulating MAIT cells and 
to a lesser extent an increase in γ/δ T-cells compared to normal healthy controls, consistent 
with both quantitative and qualitative differences in innate T-cell immunity in CF. 
Importantly, lung disease severity, systemic inflammation, clinical status and the presence or 
absence of chronic P. aeruginosa infection were all significantly related to the number of 
circulating MAIT cells in peripheral blood. 
 
The reduction in absolute lymphocyte counts as lung disease severity increases in the current 
study is consistent with a single previous study of peripheral blood lymphocytes in children 
with CF(276). Similar to this earlier study, a reduction in the percentage of NK-cells was also 
seen in subjects with CF, however, in contrast, no difference in the percentage of CD4+ T 
cells was seen and the percentages of other major lymphocyte subsets were similar between 
CF subjects and healthy control subjects(276). NK-cells represent an innate, cytotoxic subset 
of lymphocyte which primarily respond to viral infections and tumour cells(279). In addition, 
NK cells provide critical support to the eradication of bacterial pulmonary infection 
(including P. aeruginosa), principally through the generation of Th2 cytokines and IFN-
γ(280, 281). 
 
A higher percentage of B-cells was seen in CF subjects not infected with P. aeruginosa and a 
trend towards lower concentrations in subjects who were undergoing treatment for an acute 
pulmonary exacerbation. B-cells are critical for pulmonary protection against encapsulated 
bacteria and B-cells cultured in vitro respond to the mucoid exopolysaccharide of P. 
aeruginosa(282). Further longitudinal studies are required to delineate the role of B-cells 
during acute pulmonary exacerbations and to determine whether changes in circulating 
numbers can be attributed to peripheral destruction, tissue sequestration or transformation to 
plasma cells. 
 
The association between MAIT cells counts and P. aeruginosa infection, severe lung function 
impairment, increased systemic inflammation and acute pulmonary exacerbations in subjects 
with CF may suggest that MAIT cell deficiency is associated with susceptibility to 
pulmonary infection in CF. However, the sub-group of CF subjects undergoing a pulmonary 
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exacerbation may have been biased towards a lower MAIT cell concentration, as more 
subjects in this sub-group were male and in general they had poorer baseline lung 
function(283). Furthermore, these data are cross-sectional and do not inform on whether low 
MAIT cell numbers contribute to P. aeruginosa colonisation and disease progression, or 
whether low numbers simply reflect depletion of MAIT cells in the circulation, because of 
recruitment to the airway mucosa. 
 
MAIT cells provide a pivotal link between the innate and adaptive immune responses. The 
semi-invariant T-cell receptor on MAIT cells recognises metabolite derivatives of pathogens 
(e.g. vitamin B (riboflavin and folic acid)) presented combined to MR-1(284). Activated 
MAIT cells produce high concentrations of pro-inflammatory interleukin (IL)-17(220), which 
invokes a potent cascade of cytokines and chemokines (e.g. IL-8 and G-CSF) that promote 
neutrophil migration into the airways. Interleukin-17 is involved in neutrophil recruitment in 
CF and high concentrations have been described in sputum and bronchoalveolar lavage fluid 
of subjects with CF infected with P. aeruginosa and also in those patients with severe 
disease(55, 56, 285). 
 
Mouse models demonstrate MAIT cell recruitment into the lungs at a very early stage of 
bacterial infection and sustained MAIT cell responsiveness during the late stages of infection 
contributes towards an ongoing cytokine response(72). In mice with selective MAIT cell 
deficiency the immune response was ineffective in controlling pulmonary infection(72).  
 
Whilst we provide the first description of circulating MAIT cells in CF, understanding of the 
role of MAIT cells in human disease is limited. A reduction in the proportion of circulating 
MAIT cells has been reported in subjects with human immunodeficiency virus (HIV), 
Mycobacterium tuberculosis (MTB) and other severe pulmonary infections, and sepsis(69, 
70, 286-288). In HIV infection, blood MAIT cells concentrations decrease progressively from 
time of infection, however, MAIT cell density remains relatively preserved in rectal mucosa, 
suggesting possible preferential recruitment and thus loss from the circulating pool(289, 290). 
Similarly, MTB reactive MAIT cells are enriched in lung lymph of healthy people when 
compared to matched blood samples(291). Collectively, the results of these earlier studies 
and our current work suggest that although blood MAIT cell counts may not reflect tissue 
concentrations, they may still prove to be a useful, surrogate biomarker of the immune 
response within the lung(292). We demonstrate a strong, inverse relationship between MAIT 
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cell counts and CRP and the specificity of MAIT cell responsiveness to bacterial and fungal 
infections, offers the potential for improved specificity compared to CRP, which will respond 
to both viruses and non-infective sources of systemic inflammation(293). Further mechanistic 
studies of MAIT cells in CF, including assessment in the actual airway will provide novel 
insights into their role in innate and adaptive immunity in the CF lung, including whether 
effective vaccines can be developed that boost MAIT cell function to allow eradication of key 
bacterial pathogens. 
 
γ/δ T-cells represent a minor population of circulating T-cells, which has the capacity to 
expand rapidly in response to bacterial infection(66). γ/δ T-and MAIT cells share many 
similarities; they both produce IL-17 and preferentially migrate to mucosal surfaces from the 
circulation(67). In murine pulmonary infection models, γ/δ T-cells rapidly accumulate in the 
lung, in response to a range bacterial pathogens, where they facilitate the influx of neutrophils 
and subsequent bacterial clearance(66). The small increase in the proportion of γ/δ T-cells in 
the blood of CF subjects in the current study is consistent with findings of a single previous 
study in CF(68). However, the relationship between γ/δ T-cells and clinical parameters in CF 
subjects were only significant when absolute γ/δ T-cell concentrations were considered and 
these relationships may simply reflect changes in the absolute numbers of T-cells, rather than 
any implying any specific role for γ/δ T-cell in pathology. 
 
Our current study has several limitations. Firstly, cross-sectional data collection, does not 
inform whether a causal relationships exists between lymphocytes subsets and clinical 
parameters. Furthermore, the limited number of patients included in the analysis of stable 
disease versus pulmonary exacerbation, and inclusion of only five patients not infected with 
P. aeruginosa means type I statistical errors are possible. Longitudinal studies which collect 
blood samples from the same subject before and after the acquisition of P. aeruginosa, or 
during a pulmonary exacerbation and again during a period of stable disease are required. 
Finally, blood lymphocyte population may not reflect airway populations and studies which 
correlate lymphocyte concentrations in airway biopsies to those in the blood are anticipated.  
 
4.6 Conclusion. 
 
In summary, we describe important differences in the proportions of circulating MAIT and 
γ/δ T-cell in adult patients with CF, compared to healthy control subjects. Reduced numbers 
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of MAIT cells were associated with P. aeruginosa pulmonary infection and more severe lung 
disease. Our findings provide the impetus for future studies examining the utility of MAIT 
cells in immunotherapies and vaccine development, and longitudinal studies of MAIT cells as 
biomarkers of CF pulmonary infection. 
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Chapter 5. The effects of bio-active metals in the CF airway on disease severity. 
 
5.1 Abstract. 
 
Background: Bio-active trace metals have been identified in respiratory tract secretions of 
subjects with lung disease and may potentially influence bacterial virulence, inflammation 
and disease severity. We measured a diverse range of metal ions in sputum samples from 
subjects with CF and non-CF bronchiectasis (NCFB) compared to healthy controls and 
examined their relationship to airway inflammation, disease severity and the presence of 
bacterial pathogens. 
 
Methods: We studied 45 subjects with CF, 8 with NCFB and 8 healthy controls. Metal 
concentrations were measured in sputum supernatant by inductively-coupled plasma mass 
spectrometry and correlated with sputum inflammatory cell counts, lactate dehydrogenase 
(LDH) and interleukin (IL)-8 concentrations, lung function, clinical status and participant 
demographics. 
 
Results: Sputum from subjects with CF and NCFB contained increased concentrations of 
magnesium, calcium, iron and zinc. Metal ion concentrations correlated positively with LDH 
levels. The concentrations of magnesium, iron and zinc positively correlated with IL-8. A 
sub-group of CF subjects with severe lung disease demonstrated increased sputum 
molybdenum concentrations. 
 
Conclusion: Elevated concentrations of sputum metal ions appear to be associated with 
cell/tissue necrosis and inflammation in subjects with CF and NCFB. Sputum molybdenum 
concentrations may be a biomarker of severe CF airways disease.  
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5.2 Introduction. 
 
The majority of individuals with cystic fibrosis (CF), the most common lethal genetic 
condition in Caucasians, will die prematurely from complications of chronic pulmonary 
sepsis(127). Intermittent airway infection and inflammation in CF begins in infancy, resulting 
in early onset bronchiectasis in many children(294). By adulthood, chronic, poly-microbial 
infection is established, in which Pseudomonas aeruginosa is the dominant pathogen in more 
than eighty percent of patients(1). The host immune response to infection in CF is intense and 
persistent, but is ineffective in clearing bacterial infection from the airways and contributes to 
local tissue destruction through the generation of proteolytic enzymes and reactive oxygen 
species (ROS)(295). 
 
As pulmonary disease progresses, plugging of the distal airways by dehydrated sputum, 
creates micro-aerobic or frankly anaerobic pockets, with low pH and altered nutrient 
availability(212, 213). The highly abnormal environment within these regions drives 
phenotypic adaptation and alters the virulence of the incumbent bacteria, favouring pathogens 
capable of survival in low oxygen environments(213). 
 
Bio-active trace metals (biometals) are essential co-factors in a wide range of human and 
bacterial enzyme systems, however, strict regulation of their bioavailability is essential to 
prevent toxicity(215). A limited number of previous studies in patients with CF, non-CF 
bronchiectasis and chronic bronchitis have demonstrated increased iron (Fe), zinc (Zn) and 
copper (Cu) concentrations in airway secretions and have postulated that these metals may 
influence disease severity(179, 216). 
 
There is increasing interest in Fe in the CF lung. In vitro studies demonstrate that Fe strongly 
influences the ability of P. aeruginosa to form co-dependent bacterial communities 
(biofilms), which represent the major barrier to the eradication of established airway 
infection. Manipulation of Fe availability has therefore been proposed as a novel therapeutic 
strategy for the treatment of chronic P. aeruginosa infection(196, 217). An observational 
study by Gray and colleagues has previously demonstrated increased concentrations of Zn 
and Cu in the CF lung(216), and in separate in vitro studies these metals have been shown to 
induce P. aeruginosa resistance to carbapenem antibiotics(218). From the host perspective, 
airway Fe and other redox active biometals may catalyse the production of ROS and promote 
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inflammation(214). Conversely, Cu and Zn are key components of airway anti-inflammatory 
superoxide dismutases (SODs)(296). The origin of airway metal ions has not been 
determined, with potential sources including vascular leak, channelopathies and release from 
necrotic airway cells, or the bacteria themselves.  
 
In this study, we expand on previous work by examining a more diverse range of biometals in 
expectorated sputum samples from patients with CF and non-CF bronchiectasis (NCFB). 
Sputum biometal concentrations are compared to those in healthy controls, and correlated 
with sputum lactate dehydrogenase (LDH) as an index of local tissue necrosis and interleukin 
(IL)-8 as a marker of airway inflammation and host immune response. To examine the 
influence of infection and clinical status on biometal concentration, we included a sub-group 
of patients with CF who were not infected with P. aeruginosa and followed a group of P. 
aeruginosa infected patients through treatment of a pulmonary exacerbation with a course of 
intravenous antibiotic therapy.  
 
Calcium (Ca), magnesium (Mg), manganese (Mn), Zn and Cu were selected for their 
importance in inflammatory pathways(214, 296, 297). Molybdenum and Fe were selected for 
their potential importance to bacterial virulence and anaerobic respiration(179, 298). Finally, 
nickel (Ni) and lead (Pb) were included as potential indicators of environmental 
contamination(299, 300). 
 
5.3 Methods. 
 
5.3.1 Participants and sample collection. 
 
Participants were recruited from The Prince Charles Hospital, Queensland and Royal Hobart 
Hospital, Tasmania, Australia. Institutional human research and ethics committee approval 
was gained from both sites (HREC2008:2885 and H0009813 respectively). Sixty-seven 
spontaneously expectorated sputum sample were collected from 45 subjects with CF and a 
single sputum sample was collected from eight subjects with NCFB. Induced sputum was 
collected from eight healthy controls following inhalation of nebulised 4.5% hypertonic 
saline. For cross-sectional analyses, the initial sputum sample collected from each subject 
was used. Eleven subjects with CF provided samples at several time-points during 
intravenous antibiotic treatment of a pulmonary exacerbation. Participant demographics, 
 135 
 
including infecting pathogens were recorded (Table 5.1). None of the participants reported 
regular tobacco smoking. 
 
5.3.2 Sputum processing. 
 
Sputum plugs free of salivary contamination were separated from the expectorated sputum 
samples and homogenised with dithiothreitol as previously described(301). Homogenised 
samples were diluted with phosphate buffered saline (dilution factor 1:10) and centrifuged to 
pellet cells. The cell free supernatant was removed and stored at -80°C for later batch analysis 
of biometals. The cell pellet was resuspended and total inflammatory cell count (TCC) 
performed using standard methodology(301). 
 
5.3.3 Inductively coupled plasma mass-spectrometry (ICPMS) analysis. 
 
To prepare samples for ICP-MS, 500 μL of sputum supernatant was digested overnight in an 
acid-cleaned tube containing 500 μL of 3M double-distilled nitric acid (HNO3) and 1 mL of 
an internal standard spike solution (6He, 61Ni, 103Rh, 115In, 187Re and 209Bi). Digested samples 
were diluted to 10 mL with 0.3M HNO3 and analysed using a Thermo Fischer X Series 
ICPMS machine. Four replicates per sample were averaged for the final calculation. For 
calibration and to establish recovery rates, standard reference materials W2 and SLRS5 and 
multi-element standards were analysed at the beginning and the end of the run. Internal 
standards were used to correct for internal drift. A monitor solution, used to correct for 
external drift, and an instrument blank solution, used to monitor baseline drift and memory 
effects, were analysed at regular intervals throughout the run.  
 
 
5.3.4 LDH and IL-8 measurement. 
 
LDH activity was determined in thawed sputum supernatants warmed to 37°C using a LDH 
colorimetric assay kit (Abcam Inc, Cambridge, MA) according to the manufacturer’s 
protocol. IL-8 (biolegend, USA) concentration was measured according to the manufacturer’s 
protocol with a detection range between 31.25-4000 pg/ml. Each sample was diluted as 
necessary to fall in the linear range and assayed in duplicate. 
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5.3.5 Air quality assessment. 
 
To examine whether atmospheric pollutants potentially contributed to sputum metal 
concentrations, we recorded the level of atmospheric particulate matter 10 micrometres or 
smaller (PM10) as reported by the Queensland Department of Environment and Heritage 
Protection (http://www.ehp.qld.gov.au/air/data/search.php) for the city of Brisbane on the day 
a sputum sample was collected. These data were available for subjects sampled through the 
Prince Charles Hospital, but no similar data were available for Tasmanian participants. 
 
5.3.6 Statistical analysis 
 
Between-group differences in continuous variables were analysed by independent samples t-
test, analysis of covariance, Mann-Whitney U or Kruskal-Wallis H test, depending on 
number of independent groups and normality of the data. Pearson’s correlation was used to 
examine relationships between lung function, TCC, IL-8, LDH, PM10 and biometal 
concentrations. A p-value <0.05 was considered to represent statistical significance. Data 
analysis was performed using PASW, Version 18.0 (SPSS Inc. Chicago, IL, USA) 
 
5.4 Results. 
 
5.4.1 Cross-sectional comparisons 
 
Sixty-one samples (8 normal, 8 NCFB, 45 CF) were included in the cross-sectional analysis. 
Sputum from subjects with CF and NCFB demonstrated a high TCC and contained 
significantly higher concentrations of Mg, Ca, Fe and Zn compared to healthy controls (Table 
5.2).  
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Table 5-1 Participant Demographics 
 Normal (n=8) CF (n=45) Non-CF Bronchiectasis 
(n=8) 
Age (years) 57 (7) 29 (12) 60 (10)b 
Sex (M:F) 6:2 28:17 4:4 
FEV1 % predicted 106 (10) 53 (23)a 33 (15)c 
FVC % predicted 110 (16) 65 (21)a 61 (6)c 
BMI n/a 21 (3)b 25 (4)d 
Airway pathogens (n, %) 
- Pseudomonas aeruginosa 
- MSSA 
- Aspergillus spp 
- MRSA 
- Burkholderia spp 
- Haemophilus influenzae 
 
- 
- 
- 
- 
- 
- 
 
33 (73%) 
16 (36%) 
9   (20%) 
2   (4%) 
3   (6%) 
1   (2%) 
 
6 (75%) 
- 
2 (25%) 
- 
- 
1 (13%) 
 
Values reported as mean (standard deviation) unless otherwise stated, M:F: Male:Female 
ratio, data unavailable for a one, b two, c three, d four subjects, MSSA: methicillin sensitive 
Staphylococcus aureus, MRSA: methicillin resistant Staphylococcus aureus, spp: species. 
BMI: Body mass index. n/a: not available. 
---------------------------------------------------- 
 
Sputum metal concentrations were compared to published data on biometal concentration in 
normal serum, whole blood and pleural fluid (Table 5.2)(302-306). Sputum from subjectts 
with CF and NCFB contained higher metal concentrations than serum and pleural fluid 
(except for Cu). Sputum from healthy controls contained lower concentrations of biometals 
than serum, pleural fluid and whole blood (except for Pb which was higher than in serum and 
pleural fluid). 
 
In patients with CF, two distinct cohorts of subjects were detected with and without 
significant concentrations of Mo (Figure 5.1). Subjects with “elevated” Mo concentrations 
had lower FEV1% predicted, but also lower TCC (Table 5.4).  
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Table 5-2 Comparison of sputum inflammatory markers and biometals in healthy controls, CF and non-CF bronchiectasis 
 
 
 
 
Values reported as median (interquartile range), data unavailable on a one patients, b three patients, c four patients, d six patients, mg/L: 
milligrams per litre, µL/L: micrograms per litres, ng/ml: nanograms per millilitre, significantly different to normal at g p<0.001, f p<0.01, e 
p<0.05 level, significantly different to CF at ip<0.01, h p<0.05 level (Mann Whitney U test).  
 Normal (n=8) CF (n=45) Bronchiectasis (n=8) Pleural 
Fluid [21] 
Serum 
[Reference] 
Blood  
[Reference] 
TCC (10^6 cell/ml) 0      (0-1) 12       (4-21)g 24       (12-35)f    
LDH (mU/ml) 39    (0-95)b 50       (1-247)d 13       (3-1657)a    
IL-8  (ng/ml) 28    (15-64)b 135     (84-279)c,f 103     (13-292)a    
       
Mg    (mg/L) 4       (2–7) 30       (19-44)g 33       (27-39)f 18 22           [295]  
Ca     (mg/L) 45     (28–58) 102     (76-123)g 124     (78-156)f 71 96           [295]  
Mn    (µg/L) 5       (2-9) 6         (4-17) 6         (4-10) 1  1.0          [295] 12           [296] 
Fe      (µg/L) 0       (0-37) 797     (398-1292)g 1075   (862-1324)f n/a 4690       [298] 476000   [296] 
Ni      (µg/L) 12     (1-60) 5         (0-23) 26       (2-99) n/a 2.2          [29] 2.7          [296] 
Zn     (µg/L) 179   (103-597) 1285   (678-1811)g 537     (401-838)c h 283 474         [295] 5800       [296] 
Cu     (µg/L) 106   (55.3-196) 173     (128-257) 226     (130-314) 530 1189       [295] 830         [296] 
Mo    (µg/L) 0       (0) 0         (0-181)e 0         (0)i 1 1.2          [295] 0.9          [296] 
Pb     (µg/L) 9       (4-21) 3         (1-6)e 2         (1-5)e 6 1.3          [295] 26           [299] 
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Table 5-3 Correlation co-efficients of biometals in all sputum samplesc,d,e 
 Ca Mn Fe Zn Cu FEV1 % 
Predicted 
TCC IL-8 LDH PM10 
Mg 0.89a 0.13 0.79a 0.75a 0.42a -0.20 0.05 0.42a 0.44a 0.05 
Ca - 0.15 0.80a 0.67a 0.49a -0.16 -0.02 0.23 0.33a 0.11 
Mn - - 0.29a 0.12 0.06 0.28b -0.13 0.15 -0.14 -0.14 
Fe - - - 0.75a 0.47a -0.11 -0.08 0.39a 0.40a 0.03 
Zn - - - - 0.46a -0.18 0.02 0.38a 0.39a 0.03 
Ni - - - - - -0.30b -0.01 0.03 0.11 0.03 
Cu - - - - - -0.20 -0.15 0.23 0.32a 0.04 
Mo - - - - - -0.38a -0.31 0.18 0.02 -0.03 
Pb - - - - - -0.08 -0.13 -0.19 -0.10 -0.03 
 
Values: Pearsons correlation - r values, a p<0.01, b p<0.05. cCorrelation of Ni, Mo and Pb with other metals were not significant and are not 
included. dCorrelations with FEV1 % predicted, TCC, IL-8 and LDH do not include healthy control data. 
eCorrelations with PM10 are based on 
43 samples obtained from subjects with CF recruited from Queensland, where comparative air-quality data was available. FEV1 % predicted: 
percentage predicted forced expiratory volume in one second. TCC: total inflammatory cell count. IL: interleukin. LDH: lactate dehydrogenase. 
PM10: Particulate matter 10 micrometres or smaller in diameter. 
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Figure 5-1 Concentration of molybdenum in sputum samples. 
 
Distribution of sputum sample Molybdenum concentrations by disease type. Circle, represents CF 
patient samples which were classified as containing a high Molybdenum concentration in 
subsequent analyses (see Table 5-4) 
---------------------------------------------------- 
 
Six subjects with NCFB and 33 with CF were infected with P. aeruginosa. CF subjects infected 
with P. aeruginosa had lower lung function (Median FEV1 % predicted 38% v 71%, p<0.01) and 
higher sputum concentration of IL-8 (165 v 70 ng/ml, p<0.01), Ca (105 v 74 mg/L, p<0.01) and Mg 
(22 v 47 mg/L, p<0.05) compared to subjects without P. aeruginosa infection, however TCCs and 
levels of other measured metals were not significantly different (Table 5.5). 
 
5.4.2 Relationship between biometals, LDH, IL-8 and PM10 within samples. 
 
A correlation analysis, including all sputum samples demonstrated that the concentrations of Mg, 
Ca, Fe, Zn and Cu were all strongly correlated with one another (Table 5.3). Conversely, no 
relationship was seen between concentrations of Pb, Mo or Ni. In sputum samples from subjects 
with CF and NCFB, both LDH and IL-8 concentrations positively correlated with the concentration 
of Mg, Fe and Zn, and LDH alone correlated with Ca and Cu concentrations (Table 5.3). 
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Table 5-4 Comparison of CF patients with elevated and non-elevated molybdenum levels. 
 
 Non-elevated Mo (n=31) Elevate Mo (n=14) p-value 
Age    (years) 27         (20-39) 29         (19-38) 0.90 
Sex     (M:F) 19:12 9:5  
BMI   (kg m-2) 20         (19-24) 20         (17-22) 0.42 
FEV1 (% predicted) 53         (37-78) 36         (28-58) 0.09 
FVC   (% predicted) 67         (50-88) 56         (41-71) 0.04 
    
TCC  (106 cell/mL) 15         (6-26) 5           (2-10) 0.01 
LDH  (mU/ml) 43         (1-131) 56         (1-680) 0.13 
IL-8   (ng/L) 105       (81-278) 232       (126-298) 0.41 
    
Mg    (mg/L) 33         (19–47) 27         (18-32) 0.17 
Ca     (mg/L) 105       (77–136) 90         (74-108) 0.16 
Mn    (µg/L) 6           (4-19) 7           (3-16) 0.73 
Fe      (µg/L) 797       (476-1242) 852       (347-1517) 0.93 
Ni      (µg/L) 1           (0-21) 21         (10-33) 0.01 
Zn     (µg/L) 1021     (587-1377) 1794     (835-2149) 0.04 
Cu     (µg/L) 185       (131-253) 150       (117-269) 0.49 
Pb     (µg/L) 3           (1-6) 2        (0-7) 0.27 
 
Non-elevated Mo: <20 µg/L, Elevated Mo >= 20 µg/L. Data given as median (interquartile Range). 
Significant difference assessed by Mann Whitney U test. 
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Table 5-5 Comparison of CF subjects, infected and non-infected with Pseudomonas 
aeruginosa. 
 P. aeruginosa 
Infected (n=33) 
P. aeruginosa   
Non-infected (n=12) 
p-value 
Age    (years) 29         (22-36) 19         (17-41) 0.10 
Sex     (M:F) 19:14 9:3  
BMI   (kg m-2) 21         (20-22) 20         (19-25) 0.93 
FEV1 (% predicted) 38         (27-58) 71         (54-91) <0.01 
FVC   (% predicted) 55         (44-71) 78         (62-99) <0.01 
    
TCC  (106 cell/mL) 11         (5-19) 17         (4-55) 0.30 
LDH  (mU/ml) 54         (3-270) 2           (0-110) 0.10 
IL-8   (ng/L) 165       (86-338) 70         (70-90) <0.01 
    
Mg    (mg/L) 31         (22–47) 19         (13-33) <0.05 
Ca     (mg/L) 105       (87–132) 74         (74-108) <0.01 
Mn    (µg/L) 6           (4-18) 6           (3-18) 0.62 
Fe      (µg/L) 857       (460-1292) 649       (304-1271) 0.29 
Ni      (µg/L) 9           (0-23) 2           (0-21) 0.73 
Zn     (µg/L) 1304     (678-1693) 983       (635-2279) 0.88 
Cu     (µg/L) 185       (143-288) 130       (94-183) 0.05 
Mo    (µg/L) 0           (0-187) 1           (0-92 0.70 
Pb     (µg/L) 3           (0-7) 3           (1-6) 0.40 
 
Data given as median (interquartile Range). Significant difference assessed by Mann Whitney U 
test. 
 
---------------------------------------------------- 
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Comparative PM10 data was available for 43 sputum samples from 23 CF subjects. There was no 
correlation between PM10 and metal concentrations in sputa on the day of collection (Table 5.3). 
 
5.4.3 Sputum Biometals during pulmonary exacerbations. 
 
Four CF subjects had increased sputum Pb levels on admission, which fell to trace levels during the 
course of the admission. Sputum Fe concentration increased during treatment in three subjects, of 
which, two received intercurrent iron infusions to correct severe iron deficiency. There was no 
consistent change in sputum concentrations of the other metals during treatment of a pulmonary 
exacerbation (Figure 5.2). 
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Figure 5-2 Longitudinal changes in sputum biometals for subjects with CF undergoing 
treatment for a pulmonary exacerbation. 
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Figure 5.2 continued Longitudinal changes in sputum biometals for subjects with CF 
undergoing treatment for a pulmonary exacerbation. 
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5.5 Discussion. 
 
This work provides important new insights into the inflammatory milieu present in the lungs of 
patients with CF and NCFB. A diverse range of biometals were present in the sputum of subjects 
with these suppurative lung diseases, several of which have the potential to significantly influence 
both host immunity and bacterial virulence(307).  
 
Defining the importance of the biometals we detected in sputum and how these metals relate to lung 
disease severity will advance our understanding of the lung micro-environment in diseases 
characterised by chronic bacterial infection. Accurately characterising the presence of biometals, 
will also provide information that will be relevant to the development of in vitro infection models 
and potentially, identify targets for novel therapies(196). 
 
The strong positive correlation between the concentrations of Ca, Mg, Fe, Zn and Cu suggests that 
these metals originate from a common source, or reflect a common disease process. LDH has 
previously been identified as a surrogate marker of pulmonary tissue damage and the positive 
correlation between several of the biometals detected and LDH levels supports cell injury as a 
probable contributor to the presence of some of  these biometals(308). The concentration of sputum 
biometals more closely represent levels seen in whole blood compared to serum (Table 5.2) and 
several metals (Mg, Fe and Zn) correlated positively with the concentration of pro-inflammatory IL-
8, adding further support to the hypothesis that release of these metals is associated with local tissue 
damage.  
 
Consistent with previous studies, CF subjects infected with P. aeruginosa had worse lung function 
and higher sputum IL-8 concentration, than their non-infected counterparts(309). Surprisingly, there 
was a trend towards lower TCCs in the P. aeruginosa infected patients, however, sputum 
concentrations of Mg and Ca were significantly higher, which may again support a hypothesis that 
these metals are released from necrotic immune cells in the setting of heightened inflammation. 
From our results, it is not possible to determine whether the biometals originated from injured lung 
tissue or from luminal inflammatory cells and investigation of metal levels within the airway wall 
or lung parenchyma are required to address this question.  
 
Other potential sources of biometals in sputum should be considered, including micro-vascular 
leakage, cell membrane channelopathies and contamination from inhaled particulates. We have 
previously reported increased concentrations of micro-albumin in CF sputa, which may suggest 
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microvascular leakage is contributory(177), but sputum biometal levels exceeded those reported in 
serum, which argues against this being the sole explanation(303-305).  
 
CFTR-mutant airway epithelial cells (AECs) appear to “leak” Fe in vitro, which in-turn promotes 
growth of P. aeruginosa on their apical cell surface membrane, and suggests specific 
channelopathies may contribute to airway metal accumulation(180). For example, divalent metal-
ion transporter (DMT)-1 is important in airway Fe detoxification and, in DMT-1 deficient rats, Fe 
accumulates in the airways, resulting in increased oxidative stress and inflammation(310). This 
observation is important, as abnormal function of metal transport defects may be amenable to 
therapeutic manipulation to limit the availability of metals to pathogenic bacteria. 
 
The contribution of inhaled particulate matter to sputum metal concentrations was assessed by 
measurement of sputum of Pb and Ni concentrations and correlation of sputum biometal 
concentrations to atmospheric PM10 levels on the day of sample collection. Lead was detectable in 
the sputa of four CF subjects on admission to hospital, but not at subsequent time-points, raising the 
possibility that this metal was environmentally derived (e-figure 1). However, PM10 values did not 
correlate with sputum metal content in any of the subjects. Furthermore, Pb and Ni concentrations 
in subjects with CF and NCFB were not significantly different to those found in healthy controls. 
Taken together, these findings strongly suggest that environmental exposure to metals has minimal 
impact on sputum biometal content. 
 
An important new finding is the identification of a distinct group of CF subjects with “elevated” 
concentrations of sputum Mo. Subjects with elevated Mo overall had more severe lung disease and 
a sub-group had CF related liver disease. Molybdenum is able to cycle between reduced (Mo4+) and 
oxidised (Mo6+) states under normal physiological conditions and facilitate the transfer of atomic 
oxygen between substrates in anoxic environments, which makes it essential to virtually all forms 
of life(298). In humans, Mo co-factored proteins are incorporated into the flavoenzymes, which 
catalyse critical detoxification pathways(311). Increased serum Mo concentrations have been 
reported in patients with liver disease, a finding not inconsistent with our sputum findings, although 
we did not assess Mo levels in serum to confirm a corresponding increase in systemic levels(312). 
In bacteria, Mo is an essential component of nitrate reductase, which catalyses the denitrification of 
nitrate during anaerobic respiration(298). Whilst P. aeruginosa is an aerobic bacterium, it can thrive 
under microaerobic and anaerobic conditions through the utilisation of nitrogen sources(313). 
Under anaerobic conditions, P. aeruginosa increases the production of Mo containing proteins and 
mutant strains that are unable to incorporate Mo have attenuated virulence(314). The evidence for 
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anaerobic bacterial respiration in the diseased CF lung is compelling, with the presence of a variety 
of obligate anaerobes identified in addition to P. aeruginosa(74, 313). It is biologically plausible 
that airway Mo may promote anaerobic respiration in resident bacteria, but this requires further 
investigation. Future, longitudinal studies, which correlate Mo concentrations with, clinical status 
(stable versus pulmonary exacerbation), lung function decline, infecting pathogens and serum Mo 
levels are required to determine its source and relevance to bacterial virulence and outcomes in 
patients with CF. 
 
Increased Fe in the sputum of patients with CF has been demonstrated in several studies(176-179). 
Iron poses a risk to the lung through generation of toxic hydroxyl radicals and oxidative stress via 
Fenton chemistry and, as previously discussed, Fe has been shown to influence P. aeruginosa 
behaviour in vitro(217). Furthermore, Fe concentrations positively correlate with P. aeruginosa 
colony counts in the sputum of patients with CF confirming its importance in vivo(179). 
 
Magnesium has generally been considered to be anti-inflammatory, but animal studies have shown 
that it may inhibit phagocytosis and impair the oxidative burst capacity of neutrophils, which will 
be detrimental in the setting of chronic infection(315). From a bacterial perspective, conflicting in 
vitro studies suggest Mg may inhibit formation of new P. aeruginosa biofilms, but protect 
established biofilms from disruption(316).  
 
Calcium was also present in high concentrations in sputa from patients with CF and NCFB, and in 
vitro studies have demonstrated that Ca-dependent signalling enhances P. aeruginosa cell 
adherence, including adherence to AECs(317). Calcium increases P. aeruginosa biofilm thickness, 
and promotes the production of pyocyanin and other virulence factors(318). Pyocyanin itself, which 
is an important P. aeruginosa exotoxin, disturbs AEC Ca homeostasis, which will serve to further 
increase airway Ca concentrations(319).  
 
The high concentration of Zn found in CF and, to a lesser extent, NCFB sputa is consistent with a 
single, previous publication. This finding is surprising given the high prevalence of systemic Zn 
deficiency reported in CF, and may therefore suggest selective Zn loss into the airways(300, 320). 
Human AEC strongly express the anti-oxidant Cu-Zn-SOD and systemic Zn deficiency increases 
airway inflammation and susceptibility to oxidative stress(296). Zinc co-factored 
metalloproteinases, such as ADAM33, contribute to airway remodelling in response to repeated 
insults(321). In vitro and animal models suggest Zn restores defective chloride transport by 
activating alternative Ca-dependent chloride channels and Zn supplementation has been shown to 
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be of modest benefit in reducing antibiotic requirements in children with CF(320). In bacteria, Zn is 
an essential metal, but also potentially toxic and its uptake is tightly regulated(218). P. aeruginosa 
Zn uptake is regulated by the operon CzcRS, which in the presence of Zn promotes expression of 
the metal efflux pump CzcCBA. Additionally, CzcRS down regulates OprD that confers resistance 
to carbapenem antibiotics, suggesting an increase in Zn within the airway may influence antibiotic 
susceptibility(218). The net effect on disease outcomes in CF and NCFB of increased airway Zn 
concentrations remains uncertain, given the anti-inflammatory properties versus potential promotion 
of antibiotic resistance, and requires further investigation. 
 
This study has a number of limitations. Studies of airway pathology based on expectorated sputum 
are intrinsically associated with sampling variability and confounded by the possibility of 
oropharyngeal contamination, but we were very careful to select only airway plugs and salivary 
contamination with this practice is minimal(322).  Only a small numbers of healthy controls and 
patients with NCFB, but our numbers are comparable with earlier reports(176, 178, 216). There was 
no change in sputum metal ion concentrations during treatment of a pulmonary exacerbation, 
suggesting that the measurement of metals has limited potential as a biomarker of therapeutic 
response. However, patients who provided serial samples were at the severe end of the disease 
spectrum. These individuals often respond sub-optimally to antibiotic treatment, in terms of their 
clinical improvement, reduction in bacterial numbers and inflammation, which may have limited 
our ability to detect meaningful changes(322). Future studies should examine whether biometal 
concentrations fluctuate in response to treatment in patients with milder disease, and also at a much 
earlier time-point in the disease process, i.e. prior to the onset of infection. Additionally, studies in 
subjects at an earlier disease time-point may allow metal concentrations to be correlated with the 
presence of different inflammatory cell types (i.e neutrophils versus macrophages), which is not 
possible in the adult subjects, with severe disease, where airway inflammation is dominated by 
neutrophils. Finally, analysis of the impact of specific bacterial infections, e.g. MRSA and 
Burkholderia species, on biometal levels is limited by the study size. 
 
5.6 Conclusion. 
 
In summary, this is the most extensive analysis of sputum biometals in patients with CF and NCFB 
undertaken to date. The positive correlation between sputum LDH and biometal concentrations 
suggests that local cell damage is associated with airway metal content, however, whether local 
tissue injury is the source or a consequence of the presence of redox active biometals in the airway 
requires further investigation. A sub-group of CF patients with severe lung disease were identifiable 
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by the presence of increased Mo in their sputum. It is likely that the complex composition of the 
biometals milieu in the lung strongly influences the behaviour of both the host immune response as 
well as bacterial pathogens. Mechanistic studies are required to establish the source of the metals 
detected and to determine their relevance to oxidative stress, impaired immune function and the 
promotion of bacterial virulence. Novel therapeutic interventions that modulate the availability of 
these biometals may reduce airway infection and substantially impact on disease progression. 
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Chapter 6. HFE as a Gene Modifier in CF 
 
6.1 Abstract 
 
Aims: Genetic modifiers contribute to variable disease phenotype in cystic fibrosis (CF). We 
explore the association between mutations in the haemochromatosis (HFE) gene and disease 
severity in adults with CF. 
 
Methods: HFE genotyping was performed in 163 adults with CF attending a single centre. Results 
were correlated with lung disease severity, prevalence of CF-related diabetes (CFRD) and history of 
meconium ileus (MI) or distal intestinal obstruction syndrome (DIOS). 
 
Results: Subjects with the C282Y substitution in the HFE protein (C282Y mutation) had a lower 
FEV1 percentage predicted (51% versus 66%, p=0.032) and accelerated rate of FEV1 decline (-
110mL versus -80mL per year respectively, p<0.001) compared to subjects with a normal HFE 
genotype. C282Y substitutions were associated with increased rates of CFRD (58% versus 33%, 
P=0.022) and MI or DIOS (38% versus 19%, p=0.045).  H63D HFE substitutions were associated 
with a more rapid rate of decline in forced vital capacity and increased risk of MI or DIOS. 
 
Conclusions: In subjects with CF, the C282Y HFE substitution was associated with worse lung 
function, and increased rates of CFRD and gastrointestinal complications. The H63D HFE 
substitution also impacted on disease phenotype, but to a lesser extent. The results support a role for 
HFE gene mutations as modifiers of CF phenotype. 
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6.2 Introduction 
 
Cystic fibrosis (CF) is an autosomal recessive, multi-organ disease, which results from mutations of 
the CF transmembrane conductance regulator (CFTR) gene. The vast majority of deaths and 
morbidity result from complications of CF-related lung disease(1, 3). Phenotype/genotype studies 
have demonstrated considerable variability in the severity of lung disease despite patients having 
the same CFTR genotype. This variability may reflect non-CFTR genetic modifiers, differences in 
environmental factors, and access to and the nature of clinical care(18). Genetic modifiers may alter 
CFTR function, or modify the CF phenotype at the molecular, cellular, systemic or organismal 
level(19). Studies utilising a combination of candidate gene and genome wide association studies 
(GWAS) have identified mutations in genes which encode immune mediators (including mannose 
binding lectin (MBL), transforming growth factor β, interferon-related developmental regulator 1 
and interleukin 1), anti-oxidants (e.g. glutathione pathways), ion transporters (e.g. solute carrier 
family genes), pancreatic β-cell function (transcription factor 7-like 2) and Serpin peptidase 
inhibitor, clade A (SERPINA)-1  as potentially important modifiers of  the CF phenotype(18, 20-24, 
323, 324).  
 
In hereditary haemochromatosis (HH), another common clinically important, autosomal recessive 
condition in Caucasian populations, mutations in the HFE gene impact on systemic iron 
homeostasis by inhibiting the production and release of the regulatory protein hepcidin from the 
liver in response to iron loading(145). A single point mutation in the HFE gene (leading to the 
C282Y substitution in the HFE protein) accounts for >90% of cases of HH(145). Homozygotes for 
the C282Y mutation demonstrate the most severe iron loading and phenotype, typified by liver 
fibrosis and cirrhosis, small joint arthropathy and diabetes mellitus(145). A second HFE gene 
mutation (leading to the H63D substitution), whilst more prevalent in the population, is typically 
only associated with iron loading when present in combination with the C282Y mutation (i.e. 
compound heterozygotes), and then only infrequently. The presence of a single HFE gene mutation 
does not usually result in an iron loading phenotype, nevertheless heterozygotes with either a 
C282Y or H63D mutations may be at increased risk of liver disease, neurodegenerative disease, 
type II diabetes and malignancy, suggesting either impaired iron handling at a cellular level or some 
iron-independent function of HFE(325-328). 
 
In our earlier small study, subjects with CF who had co-inherited a HFE gene mutation had more 
severe CF lung disease(174). Furthermore, two studies of children with CF have reported an 
association between the C282Y mutation and the risk of meconium ileus (MI) at birth(173, 175). 
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This current study further explores the association between HFE gene mutations and CF, including 
CF-related lung disease, risk of CF-related diabetes (CFRD) and bowel obstruction (MI and distal 
intestinal obstruction syndrome [DIOS]) in adults with CF. 
 
6.3 Methods 
 
Subjects over 18 years of age with CF were recruited from the Adult CF Centre of The Prince 
Charles Hospital, Brisbane, Queensland, Australia. The study was approved by the Prince Charles 
Hospital, Human Research and Ethics Committee (HREC/11/QPCH/36) and all subjects provided 
written informed consent before participating. 
 
Clinical demographics recorded included CFTR genotype, age, best lung function (forced 
expiratory volume in 1 second [FEV1] and forced vital capacity [FVC]), body mass index (BMI) in 
the previous 12 months, CFRD, CF-related liver disease (CFLD), history of MI or DIOS and 
presence of Pseudomonas aeruginosa in routine sputum cultures. CFRD was defined broadly to 
incorporate impaired glucose tolerance, indeterminate glycaemia (raised glucose during an oral 
glucose tolerance test) and CFRD with or without fasting hyperglycaemia(329). MI was defined as 
failure to pass meconium in the first days following birth, with associated clinical and radiological 
features of obstruction(330). DIOS was defined as a history of complete or incomplete intestinal 
obstruction during the lifetime of the patient, with evidence of a faecal mass at the ileo-caecal 
junction clinically or radiologically, and associated symptoms of abdominal pain and vomiting(330) 
(331). 
 
In order to compare lung function predicted values between subjects of variable age, each subject 
was allocated a lung disease phenotype (mild, severe, neither mild nor severe), based on their age 
and best FEV1 predicted value in the year of enrolment, using previously published 
nomograms(332). In addition, all available historical lung function measurements (from 1998 
onwards) for each subject were recorded and used to compare the rate of lung function decline 
between HFE genotype groups.  
 
Venous blood (6 mL) was collected into a lithium heparin tube. Two hundred microlitres of whole 
blood and 500 µL of plasma were stored at -80oC for later batch analysis of HFE genotype and 
hepcidin level, respectively. Genomic DNA was extracted from 100 µL of stored whole blood using 
a DNeasy® Blood and Tissue kit (Qiagen) as per the manufacturer’s protocol. The presence of 
C282Y and H63D HFE gene mutations was determined by real-time polymerase chain reaction 
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(TaqMan® primers and Universal PCR Master Mix from Applied Biosystems®) using established 
methodologies(333). Plasma hepcidin-25 concentration was determined by high-performance liquid 
chromatography, with online extraction, coupled to tandem mass spectrometry (HPLC-MS) using 
established methods which have been described in detail previously(334). The assay has an 
analytical range of 5–100 ng/mL (r2>0.990) with inter- and intra-day accuracy and imprecision 
across the analytical range of 95.4–106% and <9.9% respectively. Serum ferritin, soluble transferrin 
receptor (sTfR), transferrin saturation, total iron and haemoglobin levels were measured from a 
simultaneously collected blood sample by Queensland Health Pathology Service, Australia. The 
sTfR to Log10[ferritin] ratio (sTfR ratio) was calculated as marker of iron stores in the setting of 
systemic inflammation(152).  
 
6.3.1 Statistical Analysis 
 
Data analysis was performed using PASW, Version 18.0 (SPSS Inc. Chicago, IL, USA). Between-
group differences of continuous variables were analysed by Mann-Whitney U test. Differences in 
categorical variables were determined by Chi-squared tests, or by Fishers exact test where the 
predicted number of subjects in each group was less than five. Differences in lung function decline 
between the groups were determined by linear, mixed effects modelling. Only subjects in whom a 
minimum of five lung function measurements over a minimum of two years were available were 
included in the analysis of rate of lung function decline, in order to limit potential skew from 
inclusion of subjects with limited data points (median 30 measurements per subject [interquartile 
range 21-45], median time from first to last measurement 8.8 years [interquartile range 4.5-12.4 
years]. To account for the effects of variable CFTR genotypes and P. aeruginosa infection on 
outcomes, repeat analysis was performed on sub-groups of subjects who were homozygous for the 
common F508del CFTR gene mutation or infected with P. aeruginosa. For the purposes of 
statistical analysis, patients were segregated into three groups on the basis of their most “severe” 
single HFE gene mutation - normal HFE genotype, H63D mutation (H63D heterozygotes and 
homozygotes), and C282Y mutations (C282Y heterozygotes, homozygotes and compound 
heterozygotes). 
 
6.4 Results 
 
HFE genotype was determined for 163 adult CF subjects. Sixty-one subjects carried a HFE gene 
mutation (H63D: 33 heterozygotes, 4 homozygotes, C282Y: 20 heterozygotes, 1 homozygote and 3 
H63D/C282Y compound heterozygotes) and a normal, wild-type HFE genotype was present in 102 
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patients. The clinical characteristics of subjects are seen in Table 6.1. Longitudinal lung function 
data were available for 151 subjects. 
Table 6-1 Subject demographics 
 
HFE genotype Wild-type 
(n=102) 
H63D 
(n=37) 
P-
value$ 
C282Y 
(n=24) 
P-
value# 
Male gender n (%) 63  (62) 22  (60) 0.81 14  (58) 0.76 
Age (years) 27  (23-34) 29  (26-39) 0.09 27  (22-32) 0.58 
      
FEV1 (Litres) 2.3 (1.8-3.1) 2.4 (1.6-3.1) 0.80 2.0 (1.6-2.5) 0.05 
FEV1 % predicted 66  (48-82) 65  (43-84) 0.80 51  (36-69) 0.032 
FVC   (Litres) 3.8 (3.0-4.7) 3.8 (3.2-4.9) 0.59 3.3 (3.0-3.8) 0.07 
FVC % predicted 82  (69-93) 84  (72-95) 0.63 73  (58-81) 0.023 
      
BMI 23  (21-25) 23  (21-26) 1.00 21  (19-25) 0.17 
      
CFTR genotype                     n (%)      
- F508del Homozygote 54 (53) 19 (51) 0.74 13 (53) 0.89 
- F508del Heterozygote 39 (38) 13 (35)  9   (38)  
- Other 7   (7) 3   (8)  1   (4)  
- Unknown 2   (2) 2   (5)  1   (4)  
      
CF Pulmonary Phenotype     n (%)      
- Mild 71 (70) 26 (74) 0.75 9   (39) 0.022 
- Not mild / not severe 25 (25) 8   (23)  11 (48)  
- Severe 6   (6) 1   (3)  3   (13)  
      
CF-Related Diabetes*           n (%) 33 (33) 14 (38) 0.60 14 (58) 0.022 
      
CF-Related Liver Disease     n (%) 9 (9) 2 (5) 0.49 1 (4) 0.69 
      
CF-Related Pancreatic Insufficiency n (%) 91 (89) 34 (92) 0.76 22 (92) 1.00 
      
Gastrointestinal Complications^ n (%) 19 (19) 14 (38) 0.019 9 (38) 0.045 
      
Sputum Microbiology      
- Pseudomonas aeruginosa 87 (85) 36 (97) 0.07 22 (92) 0.52 
 
Continuous variables are expressed as median and inter-quartile range. Differences between Wild-
type and $H63D or #C282Y genotypes were examined by Mann-Whitney U-test. Differences between 
categorical variables were examined by chi-squared or Fishers exact tests, dependent on the number 
of categories and predicted cell values. *Two subjects with type II diabetes mellitus were excluded from 
analysis. ^Meconium ileus or distal intestinal obstruction syndrome, HFE: Haemochromatosis gene, FEV1: 
Forced expiratory volume in one second, FVC: Forced vital capacity, BMI: Body mass index, CFTR: Cystic 
fibrosis transmembrane conductance regulator gene, CF: Cystic fibrosis 
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6.4.1 Relationship between HFE gene mutations and lung function 
 
Subjects with a C282Y mutation had lower FEV1 (51% versus 66%, p=0.032) and FVC (73% 
versus 82%, p=0.023) percentage predicted values compared to subjects with a normal HFE 
genotype (Table 6.1). A greater proportion of subjects with a C282Y mutation had a severe lung 
phenotype compared with subjects who had a normal HFE genotype (13% versus 6%, p=0.022). No 
difference was seen in cross-sectional lung function or pulmonary phenotype between subjects with 
a H63D and normal HFE genotype (Table 6.1).  
 
Subjects with a C282Y HFE mutation experienced an increased rate of decline in FEV1 and FVC 
when compared to subjects without a HFE gene mutation. Similarly, subjects with a H63D 
mutation experienced a more rapid decline in FVC than subjects without a HFE gene mutation 
(Table 6.2). When the analysis was limited to F508del CFTR homozygotes (n=79), the association 
with lung function decline (FEV1 and FVC) in subjects with H63D and C282Y mutations was 
exaggerated (Table 6.3). Between group differences in rates of lung function persisted in a sub-
group analysis limited to subjects infected with P. aeruginosa (n=136) (Table 6.4).  
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Table 6-2 Mixed effect model – Rate of lung function decline 
 
 
 
 
 
 
 
 
 
 
 
 
FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, S.E: standard error 
 
Table 6-3 Rate of lung function decline in F508del homozygotes sub-group (n=79). 
 
 
 
 
 
 
 
 
 
 
 
 
 
FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, S.E: standard error 
 
 
 
 FEV1 FVC 
  Estimate S.E. P-value Estimate S.E. P-value 
Percentages predicted       
Intercept (Wild type) 70.26 2.07  79.87 1.77  
- H63D 74.27 4.05 0.32 84.23 3.46 0.21 
- C282Y 61.93 4.88 0.09 72.09 4.16 0.06 
Decline per year (Wild type) -1.71 0.05  -0.79 0.05  
- H63D -1.80 0.10 0.35 -1.05 0.10 0.01 
- C282Y -2.18 0.12 <0.001 -1.39 0.12 <0.001 
       
Litres       
Intercept (Wild type) 2.80 0.09  3.99 0.11  
- H63D 2.95 0.18 0.40 4.23 0.21 0.26 
- C282Y 2.52 0.21 0.18 3.65 0.26 0.18 
Decline per year (Wild type) -0.08 0.002  -0.06 0.003  
- H63D -0.08 0.004 0.35 -0.07 0.004 0.002 
- C282Y -0.11 0.12 <0.001 -0.09 0.004 <0.001 
 FEV1 FVC 
  Estimate 
(%) 
S.E. P-value Estimate 
(%) 
S.E. P-value 
Percentage predicted       
Intercept (Wild type) 72.30 2.86  82.02 2.30  
- H63D 74.49 5.69 0.70 86.48 4.58 0.33 
- C282Y 62.75 6.50 0.14 74.19 5.21 0.14 
Decline per year (Wild type) -1.65 0.05  -0.79 0.07  
- H63D -2.10 0.12 <0.001 -1.21 0.14 0.002 
- C282Y -2.50 0.15 <0.001 -1.80 0.17 <0.001 
       
Litres       
Intercept (Wild type) 2.90 0.13  4.10 0.15  
- H63D 3.06 0.26 0.53 4.45 0.30 0.24 
- C282Y 2.54 0.30 0.22 3.68 0.35 0.23 
Decline per year (Wild type) -0.08 0.002  -0.06 0.004  
- H63D -0.10 0.004 <0.001 -0.08 0.007 <0.001 
- C282Y -0.12 0.006 <0.001 -0.11 0.008 <0.001 
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Table 6-4 Rate of lung function decline in P. aeruginosa infected sub-group (n=136). 
 
 
 
 
 
 
 
 
 
 
 
 
FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, S.E: standard error 
 
----------------------------------------------------- 
 
6.4.2 Relationship between HFE genotype, CFRD and bowel obstruction. 
 
There was higher prevalence of CFRD in subjects with a C282Y mutation compared to subjects 
with a normal HFE genotype (58% versus 33% respectively, p=0.022). The prevalence of CFRD 
was not different in subjects with a H63D mutation compared to subjects with a normal HFE 
genotype (Table 6.1). When the analysis was limited to F508del homozygotes, there was no 
significant association between HFE mutations and CFRD (Table 6.5). 
 
A history of MI and/or DIOS was more common in subjects with either H63D or C282Y mutations 
compared to subjects with a normal HFE genotype (38% in each HFE mutation group versus 19%, 
p=0.019 and p=0.045 respectively) (Table 6.1). When the analysis was limited to F508del 
homozygotes, the increased risk of DIOS persisted in subjects with a C282Y genotype (Table 6.5). 
 
 
 
 
 
 FEV1 FVC 
  Estimate 
(%) 
S.E. P-value Estimate 
(%) 
S.E. P-value 
Percentage predicted       
Intercept (Wild type) 69.08 2.25  78.54 1.93  
- H63D 73.49 4.20 0.30 83.58 3.61 0.16 
- C282Y 61.95 4.98 0.15 72.10 4.26 0.13 
Decline per year (Wild type) -1.74 0.05  -0.83 0.06  
- H63D -1.80 0.10 0.53 -1.04 0.11 0.05 
- C282Y -2.19 0.12 <0.001 -1.38 0.13 <0.001 
       
Litres       
Intercept (Wild type) 2.77 0.10  3.92 0.12  
- H63D 2.92 0.19 0.29 4.18 0.26 0.24 
- C282Y 2.52 0.22 0.26 3.64 0.27 0.30 
Decline per year (Wild type) -0.09 0.002  -0.06 0.003  
- H63D -0.09 0.004 0.40 -0.07 0.005 0.009 
- C282Y -0.11 0.005 <0.001 -0.09 0.006 <0.001 
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Table 6-5 Subject demographics for F508del homozygous  
 
 Wild Type 
(n=54) 
H63D 
(n=19) 
P-
value 
C282Y 
(n=13) 
P-
value 
Male gender                            n (%) 32 (59) 13 (68)  8 (62)  
Age (years) 27  (22-35) 29  (22-36) 0.49 23  (19-29) 0.12 
      
FEV1 (Litres) 2.3 (1.9-3.2) 2.5 (1.6-3.8) 0.85 2.0 (1.4-2.7) 0.09 
FEV1 % predicted 69  (69-83) 64  (43-84) 0.69 51  (36-74) 0.08 
FVC   (Litres) 3.8 (3.0-4.9) 4.2 (3.2-5.2) 0.46 3.3 (2.7-3.7) 0.13 
FVC % predicted 82  (71-94) 86  (74-94) 0.63 73  (52-87) 0.07 
      
BMI 22  (21-25) 23  (21-25) 0.95 22  (19-26) 0.49 
      
CF Pulmonary Phenotype       n (%)      
- Mild 38 (70) 13 (72) 0.99 4   (31) 0.018 
- Not mild / not severe 13 (24) 4   (22)  6 (46)  
- Severe 3   (6) 1   (6)  3   (23)  
      
CF-Related Diabetes             n (%) 19 (35) 5 (26) 0.48 6 (46) 0.53 
      
CF-Related Liver Disease      n (%) 7 (13) 1 (5) 0.67 1 (8) 1.00 
      
Gastrointestinal Complications^ n (%) 9 (17) 8 (42) 0.05 8 (62) 0.002 
 
Continuous variables expressed as median and inter-quartile range. Difference between Wild type 
and $H63D or #C282Y genotype examined by Mann-Whitney U-test. Differences between 
categorical variables were examined by chi-squared or Fishers exact tests, dependent on the number 
of categories and predicted cell values. ^Meconium ileus or distal intestinal obstruction syndrome, 
HFE: Haemochromatosis gene FEV1: Forced expiratory volume in one second, FVC: Forced vital 
capacity, BMI: Body mass index, CFTR: Cystic fibrosis transmembrane conductance regulator 
gene, CF: Cystic fibrosis 
----------------------------------------------------- 
 
6.4.3 Relationship between HFE genotype, systemic iron indices and hepcidin. 
Transferrin saturations were significantly higher in subjects with a C282Y mutation compared to 
those with a normal HFE genotype. Otherwise, indices of iron status and hepcidin levels were 
similar in subjects with different HFE genotypes (Table 6.6). 
 
 
 
 160 
 
 
 
Table 6-6 Biochemical profiles 
 Normal 
Range 
HFE Genotype 
Wild Type 
(n=102) 
H63D  
(n=37) 
P-
value$ 
C282Y  
(n=24) 
P-
value# 
Haemoglobin (g/L) 135-180 137 (128-
145) 
138 (132-
152) 
0.29 131 (120-150) 0.24 
WCC (x109cells/L) 4-11 8.9  (7.1-
11.2) 
7.9 (6.0-10.7) 0.25 7.4 (6.2-9.8) 0.07 
Neutrophils (x109cells/L) 2-8 5.8 (4.1-8.1) 4.7 (3.4-7.5) 0.21 4.6 (3.5-7.1) 0.15 
       
ALP (U/L) 53-128 94 (77-121) 95 (83-113) 0.84 84 (69-121) 0.47 
AST (U/L) <45 22 (18-30) 22 (16-32) 0.65 20 (16-41) 0.75 
ALT (U/L) <35 25 (17-41) 25 (16-48) 0.96 21 (12-50) 0.40 
       
Iron (µmol/L) 12-31 9 (6-14) 11 (7-16) 0.36 11 (8-16) 0.20 
Transferrin Saturations (%) 15-45 15 (10-21) 18 (12-25) 0.16 20 (15-27) 0.011 
Ferritin (µg/L) 30-300 40 (23-67) 43 (28-67) 0.68 53 (39-70) 0.15 
STfR (mg/L) 0.8-1.8 1.2 (1.0-1.4) 1.2 (1.0-1.4) 0.52 1.1 (0.9-1.2) 0.05 
STfR ratio# <2.0 0.7 (0.6-0.9) 0.7 (0.5-0.9) 0.42 0.7 (0.5-0.8) 0.09 
       
Hepcidin (ng/L) N/A 7.9 (2.5-24.7) 6.7 (2.9-20.2) 0.53 8.1 (1.8-15.4) 0.47 
CRP (mg/L) <5 4.4 (2.0-12.0) 4.4 (2.2-14.8) 0.40 11.5 (3.8-25.0) 0.023 
 
Variables expressed as median and inter-quartile range. Difference between Wild type and $H63D or 
#C282Y genotype examined by Mann-Whitney U-test. WCC: White cell count, ALP: Alkaline 
phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, STfR: Soluble 
transferrin receptor, STfR rato: STFR/Log10[ferritin], CRP: C-reactive protein, N/A: Not available. 
----------------------------------------------------- 
6.5 Discussion 
 
In this study, we demonstrate an association between both the C282Y and H63D HFE mutations 
and an accelerated rate of decline in lung function and occurrence of MI and/or DIOS in subjects 
with CF when compared to subjects with a normal HFE genotype. This disease modulating effect 
was particularly strong in those patients with the most common F508del homozygote CF genotype. 
The C282Y mutation, which is usually associated with the greatest degree of iron loading, was 
associated with a more severe CF clinical phenotype than the H63D mutation, which extended to a 
weak association with an increased risk of CFRD. These findings support our earlier published 
work and strongly suggest that the presence of a mutation in the HFE gene may modulate CF 
pulmonary and gastrointestinal disease phenotypes(174).  
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Identification of gene modifiers in CF may direct new therapeutics and biomarker development(20, 
335). A number of modifier genes have been studied in CF with a predominant focus on 
polymorphisms in genes that are involved in the innate immune system, antioxidant and anti-
protease defences, or tissue repair(20). Gene modifiers may contribute to the CF disease phenotype 
by altering the expression and/or function of CFTR, or they may exert indirect effects. For example, 
mannose binding lectin (MBL) is an important pathogen pattern recognition receptor in the lung 
which opsonises invading pathogens to promote immune cell phagocytosis(336). The O/O and 
XA/O MBL2 genotypes occur in 10-15% of the CF population and result in significantly reduced 
MBL production. These two mutations are associated with poorer lung function, an increased risk 
of P. aeruginosa infection, and increased likelihood of death or need for transplantation in CF(337). 
Several other potential gene modifiers of the CF phenotype have been identified, but these are 
present in only a small proportion of individuals with CF(18, 20).  
 
The airways of subjects with CF contain increased amounts of iron and the dominant CF pulmonary 
pathogen, P. aeruginosa, has an obligatory requirement for iron for replication and respiration(169, 
179, 196, 265, 338). In vitro studies demonstrate that CF bronchial epithelial cells “leak” iron at 
their apical surface, which in turn promotes P. aeruginosa biofilm growth(180). The potential 
importance of iron homeostasis in CF supports the study of the role of HFE gene mutations, 
especially given the central importance of HFE in controlling body iron levels. Furthermore, in 
contrast to many other previously explored modifying factors, iron homeostasis may be modifiable 
with therapeutic manipulation through dietary modification or potentially, the use of agents that 
chelate iron(338, 339). 
 
Chronic P. aeruginosa infection is strongly associated with accelerated rate of lung function decline 
in CF and represents a potential confounder in modifier gene studies(94). The prevalence of P. 
aeruginosa infection in our study was similar among subjects with each HFE genotype (Table 6.1) 
and when analysis was limited to subjects infected with P. aeruginosa, rates of decline in lung 
function remained highest in subjects with a C282Y mutation (Table 6.4). 
 
The risk of development of bowel obstruction (MI or DIOS) has been ascribed to modifier genes in 
CF previously, and importantly gastrointestinal complications in childhood have been shown to 
predict for worse long term pulmonary outcomes(20, 324, 340). A relationship between an 
increased risk of MI in infants and the C282Y mutation was originally suggested in an Irish 
study(173, 175). However, this association was not supported by a more recent multi-national 
GWAS, which identified five SNPs (three on chromosome 1 and two on the X chromosome), in the 
 162 
 
region of two solute carrier family genes (SLC6A14 and SLC26A9) that were associated with an 
increased risk of MI, but did not identify any SNPs in the region of the HFE gene(324). The GWAS 
included more subjects (> 3000 individuals) than our current study and limited the analysis to 
occurrence of MI in newborns, whereas our study has broadened the clinical diagnosis to include 
bowel obstruction secondary to DIOS. (341). A further analysis of the GWAS data is warranted to 
include patients with a history of DIOS and MI, but the current findings are in agreement with our 
earlier study conducted in the CF population living in Tasmania, and our studies are also supported 
by earlier published work from Ireland that showed an increased risk of MI in patients with a 
C282Y HFE mutation, which we now demonstrate also extends to patients with the H63D HFE 
genotype.  
 
We observed an association between the C282Y mutation and prevalence of CFRD, supporting the 
findings of our earlier work. In the general population, the development of type II diabetes is 
influenced by genetic and environmental factors(342). Single nucleotide polymorphisms (SNPs) in 
several genes (including SLC26A9 and TCF7L2) have been linked to an increased risk of 
developing type II diabetes and these SNPs also appear to increase the risk of developing 
CFRD(20). The C282Y mutation and iron loading independent of HFE genotype have been 
identified as additional risk factors for the development of type II diabetes and HFE mutations are 
associated with increased diabetes-related morbidity and mortality in the general population(343-
345).  Additional investigation of the relationship between HFE gene mutations and CFRD is 
required in a larger CF population to further define this association. 
 
Only four subjects in the current study had a HFE genotype typically associated with clinically 
significant systemic iron loading (one C282Y/C282Y homozygote and three C282Y/H63D 
compound heterozygotes), nevertheless, there is precedence for single HFE gene mutations 
impacting disease phenotype. For example, subjects with hepatitis C virus (HCV) infection who are 
heterozygous for the C282Y mutations display increased serum ferritin, liver iron levels and hepatic 
fibrosis compared with HCV infected subjects with a normal HFE genotype(327). An association 
with increased liver disease severity is also evident in HFE mutation heterozygotes who have co-
existent porphyria cutanea tarda and non-alcoholic steatohepatitis(346, 347). Abnormal cerebral 
iron homeostasis is evident in the pathogenic lesions associated with many neurodegenerative 
diseases and consistent with the importance of iron to central nervous system disease,  
heterozygosity for the H63D mutation is associated with an increased risk of motor neurone 
disease(328),(348).  
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In our cohort, serum hepcidin levels and markers of iron status were not significantly different in 
CF subjects with different HFE mutations, suggesting that subjects with predisposing HFE 
mutations were not iron loaded systemically at the time the study was performed. Nevertheless, it 
remains possible that a single HFE mutation, although not sufficient to disturb iron concentrations 
at the systemic level in CF, may promote disease by further exacerbating iron mishandling caused 
by CFTR mutations at the cellular level. Our data suggest a greater influence for the C282Y, 
compared to H63D mutation on CF disease phenotype, and the overall impact of HFE mutations 
appeared to be greatest in the gastro-intestinal tract, followed by respiratory and endocrine systems. 
The explanation for this apparent difference in organ susceptibility to dysregulated iron homeostasis 
is uncertain and requires further investigation.  
 
The study has a number of limitations. Firstly, this was a single centre study and included a 
relatively small population compared to other large, multi-centre gene modifier studies which have 
recruited up to 2500 patients in order to maximise statistical power and limit the potential for Type I 
errors(21, 349). We have, however, replicated our earlier findings generated in a separate CF 
population of an association between C282Y and H63D mutations and disease severity, and the link 
between iron and disease severity has strong biological rationale. Furthermore, large, multicentre 
studies may be negatively impacted by the confounding effect of different environmental and 
treatment exposures between centres(349). The second limitation of our study is that recruitment 
was not limited to CF subjects with only the most common F508del homozygote CFTR genotype. 
However, when a sub-group analysis was undertaken in F508del homozygotes, the presence of a 
HFE mutation had an exaggerated effect on the rate of decline of lung function ( Table 6.3), while 
the trend in other parameters remained similar to the larger cohort (Table 6.5 and 6.7). Thirdly, to 
maximise recruitment in the current study, blood testing was not always performed during clinical 
stability. As a consequence, subjects with a C282Y mutation were predominantly recruited during 
treatment of a pulmonary exacerbation, reflecting the fact that their health was generally poor at the 
time of study. The associated acute phase response may have perturbed a number of iron indices 
and reduced the ability to detect differences between groups by reducing systemic iron levels in the 
C282Y group as part of the innate immune iron withholding response. Nevertheless, the sTfR ratio 
is considered to be an accurate surrogate marker of body iron stores in the presence of 
inflammation, and values for this parameter were not different between groups(149). 
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Table 6-7 Biochemical profiles of DF508del homozygous subjects 
 Normal 
Range 
HFE Genotype 
Wild Type 
(n=52) 
H63D  
(n=19) 
P-
value$ 
C282Y  
(n=13) 
P-
value# 
Haemoglobin (g/L) 135-180 137 (130-144) 138 (135-157) 0.16 130 (124-149) 0.40 
WCC (x109/L) 4-11 9.3  (7.0-11.2) 7.8 (5.3-10.1) 0.29 7.4 (5.7-9.0) 0.06 
Neutrophils (x109/L) 2-8 6.0 (4.1-8.3) 4.7 (3.0-7.3) 0.19 4.4 (3.6-5.6) 0.06 
       
ALP (U/L) 53-128 97 (79-126) 96 (90-119) 0.77 85 (65-109) 0.17 
AST (U/L) <45 24 (18-30) 21 (16-34) 0.68 19 (16-38) 0.58 
ALT (U/L) <35 26 (19-42) 24 (16-44) 0.55 18 (11-52) 0.23 
       
Iron (µmol/L) 12-31 9 (6-14) 10 (8-15) 0.28 12 (8-18) 0.20 
Transferrin Saturations (%) 15-45 15 (10-21) 18 (12-23) 0.21 23 (16-31) 0.038 
Ferritin (µg/L) 30-300 44 (23-70) 45 (25-72) 0.88 55 (40-68) 0.61 
STfR (mg/L) 0.8-1.8 1.2 (1.0-1.4) 1.2 (1.0-1.3) 0.70 1.1 (0.9-1.2) 0.26 
STfR ratio# <2.0 0.7 (0.6-0.9) 0.7 (0.5-0.9) 0.72 0.7 (0.5-0.9) 0.52 
       
Hepcidin N/A 10.1 (3.4-28.0) 8.2 (3.1-28.7) 0.88 4.3 (1.6-15.1) 0.10 
CRP (mg/L) <5 5 (2.0-10.0) 4.4 (2.0-11.0) 0.98 14 (4.2-26.0) 0.08 
 
Variables expressed as median and inter-quartile range. Difference between Wild type and $H63D or 
#C282Y genotype examined by Mann-Whitney U-test. WCC: White cell count, ALP: Alkaline 
phosphatase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, STfR: Soluble 
transferrin receptor, STfR rato: STFR/Log10[ferritin], CRP: C-reactive protein 
----------------------------------------------------- 
6.6 Conclusion 
 
In summary, CF subjects who carry a HFE gene mutation, and in particular the C282Y substitution, 
demonstrate an accelerated decline of lung function and increased prevalence of MI and/or DIOS. 
Our findings support the need for mechanistic studies to further determine the effect of HFE 
mutations on iron homeostasis in CF. They also suggest that screening the CF population for the 
presence of HFE mutations may be useful to identify patients who may be at particular risk of iron-
related disease modulation. Further research is needed to determine whether interventions that limit 
iron such as dietary modification, including avoidance of iron supplements, or iron chelation 
therapy should be introduced to potentially ameliorate HFE mutation-mediated modulation of CF 
disease outcomes. 
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Chapter 7. Discussion 
 
7.1 Introduction. 
 
The work presented in this thesis had three overarching aims; i) Determine the relationship between 
treatment practices in Australian CF centres and rates of P. aeruginosa antibiotic resistance, ii) 
Determine bacterial population and host immune related factors which may influence pulmonary 
infection and response to anti-microbial therapy, and iii) Determine the relationship between 
systemic and pulmonary iron homeostasis and CF lung disease severity. The overall aim was to 
investigate antibiotic prescribing practices, lung microbiome dynamics and host immune factors 
that may contribute to chronic infection with P. aeruginosa in CF. 
 
To address Aim One; in chapter 2, data from the Australian clonal P. aeruginosa in CF study 
(ACPinCF) and the Australian CF Data Registry (ACFDR) were utilised to determine treatment 
related factors which may promote antibiotic resistance in children and adults infected with P. 
aeruginosa.  
 
To address Aim Two; in chapter 3, metagenomic techniques were applied to determine the bacterial 
composition of CF sputum samples. The airway microbiome composition was correlated with 
clinical demographics, and the changes in composition of the microbiome in response to 
intravenous antibiotics was examined by performing serial measures in subjects undergoing 
antibiotic treatment for a pulmonary exacerbation. In chapter 4, multi-colour flow cytometry was 
used to phenotype peripheral blood lymphocytes from CF subjects and healthy controls. Differences 
in lymphocyte sub-sets were compared between groups, and in subjects with CF, lymphocyte sub-
sets were correlated with parameters of infection and increased disease severity. Finally in chapter 
5, the presence of bio-active metals in the sputum of subjects with CF and NCFB was determined 
by ICP-MS and compared to concentrations found in induced sputum samples from healthy 
controls. Metal concentrations were correlated with parameters of increased airway inflammation 
and tissue damage. 
 
Finally, to address Aim Three; in chapter 5, the concentration of iron in the CF airway was 
correlated with clinical demographics and airway infection, inflammation and tissue injury. In 
chapter 6, the role of the HFE gene as a potential modifier of CF disease phenotype was explored. 
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7.2 Key Findings of this Thesis. 
 
7.2.1 Trends in P. aeruginosa antibiotic resistance in Australian CF centres. 
 
7.2.1.1 Key Findings 
 
The findings presented in Chapter 2, demonstrate the use of antibiotic therapies to manage CF 
airways disease in patients infected with P. aeruginosa vary widely between different paediatric and 
adult CF centres across Australia. Within paediatric centres the rates of MARPA correlated with the 
use of intravenous antibiotics. In both adult and paediatric centres, the treatment centre in which 
treatment was delivered was an independent predictor of intravenous antibiotic usage and of 
MARPA. 
 
Adult and children infected with a one of the major Australian shared strains (AUST-01 or AUST-
02) had an increased treatment burden. Furthermore patients infected with AUST-01 and AUST-02 
were prescribed more maintenance therapies and intravenous antibiotics, and were more likely to 
possess a MARPA isolate. 
 
7.2.1.2 Limitations 
 
Due to the complexity of the ACPinCF study it was not feasible to perform all the antibiotic 
sensitivity testing in a single laboratory, nor was it possible to test the antibiotic sensitivity of 
individual strains which were genotyped. Consequently, differences in testing techniques employed 
between states may have accounted for some of the differences in antibiotic resistance profiles. 
Similarly, the antibiotic resistance profile generated by the local laboratory may not have been 
reflective of the antibiotic resistance of the genotyped strains. 
 
This study was cross-sectional and the chronicity of infection in each subject was not determined, 
consequently, infection may have been transient in some subjects. This is important as subjects with 
transient infection are less likely to be infected with a resistant strain, and more likely have mild 
disease and respond to eradication regimens(116, 197, 198).  
 
Information about which intravenous antibiotics were prescribed, or the specific reason for 
administration was not available. This additional information would been advantageous in 
determining the impact of particular antibiotic on induction of resistance. Equally, in some centres, 
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intravenous antibiotic administration may have been performed regularly (e.g. every 3 months) and 
not driven by clinical indications (e.g. treatment limited to the management of a pulmonary 
exacerbation). This is important, as different treatment approaches may account for the variable 
rates of intravenous antibiotic usage between sites and may potentially impact antibiotic 
resistance(350). 
 
Finally, maintenance therapies were recorded from hospital dispensing data systems and patient 
medical records, which may not accurately reflect treatment adherence and thus the actual intensity 
of exposure to antibiotics.  
 
7.2.1.3 Implications for Future Work 
 
Worldwide, quality improvement projects have been undertaken in which patient care has been 
benchmarked against high performing centres(203-205). These projects have proven valuable in 
identifying key metrics of “best practice” which can be used to drive improvements in service 
delivery(203). Furthermore, in the US and Europe consensus recommendations for managing 
pulmonary exacerbations and prescribing maintenance therapies have been published to promote 
consistent and evidence-based practice(127, 202, 245). However, similar guidelines are not 
currently in place in Australia. 
 
The findings contained in chapter 2 are important, as they highlight apparent, wide variations in 
treatment practices between different Australian CF centres. Furthermore, the results indicate 
(especially among paediatric centres) that treatment practices may influence the development of 
MARPA. Although the clinical significance of MARPA remains a matter of debate(238, 239), 
increased antibiotic usage at an early age may impact on long term treatment related morbidity, 
including the development of antibiotic allergy and toxicity(5, 6, 351). Despite the variable 
treatment approaches employed, there were few differences in health related outcomes between 
centres, however, longitudinal studies will be important in determining whether the early benefits of 
aggressive antibiotic treatment in early life are sustained into adulthood. Nevertheless, the results of 
the study, represent an opportunity to open dialogue between CF treatment centres within Australia, 
to consider the development of national consensus treatment guidelines to maximise clinical benefit 
whilst minimising development of multi-antibiotic resistance.  
 
Antibiotic sensitivity testing methodologies employed, vary between the different microbiology 
laboratories involved in the routine testing of CF sputum samples, which may impact on antibiotic 
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resistance profiles generated for a P. aeruginosa strain. The adoption of standardised national 
susceptibility testing would allow the resistance profiles generated at different sites to be directly 
compared. At the population level, this would be advantageous in monitoring resistance trends and 
assist in the identification of ‘outbreaks’ of resistant strains. For the individual with CF, their 
personal antibiotic resistance profile should perhaps be monitored over time to allow the early 
detection of antibiotic resistance development and consideration of a change in antibiotic usage. 
Although this study focused in particular on P. aeruginosa infection, standardisation of 
susceptibility testing may be of equal importance for the monitoring of other CF airway pathogens. 
 
Finally, the two major Australian shared strains were associated with increased treatment burden. 
Worldwide, a number of shared strains identified in other populations have been shown to be 
associated with increased morbidity and these observations have resulted in patient segregation 
based on strain type(223). Limited data are currently available about the clinical impact of the major 
Australian shared strains(352), and longitudinal monitoring of patients infected with these strains 
will be of critical importance in informing the development of infection control policies, which in 
turn has substantial implications for resources such as physical space (i.e. single in-patient rooms 
for all CF patients) in CF centres. 
 
7.2.1.4 Proposed Future Work 
 
i) Prospective, longitudinal follow-up of paediatric subjects, to determine if early, 
 aggressive treatment of P. aeruginosa is associated with better outcomes, despite the 
 development of MARPA. 
 
ii) Prospective, longitudinal follow-up of subjects infected with a shared P. aeruginosa 
 strain, to determine whether these strains are associated with worse long-term outcomes. 
 
iii) Develop national consensus guidelines for antibiotic susceptibility testing in CF, to 
 allow direct comparison of resistance profiles between different regions and for the 
 same patient tested at different treatment centres. 
 
iv) Develop national consensus “best practice” guidelines for the management of chronic P. 
 aeruginosa infection and treatment of pulmonary exacerbations. 
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7.2.2 Response of the CF lung Microbiome to intravenous antibiotics. 
 
7.2.2.1 Key Findings 
 
The findings presented in Chapter 3, demonstrate in a group of adult CF subjects infected with P. 
aeruginosa on standard microbiological cultures, Pseudomonas spp. dominated the lung 
microbiome determined by molecular analysis in 94% of cases. Anaerobic species were also 
commonly present in the sputum, with Prevotella and Veillonella spp. being present in 72% and 
78% of samples prior to antibiotic treatment respectively. However, the relative abundance of 
anaerobic species was generally low. Sputum samples with high relative abundance of 
Pseudomonas spp. tended to have low overall microbial diversity. Conversely, increase relative 
abundance of Streptococcus spp. and Prevotella spp. correlated with increased microbial diversity. 
 
In subjects experiencing a pulmonary exacerbation, following three days of intravenous antibiotic 
therapy, the relative abundance of Pseudomonas spp. in sputa was reduced and a reciprocal increase 
in microbial diversity was seen. However, despite ongoing antibiotic pressure, by the end of the first 
week of treatment, the relative abundance of Pseudomonas spp. and overall microbial diversity 
returned to pre-treatment levels. 
 
Overall, the findings of this study suggest that intravenous antibiotics for the treatment of a 
pulmonary exacerbation have only a short-lived effect on the lung microbiome. In particular, there 
is an apparent recrudescence of Pseudomonas infection despite ongoing antibiotic pressure. These 
results add significantly to previous published work in this field. The findings challenge the 
convention of treating subjects with CF undergoing a pulmonary infection with a two week course 
of the same intravenous antibiotics and suggest alternate strategies such as rapidly cycling different 
classes of antibiotics should be explored. 
 
7.2.2.2 Limitations 
 
The results presented in this chapter are largely based on the relative abundance of each bacterial 
species, expressed as a percentage of the whole microbiome and do not reflect the absolute number 
of bacteria present. Consequently, confident comment cannot be made on whether changes in 
bacterial density follows a similar pattern as the relative abundance. However, in a sub-group of 
recruited subjects, there was a significant positive correlation between the relative abundance of 
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Pseudomonas spp and quantitative P. aeruginosa bacterial load (r2 = 0.24, p=0.04), which supports 
the conjecture that an increase in relative abundance of P. aeruginosa is accompanied by an 
increase in actual bacterial numbers. 
 
Secondly, the methods employed to sample and process sputum samples for inclusion in 
metagenomic studies are currently subject to optimisation. A matter of particular debate is the use 
of PMA to cross-link (and exclude) eDNA from biological samples(272, 273). There exists, a 
theoretical concern the extracellular DNA released from non-viable bacteria may skew the results of 
microbiome studies, especially when the antibiotic bacterial killing effects are studied(273). In the 
study included in this thesis, in order to minimise the possible effects of extended post-collection 
processing on the bacterial content of samples, we elected not to perform PMA processing. This 
decision did not limit our ability to detect differences in the lung microbiome in response to 
antibiotics. However, in the future, it will be important for researchers in this field to agree upon 
standardised testing methodologies to allow direct comparisons of results between studies(353). 
 
Finally, this study was performed in adult subjects, with moderately severe lung disease, infected 
with P. aeruginosa, and the findings may not be applicable in younger subjects with milder lung 
disease, or in subjects who do not have a P. aeruginosa infection. Further studies that examine the 
lung microbiome and how it responds to intravenous antibiotics in subjects who do not culture P. 
aeruginosa are required. 
 
7.2.2.3 Implications for Future Work 
 
Conventionally, CF subjects experiencing an infective pulmonary exacerbation are treated with a 
two week course of intravenous antibiotics(127). Typically, subjects experience progressive 
symptomatic improvement and improved lung function over the course of treatment. However, the 
results presented in this chapter suggest that the lung microbiome may rapidly become tolerant to 
intravenous antibiotics and challenges the convention of prescribing a prolonged course of the same 
intravenous antibiotics to all patients being treated for a pulmonary exacerbation. The results of this 
study may support the prescription of shorter courses of antibiotics, or the adoption of alternate 
antibiotic prescription strategies e.g. changing the antibiotics prescribed during the treatment of a 
pulmonary exacerbation. However, such treatment strategies will require careful investigation, in 
particular for the occurrence of adverse effects, including the potential for increased rates of 
antibiotic allergy and toxicity, and development of MARPA(5, 6, 235, 351). Furthermore, if clinical 
improvements cannot be attributed to changes in the lung microbiome, the clinical beneficial effects 
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of adjuvant therapies administered alongside antibiotics, including airway clearance techniques, use 
of mucolytics, rehydration and nutritional supplementation, merit greater consideration in future 
studies. Finally, as clinical improvements do not correlate with changes in airway microbiome, it 
may be that the absolute number of each bacteria species in the airway is less important than other 
factors, such as the virulence of the components of the microbiome and the effect that this exerts 
upon immune response and airway inflammation(269). 
 
7.2.2.4 Proposed Future Work. 
 
i) Perform similar lung microbiome studies in subjects with milder airways disease and also in 
 subjects before the establishment of chronic P. aeruginosa infection.  
 
ii) Examine the effects of non-antimicrobial adjunctive therapies on the airway microbiome 
 and pulmonary inflammation. 
 
iii) Randomised controlled trials, which compare the effects of conventional and alternate 
 antibiotic strategies (e.g. rapidly cycling antibiotics) on the airway microbiome. 
 
iv) Studies to explore the effects of antibiotics on the “virulence” of the component of the 
airway  microbiome. 
 
7.2.3 Lymphocyte Phenotype in CF 
 
7.2.3.1 Key Findings 
 
The findings presented in Chapter 4, demonstrate that in comparison to healthy controls, the blood 
lymphocyte population in subjects with CF contains a lower percentage of MAIT cells and a higher 
percentage of γ/δ T-cells. In CF subjects, a lower percentage of MAIT cells was associated with P. 
aeruginosa infection, increased lung disease severity and acute pulmonary exacerbations. The 
absolute numbers of γ/δ T-cells (but not proportion of lymphocytes that were γ/δ T-cells) also 
correlated with worse lung function. 
 
Total lymphocyte counts were lower in CF subjects undergoing treatment for a pulmonary 
exacerbation, when compared to stable subjects, and in CF a reduced lymphocyte count correlated 
with worse lung function. 
 172 
 
 
Overall the results of this chapter provide the basis for future investigations into the potential utility 
of MAIT cells as a biomarker in CF, and more detailed mechanistic studies to determine whether 
abnormal MAIT cell responses are implicated in the impaired pulmonary response to infection in 
CF that allows chronic infection to become established. 
 
7.2.3.2 Limitations 
 
The study presented in chapter 4 was cross-sectional, consequently, it is not possible to determine 
from the results, whether a causal relationship exists between reduced MAIT cell numbers, chronic 
bacterial infection and disease severity. Nevertheless, previous authors have determined that MAIT 
cells provide an important, early response to infection, prior to a mature, adaptive immune 
responses, which strongly suggests MAIT cells are worthy of further investigation(71, 72). 
 
The study included only a limited number of subjects in the sub-group analysis of stable disease 
compared with patients undergoing treatment for a pulmonary exacerbation and only five subjects 
not infected with P. aeruginosa. Consequently, type I statistical errors are possible in the analysis of 
these outcomes. Furthermore, all the CF subjects included in the current study were adults, with 
chronic airway infection. As a result, it was not possible to determine whether the reduction of 
MAIT cell number was as a consequence of infection, or whether a primary defect in innate T-cells 
numbers may be present in subjects with CF, which thus predisposes to bacterial infection. Future 
studies, which include young patients will be important in identifying whether defects in innate T-
cell immunity precede infection. 
 
As circulating lymphocyte populations may not accurately reflect airway populations it is possible 
that reduced numbers occur as a result of increased tissue recruitment to sites of infection(276). 
Studies which correlate airway biopsy and circulating lymphocyte numbers will be of great 
importance in elucidating the role of lymphocytes in disease pathogenesis. 
 
Finally, this study was primarily designed to be ‘hypothesis generating’ and did not examine 
measures of lymphocyte function and in particular, did not investigate the proportion of the 
lymphocytes specifically primed to respond to CF airway pathogens. 
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7.2.3.3 Implications for Future Work 
 
Despite the preliminary nature of the findings of this study, the results are of great potential interest, 
and provide several exciting avenues for future research into lymphocyte responses in CF. 
 
The different concentrations of MAIT cells between healthy and CF subjects, and the correlation of 
MAIT cell proportions with lung disease severity and clinical stability in CF, suggest that MAIT 
cell percentage may be useful as a biomarker of pulmonary infection in CF. In this setting, a 
strength of monitoring MAIT cells numbers is the restricted responsiveness of these cells to 
bacterial antigens(69), which for instance could be utilised to differentiate between pulmonary 
exacerbations triggered by viral or bacterial stimuli. The research presented in this chapter was 
limited to CF, however, differentiating between viral and bacterial triggered exacerbations is 
important in other disease setting (e.g. asthma, chronic obstructive pulmonary disease) and future 
research should explore MAIT cell proportions in other pulmonary diseases.  
 
Reduced proportions of MAIT cells in the blood of CF patients may occur as a result of reduced 
lineage differentiation, increased peripheral destruction or preferential migration from the blood to 
tissue. Determining the mechanism by which MAIT cell numbers are reduced may inform the 
development of therapeutic strategies based on augmenting MAIT cell numbers or function. 
 
Finally, blood MAIT cell concentration may not reflect pulmonary (airway) concentration and 
studies which determine the presence of MAIT cells in airway biopsy are required to determine 
whether these cells are important in protecting the lung from infection, although such studies are 
limited by ethical considerations in CF. 
 
7.2.3.4 Proposed Future Work 
 
i) Ex vivo studies of MAIT cells from subjects with CF to determine whether these cells are 
 primed to respond to CF pathogens, with a focus on their response to P. aeruginosa. 
 
ii) Ex vivo studies to compare the adaptive responses of MAIT cells isolated from the blood of 
 CF and healthy control subjects in response to stimulation by P. aeruginosa (and other CF 
 pathogens). 
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iii) Study MAIT cell proportions in children and subjects with mild lung disease to determine 
 whether differences exist prior to the onset of chronic infection. 
 
iv) Longitudinal study to determine the stability of MAIT cell proportions in the blood of CF 
 subjects over time, and variability in MAIT cell number between periods of stable disease 
 and pulmonary exacerbations. 
 
v) Examination blood MAIT cells proportion in other respiratory disease settings, with a 
 particular focus on determining their utility for differentiation between viral and bacterial 
 exacerbations. 
 
7.2.4 Bioactive metals in the CF airways. 
 
7.2.4.1 Key Findings 
 
The findings presented in chapter 5 demonstrate that airway secretions from subjects with CF and 
NCFB contain increased concentrations of iron, zinc, magnesium and calcium, when compared to 
healthy control subjects. Furthermore in subjects with CF and severe airways disease, increased 
concentrations of molybdenum were found. 
 
Sputum concentrations of magnesium, iron, zinc, calcium and copper correlated with increased 
concentrations LDH, which was measured as a surrogate markers of local tissue damage(308). 
Furthermore magnesium, iron and zinc concentrations correlated with increased concentrations of 
the pro-inflammatory cytokine IL-8. Airway biometal concentrations were not related to the 
concentration of atmospheric particulate matter, and were present in substantially higher 
concentrations than previously reported to be present in serum(303-305). Taken together these 
results suggest that biometals may arise from local tissue destruction and/or the breakdown of 
inflammatory cells within the airways. 
 
Finally, it was noteworthy that in two subjects who received intravenous iron infusions for the 
treatment of severe iron deficiency anaemia, sputum iron concentrations were substantially higher 
in samples collected after the infusion, when compared to initial samples.  
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7.2.4.2 Limitations 
 
Results presented in this chapter were based on expectorated sputum samples (and induced sputum 
in health controls) as this is the form of sampling most readily accessible in clinical practice. 
However, sputum sampling is intrinsically subject to sampling variability and may be confounded 
by oropharyngeal contamination. However, established methodology was applied to sample 
collection, in which sputum plugs were carefully separated from saliva, and this approach has been 
shown to minimise salivary contamination(322). 
 
CF and NCFB subjects included in this study were adults with severe lung disease, which may have 
limited the ability to detect differences in sputum metal concentrations between stable state and 
during pulmonary exacerbations. 
 
Finally, it is not possible to determine from the results of this study whether the metal 
concentrations in the airways are a results of airway inflammation, or whether the presence of bio-
active metals in the airways precedes and contributes towards tissue damage by stimulating the 
generation of reactive oxygen species. 
 
7.2.4.3 Implications for Future Work 
 
The results in this chapter confirm the results of previous authors in finding increased 
concentrations of zinc and iron in the airways of subjects with CF(176-179, 216). Determination of 
the concentration of bio-active metals in the airways has two implications of major importance for 
future research. Firstly, it furthers our understanding of the microenvironment of the lung, which 
will inform on the development of more accurate culture models for the study of bacterial behaviour 
in vitro. It is hoped that developing accurate in vitro models will assist in more accurately 
predicting phenotypic adaptation of pathogenic bacteria and their response to antimicrobials in vivo. 
Secondly, a number of biometals are essential to the survival of bacteria. Identifying metals which 
are associated with severe disease, may suggest opportunities for the development of novel 
therapeutic agents based on interference with bacterial access to specific metals(196).  
 
The identification of high concentrations of molybdenum in the sputum of CF subjects with severe 
disease is potentially an important finding. In bacteria, molybdenum is a co-factor of nitric 
reductase, which is an essential enzyme in anaerobic respiratory pathways(298). Molybdenum was 
not detected in the airways of healthy controls, or CF subjects with milder airways disease, which 
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may suggest that it is non-essential for normal airway physiology. Consequently, limiting the 
availability of molybdenum to bacteria, may represent a target for the development of novel 
therapeutic agents against anaerobic pulmonary infections. 
 
7.2.4.4 Proposed Future Work. 
 
i) Develop in vitro culture models with media containing bio-active metal concentrations 
 which reflect in vivo airway concentrations. 
 
ii) Explore the expression of molybdenum co-factors and nitric reductase in aerobic and 
 anaerobic P. aeruginosa cultures, grown in media containing molybdenum and in 
 molybdenum depleted medium. 
 
iii) Study the therapeutic potential of high affinity chelators targeting specific metals in vitro 
 and in animal infection models. 
 
7.2.5  HFE as a Gene Modifier in CF 
 
7.2.5.1 Key Findings 
 
In chapter 6 it is demonstrated that CF subjects who carry a HFE gene mutation experience an 
accelerated rate of lung function decline and are at increased risk of DIOS. Furthermore, rates of 
CFRD were higher in subjects with a C282Y mutation compared to healthy controls. 
 
Peripheral blood, iron and hepcidin concentrations were not different between subjects with 
difference HFE genotypes. This suggests that if HFE gene mutations modify the CF phenotype, the 
mechanism of action may be distinct from its effect on systemic iron stores, perhaps by impacting 
on iron homeostasis at a cellular level. 
 
The results presented in this chapter are consistent with the results of earlier, smaller, studies in this 
field and supports the need for further research into how HFE gene mutations may potentially 
modify the CF phenotype(173-175). 
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7.2.5.2 Limitations. 
 
This is the largest study to date to examine the effects of HFE genes on the CF phenotype, however, 
this only included 51 subjects who carried a HFE mutation (only 3 had a potential HH disease 
causing genotype) and the results may be subject to type I errors. Nevertheless, the study was 
performed in a single centre, thereby limiting the confounding effects of different environmental 
and treatment approaches on the results. In addition, the results are consistent with those of previous 
studies in the field(173-175). 
 
To improve the power of the study, recruitment was not limited to subjects with the same CFTR 
mutation and the uneven distribution of mild CF genotypes may have influenced the outcome of the 
study. However, CFTR genotypes were evenly distributed between subjects with different HFE 
genotypes and sub-group analysis limited to DF508del homozygotes demonstrated trends consistent 
with the whole group data. 
 
Finally, only the two most common HFE gene mutations were screened for, and it is possible some 
subjects carried another HH causing gene mutation. However, these mutations are rare and 
generally associated with mild HH phenotypes, and even if present are unlikely to have had a 
substantial impact on the results(354, 355). 
 
7.2.5.3 Implications for Future Work  
 
Studying the influence of modifier genes on the phenotype of a genetic disorder is important to 
improve our understanding of the pathophysiology of disease and to identify potential new 
therapeutic strategies. 
 
In earlier studies, as well as in Chapter 5 of the current thesis, increased concentrations of iron have 
been identified in the CF airways(176-179, 356). Furthermore, access to iron has been shown to 
have a powerful influence upon the phenotypic adaptation of P. aeruginosa(179, 265, 338). 
 
The results presented suggest the HFE gene mutations identified, did not influence systemic iron 
stores. However, HFE mutations, may exert more subtle effects on iron homeostasis at the cellular 
level, which influence iron handling and immune responses, and increase the risk of infection(221, 
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357, 358). Consequently, future laboratory based studies could focus on determining the effects of 
HFE mutations at the cellular level in CFTR mutant cells 
 
Finally, high rates of iron deficiency have been reported in subjects with CF and prescription of iron 
replacement therapy is common practice(169). There is currently limited information on the effects 
of iron replacement on airway iron availability and the work that has been performed has not 
considered the possible influence of HFE mutations(167, 172). Future clinical studies, should 
examine the relationship between HFE gene mutations and the availability of iron in the CF airway 
and determine whether iron supplementation regimens should be modified to prevent possible 
adverse-effects, associated with iron replacement in this potentially ‘at risk’ population. 
 
7.2.5.4 Proposed Future Work. 
 
i) Develop mouse models which combine HFE and CFTR mutations in order to study the 
 effects of the combined mutations on systemic and cellular iron handling, infection and 
 gastrointestinal complications. These studies are underway at QIMR-Berghofer and have 
 received NHMRC funding in 2014. 
 
ii) Determine whether HFE mutations correlated with increased sputum iron concentrations, 
airway inflammation and infection in subjects with CF. 
 
iii) Prospective study to screen CF subjects for HFE mutations prior to the commencement of 
 iron supplementation, in order to develop strategies to avoid over-zealous iron replacement 
 in subjects susceptible to adverse effects from systemic iron loading. 
 
7.3 Concluding Remarks 
 
The work presented in this thesis provides new insights into therapeutic, bacterial and immune 
factors, which may promote the persistence of P. aeruginosa infection at the population, individual 
patient and cellular level in CF. The findings presented identify a number of important avenues for 
future research, which may result in the development of improved techniques for monitoring 
(biomarkers) and treatment (targeting iron and other biometals) of CF related lung disease. 
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Appendix 2: Appendix to Chapter 3 
 
The following appendix constitutes data mentioned in Chapter 3: Response of the CF lung 
Microbiome to intravenous antibiotics. 
 
Appendix 2.1: Intravenous antibiotic usage, standard microbiological cultures and sensitivity 
testing results for patients enrolled in the study which constitutes Chapter 3 
Appendix 2.2: Demographics, lung function and antibiotic treatment of individual patients 
enrolled in the study which constitutes Chapter 3 
Appendix 2.3: Taxonomic classification of 16s rDNA reads from sputum samples analysed in 
the study which constitutes Chapters 3 
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Appendix 2.1: Intravenous antibiotic usage, standard microbiological cultures and sensitivity testing results for patients enrolled in the study 
which constitutes Chapter 3 
 Antibiotic sensitivity testing 
Subject Intravenous 
antibiotics 
Standard 
microbiological 
culture results 
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V
an
co
m
y
ci
n
 
P1 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S R S S S  S S  S S     
Non-Mucoid Psa R S R R R S  R R  R S     
P2 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R R S S S S  S S  S S     
Non-Mucoid Psa S S S S S S  S S  S S     
S. Maltophilia             R S   
P3 
Meropenem, 
Tobramycin, 
Azithromycin 
Mucoid Psa R R R R R R  R R  R S     
P4 
Meropenem, 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S S S S S S  S S  S S     
Non-Mucoid Psa R R R R R R  R R  R S     
MSSA               S  
P5 
Meropenem, 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S R S S S  S S  S S     
Non-mucoid Psa R R R S R R  S S  S S     
P6 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S R R R R  R S  S S     
Non-mucoid Psa R R R R R R  R S  R S     
A. fumigatus                 
P7 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S S S S S S  S S  S S     
Non-mucoid Psa R R R S R S  R S  R S     
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P8 
Meropenem, 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R R R R R R  R R  R S     
Non-mucoid Psa R S R R R S  S R  S S     
P9 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S R S S S  S S  S S     
Non-mucoid Psa R S R S S S  S R  S S     
P10 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S S S R R R  R S  S S     
MRSA               R S 
P11 
Meropenem, 
Aztreonam, 
Tobraymicn 
Mucoid Psa R S R S S S  S S  S S     
Non-mucoid Psa R R R R R R  R R  R R     
P12 
Ceftazadime 
Tobramycin 
Mucoid Psa R R R S S S  S S  S S     
Non-Mucoid Psa R S R R R R  R R  S S     
MSSA               S  
P13 
Ceftazadime, 
Tobramycin 
Mucoid Psa S S S S S S  S S  S S     
Non-mucoid Psa R R R S S S  S S  S S     
P14 
Colistin, 
Meropenem, 
Ceftazadime 
Mucoid Psa R R R R R R  R R  R S     
Non-mucoid Psa R R R R R R  R S  S S     
P15 
Colistin, 
Meropenem, 
Ceftazadime 
Mucoid Psa R S R R R R  S S  S S     
A. fumigatus                 
P16 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S R S S  S S  S S      
C. albicans                 
MRSA                 
P17 
Meropenem, 
Inhaled 
Tobramycin 
Mucoid Psa R S R S S  S S  S R S     
Non-mucoid Psa R R R R   R R  R R S     
P18 
Ceftazadime, 
Tobramycin, 
Mucoid Psa S   S S  S S   S      
Non-mucoid Psa S   S S  S S   S      
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Azithromycin MSSA                 
A. fumigatus                 
P19 
Timentin, 
Tobramycin, 
Azithromycin 
Mucoid Psa R S S S S  S S  S S      
Non-mucoid Psa R R R S S  S S  S R      
Penicillium Spp.                 
P20 
n/a Mucoid Psa S   S S   S   R      
MSSA                 
S. prolificans                 
P21 
Tazocin, 
Tobrmycin, 
Azithromycin, 
Bactrim 
Mucoid Psa R R R R R  S S  R R      
C. albicans                 
A. fumigaus                 
P22 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S S S S S  S S  S S      
Mucoid Psa R R R S S  S S  S S      
C. albicans                 
P23 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S S R S S  S S  S R      
C. albicans                 
P25 
Ceftazadime, 
Tobramycin, 
Azithromycin 
Mucoid Psa S   S S  S S   R      
Non-mucoid Psa R   S S  S S   R      
MSSA                 
 
Psa: Pseudomonas aeruginosa, S. maltophilia: Stenotrophomonas maltophilia, MSSA: methicillin sensitive Staphylococcus aureus, MRSA: 
methicillin resistant Staphylococcus aureus, A. fumigatus: Aspergillus fumigatus, C. albicans: Candida albicans, S. prolificans: Scedosporium 
prolificans. S: sensitive, R: resistant, Px: subject number. 
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Appendix 2.2: Demographics, lung function and antibiotic treatment of individual patients enrolled in the study which constitutes Chapter 3 
 
P
at
ie
n
t 
C
o
d
e 
S
ex
 
A
g
e 
(y
ea
rs
) 
T
re
at
m
en
t 
L
o
ca
ti
o
n
 
G
en
o
ty
p
e 
B
M
I 
B
es
t 
F
E
V
1
 i
n
 t
h
e 
P
re
v
io
u
s 
6
 m
o
n
th
s 
(L
) 
B
es
t 
F
E
V
1
 %
 P
re
d
ic
te
d
 
in
 t
h
e 
p
re
v
io
u
s 
si
x
 
m
o
n
th
s 
F
E
V
1
 P
ri
o
r 
to
 t
re
at
m
en
t 
(L
) 
F
E
V
1
 P
er
ce
n
t 
p
re
d
ic
te
d
 
p
ri
o
r 
to
 t
re
at
m
en
t 
F
E
V
1
 P
o
st
 T
re
at
m
en
t 
(L
) 
F
E
V
1
 P
er
ce
n
t 
p
re
d
ic
te
d
 
p
o
st
 t
re
at
m
en
t 
R
el
at
iv
e 
im
p
ro
v
em
en
t 
(%
) 
A
b
so
lu
te
 I
m
p
ro
v
em
en
t 
(%
) 
F
E
V
1
 s
ev
er
it
y
*
 
P1 M 18 Queensland DF508Homo 18.7 1.29 33% 0.93 24% 0.97 25% 4% 1% Severe 
P2 M 32 Queensland DF508/Unknown 23.9 1.24 29% 1.07 25% 1.24 29% 16% 4% Severe 
P3 M 18 Queensland DF508Homo 19.3 1.21 30% 1.13 26% 1.21 28% 8% 2% Severe 
P4 M 29 Queensland DF508Homo 20.6 0.87 21% 0.87 21% n/a n/a n/a n/a Severe 
P5 M 27 Queensland DF508Homo 25.7 3.37 84% n/a n/a 3.21 80% n/a n/a Mild 
P6 F 34 Queensland DF508Homo 20.8 1.60 50% 1.20 38% 1.44 45% 18% 7% Moderate 
P7 F 29 Queensland DF508/N1303k 17.9 1.71 60% 1.23 44% 1.53 55% 25% 11% Moderate 
P8 M 22 Queensland DF508/Unknown 17.1 1.99 47% 1.39 33% 1.87 45% 36% 12% Moderate 
P9 M 21 Queensland DF508/Unknown 18.4 1.40 37% 1.18 31% 1.36 36% 16% 5% Severe 
P10 M 37 Queensland DF508Homo 24.5 1.21 30% 0.79 20% 0.83 22% 10% 2% Severe 
P11 M 31 Queensland DF508/Unknown 21.9 1.50 28% 1.13 28% 1.33 33% 18% 5% Severe 
P12# M 27 Queensland DF508Homo 26.0 4.17 97% 3.73 87% 4.17 97% 10% 10% Mild 
P13# M 27 Queensland DF508Homo 25.1 4.19 97% 3.84 90% 4.16 96% 7% 6% Mild 
P14 F 20 Queensland G551/R1162X 16.8 0.99 29% 0.76 22% 0.99 28% 29% 6% Severe 
P15 F 52 Queensland DF508/Unknown 19.8 0.91 35% 0.89 34% 0.91 35% 2% 1% Severe 
P16 F 25 Tasmania DF508Homo 18.7 1.14 36% 0.85 27% 1.13 36% 33% 9% Severe 
P17 F 29 Tasmania DF508/1898+1G 18.5 2.24 68% 1.77 54% 1.81 56% 4% 2% Moderate 
P18 M 22 Tasmania DF508Homo 20.2 2.45 58% 1.59 38% 2.79 67% 76% 29% Moderate 
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F: female, M: male, BMI: body mass index, L: litres, *Based on best lung function values obtained in the six months prior to treatment, FEV1 
>70% mild, 40-70% moderate, <40% severe impairment. # Separate exacerbation series collected from the same patient, 12 months apart. n/a: 
not available 
P19 M 26 Tasmania DF508Homo 21.8 2.86 67% 2.85 67% 2.87 68% 1.5% 1% Moderate 
P20 M 19 Tasmania DF508/Unknown 20.7 3.27 75% 2.32 53% 3.40 76% 43% 23% Mild 
P21 M 54 Tasmania G542x/Unknown 20.7 2.14 55% 1.71 43% 1.67 42% 0% 0% Moderate 
P22 M 35 Tasmania DF508Homo 19.8 1.95 55% 1.50 37% 1.87 46% 24% 9% Moderate 
P23 M 19 Tasmania R553X/1717-1G>A 17.9 2.06 51% n/a n/a 2.00 50% n/a n/a Moderate 
P24 M 18 Tasmania DF508Homo 19.8 3.89 93% 3.79 91% 4.02 94% 3.3% 3% Mild 
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Appendix 2.3: Taxonomic classification of 16s rDNA reads from sputum samples analysed in 
the study which constitutes Chapters 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kingdom TP-1 [%] TP-2 [%] TP-3 [%] 
Bacteria 100 100 100 
Phyllum    
Proteobacteria 90.65 56.95 84.7 
Firmicutes 4.25 17.7 6.2 
Bacteroidetes 1.5 8.4 0.3 
Actinobacteria 0.25 1.4 0.2 
Fusobacteria 0.15 0.7 0 
Class    
Gammaproteobacteria 90.55 56.45 84.7 
Bacilli 2.85 9.05 5.5 
Bacteroidia 1.5 7.9 0.3 
Clostridia 1.05 2.75 0.7 
Actinobacteria 0.25 1.4 0.2 
Fusobacteria 0.15 0.7 0 
Betaproteobacteria 0 0.05 0 
Order    
Pseudomonadales 90.3 38.45 74.6 
Lactobacillales 2.85 8.65 5.5 
Bacteroidales 1.5 7.9 0.3 
Clostridiales 1.05 2.75 0.7 
Actinomycetales 0.2 0.55 0.2 
Fusobacteriales 0.15 0.7 0 
Gammaproteobacteria_incertae_sedis 0.1 0.05 0.1 
Burkholderiales 0 0.05 0 
Coriobacteriales 0 0.05 0 
Unclassified 0.25 0.25 0.4 
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Family    
Pseudomonadaceae 90.3 38.4 74.6 
Streptococcaceae 2.7 7.4 5.5 
Prevotellaceae 1.25 7.6 0.3 
Veillonellaceae 1.05 2.75 0.7 
Fusobacteriaceae 0.15 0 0 
Micrococcaceae 0.1 0.5 0.1 
Simiduia 0.1 0.05 0.1 
Carnobacteriaceae 0 0.05 0 
Coriobacteriaceae 0 0.05 0 
Unclassified 0.35 0.65 0.4 
Genus    
Pseudomonas 69.5 23.45 58.6 
Streptococcus 2.7 7.4 4 
Prevotella 1.25 6.9 0.3 
Veillonella 0.75 2.65 0.7 
Azomonas 0.3 0.1 0.2 
Fusobacterium 0.15 0 0 
Rothia 0.1 0.5 0.1 
Atopobium 0 0.05 0 
Granulicatella 0 0.05 0 
Unclassified 12.9 6.45 13.8 
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Appendix 3: Appendix to Chapter 4 
 
The following appendix constitutes data mentioned in Chapter 3: Response of the CF lung 
Microbiome to intravenous antibiotics. 
 
Appendix 3.1. Sputum microbiology of CF patients enrolled in the study which constitutes 
Chapter 3 
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1 Male 29 24.0 19.4            
2 Female 19 73.4 20.0            
3 Male 28 82.1 27.7            
4 Male 27 56.2 24.2            
5 Male 32 27.4 24.1            
6 Male 22 58.0 19.5            
7 Female 32 65.6 23.4            
8 Female 27 62.9 20.5            
9 Female 21 67.7 23.5            
10 Male 35 52.5 24.8            
11 Male 31 21.5 24.5            
12 Male 25 56.7 37.3            
13 Female 34 69.7 27.3            
14 Male 26 83.6 22.4            
15 Male 28 100.1 24.9            
16 Male 26 51.0 23.3            
17 Female 22 79.5 21.0            
18 Male 28 27.6 20.5            
19 Male 24 41.6 26.5            
20 Male 40 23.6 25.4            
21 Female 22 78.6 22.6            
22 Female 33 69.5 18.5            
23 Male 32 80.3 27.8            
24 Female 34 64.3 27.1            
25 Male 38 32.6 20.0            
 280 
 
26 Female 20 94.2 26.3            
27 Female 27 53.3 19.1            
28 Male 31 28.0 23.8            
29 Female 25 76.2 24.3            
20 Male 36 53.9 26.2            
31 Male 20 60.7 23.0            
32 Male 34 31.5 24.0            
33 Male 27 34.1 21.5            
34 Male 30 48.0 21.2            
35 Female 24 39.6 19.2            
36 Female 17 32.6 17.8            
37 Male 43 66.9 24.7            
38 Female 18 50.3 17.7            
39 Female 18 99.0 31.0            
40 Male 23 78.7 22.1            
41 Female 40 67.8 32.4            
 
